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3-FMC 3-Fluoromethcathinone 
4-APB 4-(2-Aminopropyl)benzofuran 
4-BMC 4-Bromomethcathinone 
4-EMC 4-Ethylmethcathinone 
4-FA  4-Fluoroamphetamine 
4-FEP  4-Fluoroephedrine 
4-FMA 4-Fluoromethamphetamine 
4-FMC 4-Fluoromethcathinone 
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m-CPP meta-Chlorophenylpiperazine 
MAO  Monoamine oxidase 
MDA  3,4-Methylenedioxyamphetamine 
MDAI  5,6-Methylenedioxy-2-aminoindane 
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Summary 
 
This PhD work consists of an in vitro and in vivo part. In the in vivo part, we 
investigated the role of dopamine in the acute clinical effects of 3,4-
methylenedioxymethamphetamine (MDMA, “ecstasy”) in healthy human subjects. 
The role of dopamine in the addictive effects of drug of abuse is well established, but 
whether it contributes to the acute psychotropic effects of MDMA is unclear.  
In this pharmacological interaction study, we used the dopamine and weak 
norepinephrine transporter inhibitor bupropion (Stahl et al. 2004) as a 
pharmacological tool to block the MDMA-induced dopamine release  and to study the 
role of dopamine in the effects of MDMA. We hypothesized that bupropion would 
decrease the subjective effects of MDMA to the extent that they depend on MDMA-
induced release of dopamine.  
We included 16 healthy human subjects in this double-blind, placebo-controlled, 
crossover study. Bupropion pretreatment slightly increased MDMA plasma 
concentration and prolonged but not reduced the subjective effects contrary to our 
hypothesis. Additionally, bupropion reduced the MDMA-induced elevations in plasma 
norepinephrine concentrations and the heart rate response to MDMA.  
These findings support a role for norepinephrine in the MDMA-induced 
cardiostimulant effects but no role for MDMA-induced transporter-mediated 
dopamine release in the elevated mood effects after MDMA administration. Possibly, 
most of the acute psychotropic effects of MDMA are mediated via transporter-
mediated release of serotonin and norepinephrine as previously shown (Hysek et al. 
2011, Hysek et al. 2012). 
 
In the second and main part of this work we characterized the pharmacological 
profiles of novel psychoactive substances (NPS). Specifically, we studied whether 
and how potently NPS interacted with the human transporters for norepinephrine, 
dopamine, and serotonin, stably expressed in human embryonic kidney (HEK293) 
cells. Additionally, we assessed binding affinity to the serotonin 5-HT1A, 5-HT2A, 5-
HT2C-receptors and the activation potency and activation efficacy at 5-HT2A and 5-
HT2B receptors. Furthermore, binding to alpha1A/2A-adrenergic, dopamine D1-3, 
histamine H1 receptors, as well as trace amine-associated receptor 1 (TAAR1) was 
also assessed. 
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The NPS studied in this project included para-4-halogenated amphetamine 
derivatives, which were shown to be relatively more serotonergic than their non-4-
halogenated counterparts and pyrovaleronering-substituted cathinones, which were 
highly potent dopamine transporter inhibitors with a high risk for abuse.  
Para-halogenated drugs (4-fluoroephedrine, 4-fluoroamphetamine, 4-
fluoromethamphetamine, 4-fluoromethcathinone, and 4-bromomethcathinone) also 
released monoamines, similar to MDMA, whereas pyrovalerones were found to be 
pure uptake inhibitors. Most benzofurans were similar to MDMA but slightly more 
serotoninergic than MDMA and additionally activated the serotonin 5-HT2B receptor.  
The last big group of NPS studied in this project, were novel hallucinogens, which 
predominantly interacted with the 5-HT2A receptor. This serotonin receptor subtype 
mediates the hallucinogenic and hallucinogenic-like visual effects of classic 
serotonergic hallucinogens (Vollenweider et al. 1998, Nichols 2004, Halberstadt et al. 
2013, Halberstadt et al. 2014, Halberstadt 2015).  
Compounds tested in this project included the benzodifuran 8-Bromo-2,3,6,7-benzo-
dihydro-difuran-ethylamine (2C-B-FLY), 2C-drugs with their highly potent N-(2-
methoxy)benzyl (NBOMe)-derivatives, and lysergic acid diethylamide (LSD). 
Interestingly, NBOMe derivatives displayed higher affinities at the 5-HT2A receptor 
than LSD, together with a high selectivity for 5-HT2A over the 5-HT1A receptor, 
contrary to LSD. NBOMes were partial 5-HT2A receptor agonists, similar to LSD.  
These novel drugs likely carry a high hallucinogenic potential when used 
recreationally by humans and the high binding to α1A-receptor (Ki < 1µM) may result 
in additional vasocontrictive and cardiovascular stimulant effects.  
 
Taken together, this PhD contributed to the understanding of the role of dopamine in 
the effects of MDMA, an important recreational substances.  Additionally, we 
characterized the in vitro pharmacology of many novel designer drugs, which will be 
helpful in the prediction of the clinical toxicological effects of these newly used 
recreational drugs.  
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Introduction 
Overview: Classification and relevance 
The today drug market is volatile and especially the Internet serves as an ideal tool to 
obtain any kind of psychoactive substance. NPS are sold as “bath salts”, “plant food” 
or “research chemicals” and labelled “not for human consumption” to circumvent 
legislation and mimic psychoactive effects of banned classical drugs including 
MDMA, methamphetamine, cocaine, or LSD. The European Monitoring Center for 
Drugs and Drug Addiction (EMCDDA) defines NPS as follows:  
“A new psychoactive substance is defined as a new narcotic or psychotropic drug, in 
pure form or in preparation, that is not controlled by the United Nations drug conventions, 
but which may pose a public health threat comparable to that posed by substances listed 
in these conventions” (Iversen 2015) 
Statistics of the EMCDDA show clearly an ongoing increase in the number of NPS 
detected in the EU. At least 400 NPS have been reported in the last few years and in 
2014, with 101 NPS noted by the EMCDDA, presented in Figure 1 (EMCDDA 2015, 
Wood et al. 2015). 
Most newly detected designer drugs belong to the phenethylamines and synthetic 
cathinones or to the structurally diverse group of synthetic cannabinoids. Although 
NPS are not responsible for as many deaths as alcohol, benzodiazepines, prescribed 
opioids, cocaine, or heroin (Hansen et al. 2014, Martins et al. 2015, Nichols et al. 
2015, Simonsen et al. 2015) they are a big health concern due to their unknown 
potential harm and their unknown pharmacological profile. Importantly, chemical 
substitutions may keep the effects of a controlled drug and lead to a legal alternative 
or in contrast, the chemical modification may result in totally different 
pharmacological and related toxicological effects. This makes it dangerous to 
consume NPS, since numerous NPS were involved in toxic effects and deaths alone 
or contributed to these effects in mixed-drug intoxications (Simmler et al. 2014, Dines 
et al. 2015, McAuley et al. 2015, Rickli et al. 2015, Rickli et al. 2015). Therefore the 
pharmacologic characterization of NPS is very important to assess their potential 
harm. 
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Figure 1: Number of new psychoactive substances reported to the EU Early Warning System, 
2005-2014 (EMCDDA 2015). 
 
Mechanism of action  
Monoamine uptake inhibition  
Amphetamine, MDMA, and many NPS interact with the norepinephrine (NE), 
dopamine (DA), and serotonin (5-HT) transporter (NET, DAT, and SERT, 
respectively). These plasma membrane monoamine transporters regulate the 
homeostasis of NE, DA, and 5-HT in the brain and are located in the peri-synaptic 
area, mostly expressed on the respective neurons (Torres et al. 2003). They 
terminate the signal of NE, DA, and 5-HT by reuptake of the transmitter into the 
synapse. The driven transport force is the ion gradient over the synaptic membrane 
maintained by the Na+/K+-ATPase (transporting potassium into the intracellular space 
and sodium out of the cytosol) (Sitte et al. 2015). Subsequent monoamine storage in 
the vesicles happens via the vesicular monoamine transporter 2 (VMAT2) 
(Fleckenstein et al. 2003). Designer drugs with monoamine substrate properties, like 
MDMA or methamphetamine, are also transported into the cell via the transporter 
and release the respective monoamine via the transporter into the synaptic cleft. 
Additionally, the drugs may also interfere with the VMAT2 and disturb the transmitter 
balance leading to a monoamine increase in the synaptic cytosol (Partilla et al. 
2006). Monoamine oxidase A and B (MAO A and B) inhibition by certain 
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amphetamine derivatives may further enhance their own concentration and 
potentiate the effect of the monoamine concentrations in the intra-and extracellular 
space, by inhibiting the degradation of monoamines (Leonardi et al. 1994, Scorza et 
al. 1997). In contrast to the amphetamines, we found some NPS such as the 
pyrovalerone-type cathinones to be pure and very potent monoamine uptake 
inhibitors unlike other amphetamines. Possibly the high inhibition potency of these 
compounds at the DAT and NET explains their psychotropic properties in humans.  
In our studies, we investigated in vitro interaction of NPS with the NET, DAT, and 
SERT. Some NPS were either weak or inactive at monoamine transporters (like 
hallucinogenic drugs including the 2C series, NBOMes, LSD) or they inhibited at 
least one monoamine reuptake transporter. Figure 2 shows schematically the 
potential sites of interaction of NPS with the NET, DAT, and SERT as well as other 
targets tested in in vitro studies.  
 
Monoamine release 
An increase of monoamines in the synaptic cleft can either happen via vesicular 
release or inhibition of the reuptake transporters. Amphetamine mediates its biologic 
response primarily via transporter-mediated neurotransmitter release mediated by 
the uptake transporters. Also MDMA and other compounds are taken up as 
substrates by these transporters (Eshleman et al. 2013, Simmler et al. 2013, Sitte et 
al. 2015). 
The exact mechanism, by which amphetamine and other substrates induce 
monoamine release is not fully understood. However, there are several theories for 
this phenomenon. One model describes the uptake of a substrate and subsequent 
monoamine release via alternating access hypothesis of substrate translocation at 
the monoamine transporters (Manepalli et al. 2012, Sitte et al. 2015). 
In this model, the carrier presents a pocket where substrate and co-transported 
sodium (Na+) and chloride (Cl-) can bind. With this co-transport as driving force, the 
transporter protein conformation changes and switch from the outwardfacing to the 
inwardfacing state and releases the substrate in the cytosol (Jones et al. 1999). The 
following change in the sodium gradient has been proposed as a factor for the 
subsequent induction of neurotransmitter release, since inhibition of Na+/K+-ATPase 
with ouabain increased monoamine efflux (Scholze et al. 2000). Thus this reduced 
sodium gradient can trigger a conformational change of the transporter and induce 
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monoamine release together in the presence of amphetamine and other substrates 
(Sitte et al. 2010). A second model considers the monoamine transporters working in 
a channel mode (Adam SV 2002). This model was proposed because observations 
indicated higher transporter-associated currents than the alternative access model 
could account for based on its stoichiometry. Therefore, charge was proposed to 
translocate through a channel-like transporter-state (Sonders et al. 1997). However, 
Schicker et al. (2012) found in human SERT, that uncoupled current is presented by 
a transiently formed state. Additionally, this state is in equilibrium with an inward 
facing and K+-bound SERT mode. Therefore the extent of the channel-like state is 
limited and probably not the preferred model to describe the release-mechanism 
(Schicker et al. 2012).  
A third hypothesis states an oligomer-based counter-transport model. It assumes that 
amphetamine or another substrate is taken up by one moiety of the transporter, 
which subsequently induces monoamine release through the other transporter. This 
model does not specify, which of the transporter account for the uptake of substrates 
and which one for the monoamine-release. Additionally, increasing extracellular 
substrate amount will probably reduce the release capacity, by occupancy of both 
oligomer-parts (Sitte et al. 2010).  
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	Figure 2: Schematical presentation of interaction-sites of novel psychoactive substances with 
transporters and receptors in vitro.  
1) Inhibition of NET, DAT, and/or SERT as a main site of action for many amphetamine-like 
drugs. Reduction of the monoamine clearance and recycling from the synaptic cleft, results in 
enhancement of the neurotransmitter-mediated signaling at the postsynaptic receptors. 
Monoamine reuptake transporters are driven by the potential gradient over the membrane, 
produced by the N+/K+-ATPase and co-transport of sodium and chloride. 
2) Many NPS directly bind to presynaptic TAAR1rat/mouse and also postsynaptic serotonin, 
dopamine, and histamine receptors are possible interaction sites.  
3) In addition to monoamine-reuptake inhibition described in 1), several reuptake-inhibitors serve 
also as a monoamine substrate either for NET, DAT, or/and SERT leading to a reversal of the 
monoamine transporter resulting in release of monoamines into the synaptic cleft.  
  
1 
2 
 
 
 
 
 
 
 
 
 
 
 
NPS 
ATPase'
2K+'
3Na+'
monoamines((NE,(DA,(50HT)(
5.HT1A/2A/2B/2C'
'
α1A/α2A' D1.3'/'H1'
NET/DAT/SERT'
'
Synaptic(cleft(
'
Presynapse(
'
NET:(norepinephrine(transporter;(DAT:(dopamine(transporter;(SERT:(serotonin(transporter;(NPS:(novel(psychoactive(substance;(
NE:(norepinephrine;(DA:(dopamine;(50HT:(serotonin;(TAAR:(trace(amine0associated(receptor(
(
NPS 
synaptic(vesicle(
3 
1 
2 
Monoamine uptake inhibition by NPS!!
NPS interaction with monoamine receptors and transporters !
NPS as monoamine substrates and following transporter reversal and monoamine release !3 
Postsynapse(
'
TAAR1rat/mouse'
'
Monoaminergic'neuron'
'
17
	
Serotonin receptor interactions 
The wide diversity of serotonin receptors include 7 different families with 14 serotonin 
(5-HT) receptors subtypes (Celada et al. 2013). They are G-protein coupled 
receptors (GPCR). For our studies we were interested in the 5-HT1A, 5-HT2A, 5-HT2B, 
and 5-HT2C receptor subtypes. Serotonin receptors are involved in cognition, mood, 
anxiety, psychosis, sleep, schizophrenia, temperature regulation, appetite, sexual 
behavior, blood platelet aggregation, and muscle contraction (Cox 1977, Adams et al. 
2002, Abbas et al. 2008, Przyklenk et al. 2010, Smith et al. 2010, Stein et al. 2015). 
Serotonin 5-HT1A receptors are located postsynaptically, but also on the presynaptic 
membrane and are hereby involved in the negative feedback mechanism induced by 
an increasing amount of serotonin in the synaptic cleft (Barnes et al. 1999, Celada et 
al. 2004). This subtype is broadly found in the CNS and ergolines like LSD bind to 
this receptor but not the hallucinogenic phenethylamines (Nichols 2004, Rickli et al. 
2015).  
The serotonin 5-HT2A receptor has been considered as main target important for 
hallucinogenic effects produces by psychedelics with possible modulatory 
involvement of 5-HT1A and 5-HT2C receptors (Nichols 2004). The problem with the 
elucidation of the 5-HT2C involvement is, that the 2A and 2C subtype share around 
80% transmembrane (Cordova-Sintjago et al. 2012) structure homologies which 
challenges the development of a specific 5-HT2C antagonist. Never the less, studies 
with the selective 5-HT2A antagonist ketanserin in humans and M100’907 
(Volinanserin) in animals showed the important role of 5-HT2A receptors in the in vivo 
effects of hallucinogens (Vollenweider et al. 1998, Halberstadt et al. 2014). 
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Interactions with other receptors  
NPS may also produce some of their effects by binding to monoamine-receptors 
including alpha1A, alpha2A, dopamine D1-3, histamine receptor H1, and trace amine-
associated receptor 1 (TAAR1). 
For example, NPS may produce an increase in sympathetic activation via adrenergic 
alpha1-receptors (Piascik et al. 2001). Alpha1A&2A receptors belong to the big family of 
G-protein coupled receptors. The alpha1A receptor subtype is involved in the 
physiological responses to norepinephrine and epinephrine in the cardiovascular 
system (Chen et al. 2005). Alpha2A receptors are found throughout the CNS and also 
in the periphery in platelets, the spleen, kidney, eye, blood vessels, ileum, and 
adipocytes (Saunders et al. 1999). Alpha1A activation increases smooth muscle 
contraction, whereas alpha2A receptor agonists lower the vascular resistance and 
thereby the blood pressure by a negative feedback with inhibition of NE release in 
the brain.  
Dopaminergic G-protein coupled receptors are broadly found in the brain and in 
peripheral tissues. Dopaminergic receptors regulate locomotion control, affect, 
emotion, and neuroendocrine secretion (Jaber et al. 1996). There are five dopamine 
subtypes, of which we included the D1, D2, and D3 receptor in our studies. The 
dopamine receptor D2 is possibly the most important subtype involved in learning, 
memory, psychosis, prolactin secretion, aldosterone secretion, regulation of 
sympathetic tone, regulation of renal function, blood pressure, vasodilatation, and 
gastro-intestinal tract motility. The dopamine system is also involved in several 
diseases such as Parkinson’s disease or attention deficit hyperactivity disorder 
(ADHD) and D2-antagonists are used in the treatment of schizophrenia. Dopamine D1 
and D3 receptors are additionally important in locomotor activity, reward, and 
reinforcement mechanisms (Heidbreder et al. 2010, Beaulieu et al. 2011). 
The histamine H1 receptor belongs also to the G-protein coupled receptors and is an 
important player in smooth muscle contraction, increase of vascular permeability, 
stimulation of hormone release, reduction of the heart contractibility, production of 
nitric oxide, and increase of neuronal firing (Hill et al. 1997). This receptor it is an 
important target mediating sedation, but our in vitro binding results suggest no 
involvement of the H1 receptor in the effects of tested NPS. In contrast, the G-
protein-linked TAAR1 was found to modulate neurochemical and behavioral effects 
mediated by MDMA, methamphetamine, and cocaine, in vitro and in animals. These 
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studies found modulatory effects on dopaminergic and additional serotonergic 
circuits. TAAR1 is mostly expressed intracellularly throughout the brain, especially in 
dopaminergic and adrenergic brain nuclei, and also found in the peripheral nervous 
system (Wolinsky et al. 2007, Miller 2011). Most NPS interacted with TAAR1 and 
activation of this target may modulate the addictive and acute effects of these NPS 
as similarly described for the classic stimulants (Di Cara et al. 2011, Pei et al. 2014, 
Cotter et al. 2015). 
 
Translation to clinic: Subjective effects and adverse reactions 
Since there are still newly created designer drugs flooding the market and tested in 
uncontrolled recreational settings, the risk for overdosing and drug associated toxicity 
and adverse effects is high. Therefore, staying up to date regarding the 
pharmacology of these compounds is eminent, foremost for toxicologists and 
emergency physicians to aid in choosing the most appropriate treatment in case of 
intoxications. Although, in vitro data can only partly predict in vivo toxicity, 
parameters like the DAT/SERT inhibition ratio, presented in Figure 3, help to 
estimate whether a NPS has serotonergic MDMA-like effects (increased empathy for 
others, low addictive properties, low psychostimulation, risk of hyperthermia) 
associated with a low DAT/SERT inhibition ratio or rather methamphetamine-type 
stimulant effects (stimulation, high risk for addiction) associated with a high 
DAT/SERT inhibition ratio.  
 
In addition to the receptor profile, pharmacokinetic properties such as absorption, 
route of administration, bioavailability, metabolism, and other factors contribute to the 
drug effects in vivo. Nevertheless, beside in silico binding studies (Reid et al. 2013), 
in vitro screenings are so far the first and simplest methods to pharmacologically 
characterize a novel compound and estimate its effects in vivo. 
In summary, this thesis presents in vitro receptor and transporter interaction profiles 
of several groups of NPS that help to predict the toxicity of these substances in 
humans. 
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Figure 3: Ranking of the DAT/SERT inhibition ratio (1/DAT IC50 : 1/SERT IC50) calculated for 
monoamine uptake inhibitors. 
Values are means of three to five independent experiments and 95% confidence intervals (CI). A low 
DAT/SERT inhibition ratio indicates relative more serotonergic effects, whereas a high ratio predicts 
preliminary dopaminergic properties. Values without 95% CI may have an even lower (TFMPP), very 
wide (2-AI) or higher (N,N-Dimethylcatinone, α-PVP, methylphenidate, 2-DPMP) DAT/SERT inhibition 
ratio than indicated in this figure. Dotted lines separate the drugs in the following DAT/SERT ratio 
ranges: < 0.1: TFMPP - MDMA; 0.1-1.0: 5-IAI - 4-Fluoroephedrine; 1.0-10: 4-Fluoromethamphetamine 
- Ethcathinone; 10-100: 2-AI - N,N-Dimethylcathinone; 100-500: MDPBP - Pyrovalerone; > 500: α-
PVP, methylphenidate, 2-DPMP  
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Objectives 
Study questions 
The aim of this PhD thesis was to get a better insight of the interaction of new 
psychoactive substances with monoamine transporters and a set of serotonergic and 
adrenergic receptors in vitro. Additionally, we assessed the role of the 
neurotransmitter dopamine in the acute affects of MDMA using the dopamine 
transporter inhibitor bupropion in an interaction study with MDMA in a controlled 
clinical trial in healthy human subjects.  
Publications 
 
The following section presents the peer-reviewed and published publications that 
form this PhD work, starting with the bupropion-MDMA-interaction study in healthy 
human subjects (paper 1). Then we present the monoamine transporter and receptor 
interactions profiles of designer cathinones, including also substituted amphetamines 
such as PMA, PMMA, pentylone, and others (paper 2), followed by a characterization 
of aminoindanes, piperazines, and pipradrol derivatives (paper 3). We then present 
data on MDMA-like para-halogenated NPS together with a group of potent 
catecholaminergic pyrovalerone-like (paper 4). Further, novel benzomonofurans 
served as MDMA replacement and this group of substances is discussed in paper 5 
together with the potent hallucinogenic substances and benzodifuran 2C-B-FLY 
(paper 5). Finally, paper 6 is dedicated to the hallucinogenic 2C-drugs and their new 
NBOMe analogues. LSD and mescaline are classic serotonergic hallucinogens 
included in this study as comparators. 
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ABSTRACT
3,4-Methylenedioxymethamphetamine (MDMA; “ecstasy”) is a
popular recreational drug. The aim of the present study was to
explore the role of dopamine in the psychotropic effects of MDMA
using bupropion to inhibit the dopamine and norepinephrine
transporters through which MDMA releases dopamine and nor-
epinephrine. The pharmacodynamic and pharmacokinetic interac-
tions between bupropion and MDMA in 16 healthy subjects were
investigated using a double-blind, placebo-controlled, cross-
over design. Bupropion reduced the MDMA-induced eleva-
tions in plasma norepinephrine concentrations and the heart
rate response to MDMA. In contrast, bupropion increased plasma
MDMA concentrations and prolonged its subjective effects. Con-
versely, MDMA increased plasma bupropion concentrations.
These results indicate a role for the transporter-mediated release
of norepinephrine in the cardiostimulant effects of MDMA but do
not support a modulatory role for dopamine in themood effects of
MDMA. These results also indicate that the use of MDMA during
therapy with bupropion may result in higher plasma concentra-
tions of both MDMA and bupropion and enhanced mood effects
but also result in lower cardiac stimulation.
Introduction
3,4-Methylenedioxymethamphetamine (MDMA; “ecstasy”)
is a popular recreational drug that acts by releasing dopamine
(DA), norepinephrine (NE), and serotonin (5-HT) through
their corresponding transporters (Verrico et al., 2007;Hysek et al.,
2012d). The present study (ClinialTrials.gov #NCT01771874;
http://www.clinicaltrials.gov/ct2/show/NCT01771874) was
designed to contribute to elucidation of the mechanism of
action of MDMA in humans. Specifically, we explored the
modulatory role of DA in the psychotropic effects of MDMA
by using bupropion pretreatment to block MDMA-induced
DA release. Dopamine transporter inhibition prevents the
release of DA through the DA transporter induced byMDMA or
other amphetamines (Verrico et al., 2008; Simmler et al.,
2013b). Dopamine mediates the reinforcing addictive effects of
psychostimulants, but its role in the drug-induced subjective
effects of different psychostimulants, such as euphoria, is less
clear (Wise, 2008). Bupropion inhibits the DA transporter, less
potently the NE transporter, but not the 5-HT transporter
(Richelson and Pfenning, 1984; Andersen, 1989; Stahl et al.,
2004). Using previously published methods (Simmler et al.,
2013b), we also confirmed that bupropion inhibited the human
DA, NE, and 5-HT transporter with IC50 values of 1.6, 18, and
.100 mM, respectively. Bupropion has been shown to inhibit
the amphetamine- and methamphetamine-induced release of
DA in vitro (Gruner et al., 2009; Simmler et al., 2013b) and
decrease methamphetamine self-administration in rats (Reichel
et al., 2009) andmonkeys (Schindler et al., 2011). Bupropion also
reduced methamphetamine-induced subjective and cardio-
stimulant effects in humans (Newton et al., 2005, 2006)
and may reduce drug use in subsets of methamphetamine
users (Elkashef et al., 2008; Heinzerling et al., 2014). These
findings suggest a role for DA in both the rewarding and
subjective effects of methamphetamine. In contrast, the role
of DA in the acute mechanism of action of MDMA is less
clear. In preclinical studies, DA receptor gene deletion in
mice had minimal effects on MDMA-induced behavioral
changes (Risbrough et al., 2006), and DA transporter in-
hibition did not alter the acute response to MDMA in rhesus
monkeys (Verrico et al., 2008). In contrast, 5-HT and NE
have been well documented to mediate most of the acute
psychotropic and physiologic effects of MDMA in humans
(Liechti et al., 2000; Liechti and Vollenweider, 2000; Farre
et al., 2007; Hysek et al., 2011, 2012d). In particular, in-
hibition of both the 5-HT and NE transporters with
duloxetine, which prevents the MDMA-induced release of
5-HT and NE through their respective transporters, almost
This study was supported by the Swiss National Science Foundation
(320030_149493).
Y.S. and A.R. contributed equally to this work.
dx.doi.org/10.1124/jpet.114.222356.
ABBREVIATIONS: AUC, area under the plasma concentration-time curve; AUEC, area under the effect-time curve; [11C]b-CIT-FE, N-(2-
fluoroethyl)-2b-carbomethoxy-3b-(4-iodophenyl)-nortropane; DA, dopamine; HMMA, 4-hydroxy-3-methoxymethamphetamine; 5-HT, 5-hydroxy-
tryptamine (serotonin); LLOQ, lower limit of quantification; MDA, 3,4-methylenedioxyamphetamine; MDMA, 3,4-methylenedioxymethamphetamine;
NE, norepinephrine; VAS, Visual Analog Scale.
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completely abolished the subjective and cardiostimulant
response to MDMA in humans (Hysek et al., 2012d).
We previously showed that the DA and NE transporter
inhibitor methylphenidate did not alter the subjective re-
sponse to MDMA in healthy subjects, which is consistent with
DA having no relevant contribution to the psychotropic effects
of MDMA in humans (Hysek et al., 2014). Because methyl-
phenidate produced substantial subjective effects on its own
(Hysek et al., 2014), however, this prior study was incon-
clusive. In contrast to methylphenidate, bupropion is a more
potent DA transporter inhibitor than NE transporter in-
hibitor (Stahl et al., 2004) and is more selective for DA
compared with methylphenidate, which blocks the DA and
NE transporters with equal potency (Simmler et al., 2014).
Additionally, bupropion has been proposed to bind to the
substrate recognition site on the DA transporter similarly to
MDMA, whereas psychoactive DA transporter ligands, such
asmethylphenidate and cocaine, may interact with a different
binding site on the DA transporter (Heal et al., 2014).
Bupropion reaches a high brain-to-plasma ratio and brain
concentrations above its IC50 value for DA transporter in-
hibition (Stahl et al., 2004). Thus, we investigated the effects of
pretreatment with bupropion or placebo on the pharmacody-
namics and pharmacokinetics of MDMA in healthy subjects.
We hypothesized that bupropion pretreatment would prevent
the MDMA response to the extent that the effects of MDMA in
humans depend on an interaction with the DA and NE
transporters. Specifically, we expected bupropion to reduce
the mood and cardiostimulant effects of MDMA through DA
and NE transporter inhibition, respectively.
Bupropion inhibits CYP2D6 (Kotlyar et al., 2005), which
inactivates MDMA to 4-hydroxy-3-methoxymethamphetamine
(HMMA; de la Torre et al., 2012). Therefore, bupropion can be
expected to increase plasma concentrations of MDMA. Fur-
thermore, CYP2B6, which metabolizes bupropion to hydroxy-
bupropion (Jefferson et al., 2005), is also involved in the
minor metabolic pathway of MDMA to form the psychoactive
metabolite 3,4-methylenedioxyamphetamine (MDA) by
N-demethylation, in addition to the involvement of CYP1A2
and CYP3A4 (Kreth et al., 2000). Thus, the competitive
inhibition of CYP2B6 by bupropion might alter the conversion
of MDMA to MDA, and MDMA may inhibit the metabolism of
bupropion. Thus, in addition to pharmacodynamic interactions
at the DA and NE transporters, complex pharmacokinetic
interactions between bupropion andMDMA are also likely and
were examined in the present study.
Materials and Methods
Study Design
This study used a double-blind, placebo-controlled, crossover
design with four experimental test sessions (placebo–placebo,
bupropion–placebo, placebo–MDMA, and bupropion–MDMA) that
were performed in a counterbalanced order according to a Latin-
square randomization design. The washout periods between sessions
were at least 10 days. The study was conducted at the University
Hospital of Basel in accordance with the Declaration of Helsinki and
International Conference on Harmonization Guidelines in Good
Clinical Practice and approved by the Ethics Committee of the
Canton of Basel, Switzerland, and the Swiss Agency for Therapeutic
Products (Swissmedic). The study was registered at ClinicalTrials.gov
(NCT01771874). The predefined primary endpoint of the study was
the effect of bupropion on “good drug effects” associated with MDMA.
All subjects provided written informed consent andwere paid for their
participation.
Subjects
Sixteen healthy white subjects (eight men and eight women) with
a mean6 S.D. age of 24.36 2.2 years and a body mass index of 22.76
2.1 kg/m2 were recruited from the University of Basel campus. The
inclusion criterion was 18–45 years of age. Subjects with a personal or
first-degree-relative history of psychiatric disorders or chronic or
acute physical illness were excluded as previously described (Hysek
et al., 2012a). Additional exclusion criteria were tobacco smoking
(.10 cigarettes/day) and a lifetime history of using illicit drugs more
than five times, with the exception of past cannabis use. Six subjects
had used MDMA once previously. Drug use histories are shown in
Table 1. Subjects who used any illicit drugs, including cannabis,
within the past 2 months or during the study period were excluded.
We performed drug tests at screening and before each test session
using TRIAGE 8 (Biosite, San Diego, CA). Female participants were
investigated during the follicular phase of their menstrual cycle (days
TABLE 1
Prevalence of drug use
Values are times used in life except for tetrahydrocannabinol (THC), coffee, alcohol, and smoking.
Subject Sex Age MDMA Amphetamine Cocaine LSD Psilocybin THC Coffee AlcoholUse Smoking Smoking
yr pills joints/
yr
cups/
day
drinks/wk cigarettes/
day
yr
1 M 25 0 0 0 0 0 Never 0.0 0 0 0
2 F 23 0 0 0 0 0 ,1 4.5 1 0 0
3 M 25 0 0 0 0 0 ,1 0.0 0 0 0
4 F 22 1 0 0 0 0 ,1 1.0 2 0 0
5 F 27 0 0 0 0 0 ,1 2.0 3 0 0
6 M 27 1 0 2 0 0 10–15 1.5 3 5 10
7 M 22 0 0 0 0 0 5–10 2.0 3 0 0
8 M 25 0 0 0 0 0 Never 2.0 2 0 0
9 F 27 1 0 0 0 0 ,1 2.0 3 0 0
10 F 27 1 0 0 0 0 ,1 3.5 3 3 10
11 M 25 1 0 0 0 0 ,1 3.0 5 0 0
12 M 25 1 0 0 0 0 5–10 2.0 3 0 0
13 M 24 0 0 0 1 1 2–4 2.5 7 0 0
14 F 20 0 0 0 0 0 ,1 1.0 5 0 0
15 F 22 0 0 0 0 0 2–4 0.0 2 0 0
16 F 22 0 0 0 0 0 ,1 2.0 1 0 0
LSD, lysergic acid diethylamide.
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2–14) to account for cyclic changes in the reactivity to amphetamines
(White et al., 2002). All subjects were genotyped (Hicks et al., 2013)
and phenotyped (Trojan et al., 2012) for CYP2D6 activity. The study
included 13 extensive, three intermediate, and no poor CYP2D6
metabolizers (genotyping and phenotyping congruent).
Study Outline
The study included a prescreening telephone interview, a screening
visit, four whole-day test sessions with a next-day follow-up, and an
end-of-study visit. Bupropion or placebo was administered daily for
7 days before each of the test sessions. The test sessions began at 7:45
AM. An indwelling intravenous catheter was placed in an antecubital
vein for blood sampling, and the subjects completed baseline
measurements of mood and vital signs. Bupropion (300 mg p.o.) or
placebo was administered at 8:00 AM.MDMA (125 mg p.o.) or placebo
was administered at 10:00 AM. A standardized lunch was served at
12:30 PM, and the subjects were sent home at 6:00 PM. On the day
after each test session, the participants returned to the research ward
at 10:00 AM for assessment of subjective and adverse effects and
collection of the 24-hour blood sample.
Drugs
6MDMA hydrochloride (C11H15NO2, Lipomed AG, Arlesheim,
Switzerland) was prepared as gelatin capsules (100 and 25 mg).
Identical-looking placebo (mannitol) capsules were prepared. MDMA
was administered in a single absolute dose of 125 mg, corresponding
to 1.8 6 0.2 mg/kg body weight (mean 6 S.D.). Bupropion tablets
[150 mg, Wellbutrin XR 150 mg (GlaxoSmithKline, Munchenbuchsee,
Switzerland) and mannitol as filler] were encapsulated within opaque
gelatin capsules, and identical placebo (mannitol pill with mannitol
filler) capsules were prepared. Bupropion was administered once
daily at a dose of 150 mg for 3 days, followed by administration of
300 mg of bupropion once daily for 4 days before the test days. A
similar regimen is used to initiate smoking cessation treatment with
bupropion. The subjects were reminded by a phone text message to
ingest the capsules in the morning, and medication containers were
checked to confirm that the first seven doses of bupropion were
administered. The last dose of bupropion (300 mg) was administered
onsite under supervision 2 hours before MDMA was administered.
Similar pretreatment regimens with bupropion produced 26% DA
transporter occupancy as measured by [11C]b-CIT-FE [N-(2-fluoroethyl)-
2b-carbomethoxy-3b-(4-iodophenyl)-nortropane] positron emission to-
mography 3 hours after the last dose of bupropion (Learned-Coughlin
et al., 2003) and reduced the subjective response tomethamphetamine in
humans (Newton et al., 2006).
Outcome Measures
Vital Signs. Blood pressure, heart rate, and core body tempera-
ture were assessed repeatedly 2 hours and 1 hour before and 0, 0.33,
0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, and 8 hours after MDMA or placebo
administration as previously described (Hysek and Liechti, 2012). The
cardiovascular measures were performed in duplicate after a resting
time of at least 10 minutes. The averages were calculated for the
analyses.
Pupillometry. Pupillometry was performed 2 hours and 1 hour
before and 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, and 8 hours after drug
administration. Pupil function was measured using a PRL-200 in-
frared pupillometer (NeurOptics, Irvine, CA) under dark-light con-
ditions of 6.1 6 1 lux as described previously (Hysek and Liechti,
2012). The dark-adapted pupil diameter was measured in both eyes,
and the average values were used for analyses.
Endocrine Measures. Plasma levels of prolactin and cortisol
were measured at baseline and 2 hours after MDMA or placebo ad-
ministration using radioimmunoassays (Hysek et al., 2012b). Plasma
levels of oxytocin were measured before and 1 hour and 2 hours after
administration of MDMA or placebo by radioimmunoassay (Neumann
et al., 2013). Concentrations of circulating catecholamines, including
epinephrine andNE, weremeasured at baseline and 1 hour and 2 hours
after administration of MDMA or placebo using ultra-performance
liquid chromatography–tandem mass spectrometry (Dunand et al.,
2013). Plasma epinephrine levels are mainly derived from the adrenal
medulla, whereas the entrance of NE into the plasma represents an
overflow by sympathetic nerves (Esler et al., 1990; Eisenhofer et al.,
1995). Circulating NE is therefore considered an indicator of sympa-
thetic system activation. DA in plasma does not derive from DA but
mostly from NE neurons (Goldstein and Holmes, 2008). Nevertheless,
we measured DA levels in plasma because there are no data on the
effects of MDMA on DA plasma levels.
Adverse Effects. Adverse effects were assessed using the 66-item
list of complaints (Zerssen, 1976) before and 5 and 24 hours after
MDMA or placebo administration. The scale yields a total adverse
effects score, reliably measuring physical and general discomfort.
Psychometric Scales. Subjective effects were repeatedly assessed
using previously described psychometric scales. Visual Analog Scales
(VASs; Hysek et al., 2011) were administered 2 hours and 1 hour before
and 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 24 hours after
administration of MDMA or placebo.
Pharmacokinetics. Blood samples for the determination ofMDMA,
MDA, HMMA, bupropion, hydroxybupropion, and hydrobupropion
were collected 2 hours before and 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and
24 hours after MDMA or placebo administration. PlasmaMDMA,MDA,
and HMMA concentrations were determined using high-performance
liquid chromatography–tandem mass spectrometry as described pre-
viously (Hysek et al., 2012a, 2013). Bupropion, hydroxybupropion, and
hydrobupropion were included into the analytical method, and slight
modifications were made. In brief, the chromolith speed ROD RP-18e
(50 ! 4.6 mm; Merck, Darmstadt, Germany) analytical column was
replaced by a Luna PFP (2) column (50 ! 2 mm; Phenomenex,
Torrance, CA), and bupropion, hydroxybupropion, and hydrobupropion
were added as additional analytes. Peak symmetry was improved by
online dilution of the samples with water supplemented with 0.1%
formic acid. Threohydrobupropion and erythrohydrobupropion were
quantified together as hydrobupropion because the isomeric metabo-
lites coeluted in chromatography and were indistinguishable in mass
spectrometry. The performance of the method was monitored using
quality-control samples at the lower limit of quantification (LLOQ) and
at two to four other concentrations that covered the entire calibration
range. The LLOQ values were 1 ng/ml for MDMA, MDA, HMMA, and
hydroxybupropion, 5 ng/ml for bupropion, and 0.1 ng/ml for hydro-
bupropion. The interassay precision was ,15% (LLOQ: 20%), and the
interassay accuracy ranged from 85% to 115% (LLOQ: 80%–120%) for
all the analytes.
Statistical and Pharmacokinetic Analyses
Peak effects (Emax) and peak changes from baseline (DEmax) were
determined for repeated measures. Emax and DEmax values were
analyzed by two-way repeated-measures analysis of variance, with
MDMA (MDMA versus placebo) and bupropion (bupropion versus
placebo) as within-subjects factors, using Statistica 12 software
(StatSoft, Tulsa, OK). Tukey’s post hoc comparisons were performed
based on significant main effects or interactions. The criterion for
significance was P, 0.05. Pharmacokinetic data were analyzed using
noncompartmentalmodels. Peak plasma concentration (Cmax) and the
time to reach maximal plasma concentration (Tmax) were obtained
directly from the observed concentration-time curves. For MDMA,
HMMA, and bupropion, the terminal elimination rate constant (lz)
was estimated by log-linear regression after semilogarithmic trans-
formation of the data using at least three data points of the terminal
linear phase of the concentration-time curve. The terminal elimination
half-life (t1/2) was calculated using lz and the equation t1/2 5 ln2/lz.
Determining the t1/2 values for MDA, hydroxybupropion, and hydro-
bupropionwas not possible because of their long t1/2, whichwould require
a longer sampling time. The area under the plasma concentration-time
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curve (AUC) and area under the effect-time curve (AUEC) were
calculated using the linear trapezoidal rule.
Results
Autonomic Effects. Peak effects and statistics are sum-
marized in Table 2. MDMA increased blood pressure, heart
rate, and body temperature (Fig. 1, A–D). Bupropion sig-
nificantly reduced the MDMA-induced increase in heart rate
(Fig. 1C), but it did not significantly affect the increases in
blood pressure (Fig. 1, A and B) or body temperature (Fig. 1D)
induced by MDMA. Bupropion did not alter the mydriatic
effect of MDMA on pupillary function (Table 2).
Endocrine Effects. MDMA increased plasma concentra-
tions of prolactin, cortisol, oxytocin, epinephrine, and NE
compared with placebo. Bupropion significantly reduced the
MDMA-induced increases in the plasma concentrations of NE
but not of other hormones (Table 2). Plasma levels of DA were
very low and in 75% of the measurements were below the
lower limit of detection (, 0.1 nM). None of the treatments
altered DA plasma concentrations.
Adverse Effects. The acute (up to 5 hours) and subacute
(up to 24 hours) adverse effects of MDMA were not altered by
bupropion (Table 2). Frequently reported acute adverse
effects of placebo–MDMA and bupropion–MDMA were lack
of appetite (n 5 13 for both), perspiration (n 5 11 and 12,
respectively), tremor (n5 8 and 11, respectively), restlessness
(n 5 10 and 7, respectively), dry mouth (n 5 14 and 12,
respectively), and bruxism (n5 13 for both). Subacute adverse
effects included headache (n 5 12 and 8, respectively), tired-
ness (n5 9 and 10, respectively), lack of appetite (n5 8 and 9,
respectively), difficulty concentrating (n 5 7 and 6, respec-
tively), dry mouth (n 5 5 and 9, respectively), and bruxism
(n 5 6 and 10, respectively). No severe adverse effects were
reported.
Subjective Effects. Peak effects and statistics are sum-
marized in Table 2. MDMA increased VAS ratings for “any
drug effect,” “good drug effect,” “drug high,” “drug liking,” and
“stimulated” (Fig. 2, A–E). Bupropion enhanced the positive
mood effects of MDMA, reflected by a significant increase in
AUEC values and a nonsignificant increase in maximal effect
ratings and in the bupropion–MDMA condition compared with
the placebo–MDMA condition for VAS scales ratings for “any
drug effect,” “good drug effect,” “drug high,” and “drug liking”
(Fig. 2, A–D; Table 2). MDMA-induced increases in “stimula-
tion” were not significantly altered by bupropion (Fig. 2E).
Pharmacokinetics. The drug andmetabolite concentration-
time curves are shown in Fig. 3. The pharmacokinetic pa-
rameters are shown in Table 3. Bupropion pretreatment
significantly increased the plasma concentration of MDMA
(Cmax, P , 0.01; AUC0–8, P , 0.001; AUC0–24, P , 0.001) and
prolonged its t1/2 (P, 0.01). In contrast, bupropion pretreatment
significantly decreased the plasma concentrations of MDA
(Cmax, P , 0.01; AUC0–8, P , 0.001) and HMMA (Cmax,
P , 0.001; AUC0–8, P , 0.001; AUC0–24, P , 0.001) and
prolonged the t1/2 and Tmax of HMMA (both P , 0.001). MDMA
significantly increased the plasma concentration of bupropion
(Cmax, P, 0.05; AUC0–8, P, 0.001; AUC0–24, P, 0.01). MDMA
Fig. 1. Bupropion reduced the MDMA-induced an increase in heart rate (C) compared with placebo–MDMA but not in the blood pressure (A and B) or
body temperature (D) response to MDMA. MDMA or placebo was administered at t = 0 hour. Data are expressed as mean 6 S.E.M. in 16 subjects.
*P , 0.05; ***P , 0.001 for significant differences in the maximal effects compared with placebo-placebo; ###P , 0.001 compared with placebo–MDMA.
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also slightly increased the Cmax of hydrobupropion (P , 0.05),
but it had no effect on the concentration of hydroxybupropion.
The MDMA concentration-effect plot (Fig. 4.) shows that
higher subjective effects were reached early during the drug
response in the bupropion–MDMA condition compared with
the placebo–MDMA condition at similar MDMA concentra-
tions consistent with a dynamic drug interaction. Thus,
bupropion did not reduce the MDMA response taking into
account any pharmacokinetic interactions.
Discussion
In the present study, bupropion reduced the heart rate
response to MDMA and prolonged its subjective effects. We
hypothesized that bupropion prevents the pharmacodynamic
effects of MDMA to the extent that these effects depend on DA
and NE release. Bupropion reduced the MDMA-induced
increases in circulating NE, which is a marker of sympathetic
system activation, and the cardiostimulant effects of MDMA
similarly to the selective NE transporter inhibitor reboxetine
(Hysek et al., 2011). The blockade of a- and b-adrenergic
receptors by carvedilol reduced the heart rate and blood
pressure response to MDMA (Hysek et al., 2012c). Together,
these findings indicate that NE mediates the cardiostimulant
effects of MDMA. In contrast, blocking the DA transporter
with bupropion did not reduce and actually prolonged the
positive mood effects of MDMA. Thus, DA does not appear to
be a critical mediator of the subjective effects of MDMA.
Otherwise, a reduction in the mood response would have been
expected. Methylphenidate, which inhibits the DA trans-
porter more potently than bupropion (Simmler et al., 2013b;
Heal et al., 2014), did not attenuate the subjective effects of
MDMA (Hysek et al., 2014). In contrast, several studies
showed that the subjective effects of MDMA in humans are
significantly reduced by 5-HT (Liechti et al., 2000; Farre et al.,
2007; Tancer and Johanson, 2007) and NE (Hysek et al., 2011)
transporter inhibition and almost completely blocked by dual
5-HT and NE transporter inhibition (Hysek et al., 2012d).
Additionally, bupropion did not alter adverse effects of MDMA,
in contrast to 5-HT (Liechti and Vollenweider, 2000) or 5-HT
and NE transporter inhibitors (Hysek et al., 2012d). These
clinicalmechanistic studies support the view that 5-HT andNE
are the primary mediators of the acute psychological effects of
MDMA, whereas DA appears to be less relevant. 5-HT receptor
agonists fully substituted for the discriminative stimulus
effects of MDMA in rats, but methamphetamine did not (Mori
et al., 2014). UnlikeMDMA,methamphetamine predominantly
acts on the DA system (Simmler et al., 2013a,b), and bupropion
reduced the subjective effects of methamphetamine (Newton
et al., 2006), consistent with a more important role for DA in
the action of methamphetamine.
How bupropion prolonged the subjective response to
MDMA in the present study is unclear. Bupropion has
previously been shown to similarly enhance the positive
subjective effects of cocaine (Oliveto et al., 2001). Bupropion
increased the plasma concentration of MDMA, and this
pharmacokinetic bupropion–MDMA interaction could partially
explain the enhanced psychotropic effects of MDMA induced by
bupropion. However, the concentration-effect relationship in-
dicated that bupropion also increased the subjective effects of
MDMA irrespective of its increasing effect on MDMA plasma
concentrations.
Fig. 2. Bupropion pretreatment enhanced the subjective mood effects of MDMA. The MDMA-induced area under the effect-concentration curves for
VAS scale ratings for (A) “any drug effect,” (B) “good drug effect,” (C) “drug high,” and (D) “drug liking,” but not (E) “stimulation,” were all significantly
greater after bupropion–MDMA compared with MDMA alone (#P , 0.05 compared with placebo–MDMA). MDMA or placebo was administered at
t = 0 hour. Values are expressed as mean 6 S.E.M. in 16 subjects. ***P , 0.001 compared with placebo–placebo.
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Bupropion increased the Cmax of MDMA by 15%, increased
the AUC0–24h of MDMA by 30%, and decreased the Cmax and
AUC0–24h of the MDMA metabolite HMMA by 75% and 66%,
respectively. Because MDMA is primarily metabolized to
HMMA by CYP2D6 (Segura et al., 2005; de la Torre et al.,
2012), the effects of bupropion on the pharmacokinetics of
MDMA and HMMA are explained by CYP2D6 inhibition.
Bupropion, and particularly erythro-hydrobuprion and threo-
hydrobupropion have previously been shown to inhibit
CYP2D6 (Jefferson et al., 2005; Kotlyar et al., 2005; Reese
TABLE 3
Pharmacokinetic parameters of MDMA and bupropion and metabolites
Values are mean 6 S.E.M. in 16 healthy subjects.
Cmax (ng/ml) AUC0–8 AUC0–24 t1/2 Tmax
ng/ml×h h
MDMA
Placebo–MDMA 231 6 14 1262 6 72 2576 6 156 7.4 6 0.4 2.5 6 0.2
Bupropion–MDMA 264 6 13** 1535 6 67*** 3428 6 144*** 9.2 6 0.7** 3.1 6 0.2
MDA
Placebo–MDMA 10.3 6 0.5 59.2 6 3.1 170 6 11 6.1 6 0.3
Bupropion–MDMA 8.8 6 0.5** 46.8 6 2.7*** 149 6 8.5 6.8 6 0.3
HMMA
Placebo–MDMA 123 6 22 711.2 6 99 1482 6 247 8.5 6 0.5 3.5 6 0.3
Bupropion–MDMA 29.6 6 3.3*** 169 6 18*** 492 6 54*** 15.1 6 1.1*** 6.0 6 0.3***
Bupropion
Bupropion–placebo 93.2 6 7.5 486 6 36 1030 6 69 10.3 6 0.9 5.1 6 0.5
Bupropion–MDMA 110 6 8.3# 615 6 40### 1313 6 84## 8.7 6 0.8 5.8 6 0.4
Hydroxybupropion
Hydroxybupropion–placebo 748 6 63 4976 6 337 14490 6 1273 7.3 6 0.6
Hydroxybupropion–MDMA 793 6 62 5613 6 486 16056 6 1336 7.1 6 0.6
Hydrobupropion
Hydrobupropion–placebo 37.4 6 2.1 267 6 18 769 6 51 7.0 6 0.6
Hydrobupropion–MDMA 40.9 6 2.0# 287 6 17 822 6 47 7.7 6 0.5
**P , 0.01; ***P , 0.001 compared with placebo–MDMA; #P , 0.05; ##P , 0.01; ###P , 0.001 compared with bupropion–placebo.
Fig. 3. Plasma concentration-time profiles. (A) Bupropion significantly increased the plasma concentration of MDMA (Cmax, AUC0–8, and AUC0–24) and
(B) significantly decreased the plasma concentrations of the MDMA metabolites MDA (Cmax and AUC0-8) and HMMA (C) (Cmax, AUC0–8, and AUC0–24).
(D) MDMA significantly increased the plasma concentrations of bupropion (Cmax, AUC0–8, and AUC0–24) and hydrobupropion (F) (Cmax) but had no
significant effect on hydroxybupropion concentration (E). The pharmacokinetic parameters are shown in Table 2. MDMA or placebo was administered at
t = 0 hour, and the last pretreatment administration of bupropion occurred at t = 22 hours. Values are expressed as mean 6 S.E.M. in 16 subjects.
**P, 0.01 and ***P, 0.001 indicate significant differences between placebo–MDMA and bupropion–MDMA. #P, 0.05 indicates significant difference
between bupropion-placebo and bupropion–MDMA.
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et al., 2008). Other CYP2D6 inhibitors, including paroxetine,
reboxetine, and duloxetine (Farre et al., 2007; Hysek et al.,
2011, 2012d), also increased the plasma levels of MDMA and
lowered HMMA concentrations (Farre et al., 2007; Hysek
et al., 2012d) to an extent similar to that of bupropion in the
present study. Interestingly, bupropion also decreased plasma
levels of MDA in the present study. Pure CYP2D6 inhibition
would shift MDMA metabolism from HMMA formation to
MDA formation, resulting in higher plasma MDA levels as
previously reported after reboxetine or duloxetine pretreat-
ment (Hysek et al., 2011, 2012d). Thus, in the present study,
the minor metabolic pathway of MDMA to MDA by CYP2B6,
CYP3A4, and CYP1A2 (Kreth et al., 2000) was also inhibited,
possibly via competitive CYP2B6 inhibition by bupropion
(Hesse et al., 2000).
MDMA also altered the pharmacokinetics of bupropion.
Specifically, MDMA increased the Cmax of bupropion by 18%
and AUC0–24 by 27%, together with slight increases in hydro-
bupropion and hydroxybupropion. Hydrobupropion is formed by
nonmicrosomal carbonyl reductase, and hydroxybupropion is
formed by CYP2B6 (Hesse et al., 2000; Jefferson et al., 2005).
How MDMA increased the plasma levels of bupropion and its
metabolites is unclear. CYP2B6 inhibition by MDMA could
explain the increase in plasma concentration of bupropion, but
a decrease in hydroxybupropion would be expected. The effects
of MDMA on the pharmacokinetics of bupropion could be
clinically relevant because MDMA enhanced the exposure to
bupropion and its metabolites, and all the metabolites of
bupropion are also pharmacologically active (Damaj et al.,
2004; Jefferson et al., 2005; Zhu et al., 2012).
The present study had a few limitations. First, only one dose
regimen for bupropion and one single, relatively high dose of
MDMA were used. Second, bupropion treatment produced DA
transporter occupancy in the human striatum of only 26%
(Learned-Coughlin et al., 2003). This occupancy may not have
been sufficient to prevent MDMA from interacting with the DA
transporter. It was important, however, to use a DA transporter
inhibitor with no psychoactive effects, as shown for bupropion in
the present study and previously (Peck and Hamilton, 1983;
Oliveto et al., 2001) and in contrast to methylphenidate (Hysek
et al., 2014; Schmid et al., 2014). Third, both MDMA and
bupropion exhibit stereoselective metabolism (Kharasch et al.,
2008; Steuer et al., 2014). The analytical method used in the
present study was not stereoselective. The analytical methods
are currently being developed to further address interactions
between MDMA and bupropion enantiomers.
In conclusion, bupropion–MDMA coadministration resulted
in prolonged positive mood effects but lower cardiostimulant
effects than MDMA alone. Bupropion increased the plasma
concentration of MDMA and vice versa. These findings indicate
that NE contributes to the cardiovascular effects of MDMA,
with no evidence that DA mediates the subjective effects of
MDMA.
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a b s t r a c t
Psychoactive b-keto amphetamines (cathinones) are sold as “bath salts” or “legal highs” and recrea-
tionally abused. We characterized the pharmacology of a new series of cathinones, including methe-
drone, 4-methylethcathinone (4-MEC), 3-fluoromethcathinone (3-FMC), pentylone, ethcathinone,
buphedrone, pentedrone, and N,N-dimethylcathinone. We investigated norepinephrine (NE), dopamine
(DA), and serotonin (5-HT) uptake inhibition using human embryonic kidney 293 (HEK 293) cells that
express the respective human monoamine transporter, the drug-induced efflux of NE, DA, and 5-HT from
monoamine-preloaded cells, and binding affinity to monoamine transporters and receptors. All of the
cathinones were potent NE uptake inhibitors but differed in their DA vs. 5-HT transporter inhibition
profiles and monoamine release effects. Methedrone was a more potent 5-HT than DA transporter in-
hibitor and released NE and 5-HT similar to para-methoxymethamphetamine (PMMA), para-
methoxyamphetamine (PMA), 4-methylthioamphetamine (4-MTA), and 3,4-
methylenedioxymethamphetamine (MDMA). 4-MEC and pentylone equipotently inhibited all of the
monoamine transporters and released 5-HT. Ethcathinone and 3-FMC inhibited NE and DA uptake and
released NE, and 3-FMC also released DA similar to N-ethylamphetamine and methamphetamine.
Pentedrone and N,N-dimethylcathinone were non-releasing NE and DA uptake inhibitors as previously
shown for pyrovalerone cathinones. Buphedrone preferentially inhibited NE and DA uptake and also
released NE. None of the cathinones bound to rodent trace amine-associated receptor 1, in contrast to the
non-b-keto-amphetamines. None of the cathinones exhibited relevant binding to other monoamine
receptors. In summary, we found considerable differences in the monoamine transporter interaction
profiles among different cathinones and compared with related amphetamines.
! 2013 Elsevier Ltd. All rights reserved.
1. Introduction
The illicit stimulant market has become complex. From 2005 to
2011, 34 novel cathinone-type designer drugs have been detected
in the European Union (EMCDDA, 2013). These drugs are typically
available online as “legal highs,” “bath salts,” or “research chem-
icals” (EMCDDA, 2013) and have been added to users’ club drug
repertoires (Moore et al., 2013), resulting in unknown health risks.
Intoxicationwith different cathinone derivatives has been reported
worldwide (Borek and Holstege, 2012; James et al., 2011; Prosser
and Nelson, 2012; Zuba et al., 2013). Structurally, the novel
designer cathinones are all substituted amphetamines, but their
pharmacology and toxicology show considerable variability (Dal
Cason et al., 1997; Simmler et al., 2013) and are not known in
many cases. Recent studies characterized the in vitro pharmaco-
logical profiles of cathinones, including ethylone, mephedrone,
naphyrone, butylone, methylone, flephedrone, cathinone, meth-
cathinone, pyrovalerone, and 3,4-methylenedioxypyrovalerone
(MDPV; Baumann et al., 2013; Eshleman et al., 2013; Iversen
et al., 2013; Lopez-Arnau et al., 2012; Simmler et al., 2013). These
preclinical studies allow comparisons of the pharmacological
mechanisms of action of novel designer drugs with well-known
amphetamines, including methamphetamine and 3,4-
methylenedioxymethamphetamine (MDMA).
Abbreviations: DA, dopamine; DAT, dopamine transporter; HEK, human em-
bryonic kidney; 5-HT, 5-hydroxytryptamine (serotonin); MDMA, 3,4-
methylenedioxymethamphetamine; MDPV, 3,4-methylenedioxypyrovalerone; 4-
MTA, 4-methylthioamphetamine; NE, norepinephrine; NET, norepinephrine trans-
porter; PMA, para-methoxyamphetamine; PMMA, para-methoxymethamphet-
amine; SERT, serotonin transporter; TAAR, trace amine-associated receptor.
* Corresponding author. Tel.: þ41 61 328 68 68; fax: þ41 61 265 45 60.
E-mail address: matthias.liechti@usb.ch (M.E. Liechti).
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Several novel cathinones with unknown pharmacological
characteristics have emerged. Methedrone is the b-keto-
substituted analog of para-methoxymethamphetamine (PMMA).
PMMA and para-methoxyamphetamine (PMA) are para-ring-
substituted amphetamine derivatives sold as Ecstasy, alone or in
combination with MDMA (Brunt et al., 2012). PMA and PMMA
epidemics have been described worldwide for many years
(Johansen et al., 2003; Lurie et al., 2012; Vevelstad et al., 2012). PMA
and PMMA use has been associated with high morbidity and
mortality particularly attributable to hyperthermia (Brunt et al.,
2012; Lurie et al., 2012; Refstad, 2003). Methedrone is found in
bath salt products (Marinetti and Antonides, 2013), and it may be
associated with a high risk for mortality (Wikstrom et al., 2010),
similar to PMA. PMA inhibits the serotonin (5-hydroxytrypatmine
[5-HT]) uptake transporter (SERT) and induces 5-HT release
(Callaghan et al., 2005) like MDMA. In animals, PMMA and PMA
produce effects similar toMDMA, but they aremore potent and lack
amphetamine-like stimulant effects in rodent drug discrimination
studies (Dukat et al., 2002; Glennon et al., 2007). Pharmacological
data on methedrone are unavailable. 4-Methylthioamphetamine
(4-MTA) is the methylthio analog of PMA and also a SERT inhibi-
tor (Huang et al., 1992) and 5-HT releaser (Gobbi et al., 2008; Huang
et al., 1992). 4-MTA produces MDMA-like effects in animals and
humans (Winstock et al., 2002) and is typically used by Ecstasy
users (Winstock et al., 2002). Fatalities possibly linked to 5-HT
syndrome have been described (De Letter et al., 2001).
4-Methylethcathinone (4-MEC) is reported to be available over
the Internet as “NRG-2” (Brandt et al., 2010) and is a substitute for
mephedrone (Zuba and Byrska, 2013). 4-MEC inhibits the dopa-
mine (DA) and norepinephrine (NE) transporters (DAT and NET)
and SERT (Iversen et al., 2013). Whether 4-MEC is also a mono-
amine releaser is currently unknown.
3-Fluoromethcathinone (3-FMC) has been detected in legal
highs (Archer, 2009). 3-FMC was shown to have pronounced lo-
comotor stimulant and ataxic effects in mice (Marusich et al., 2012),
but its pharmacological profile is currently unknown. The phar-
macology of its structural isomer 4-fluoromethcathinone (flephe-
drone) has recently been described (Eshleman et al., 2013; Simmler
et al., 2013).
Ethcathinone was detected in a patient who presented with
severe hyponatremia and seizures (Boulanger-Gobeil et al., 2012).
Ethcathinone is the b-keto analog of N-ethylamphetamine, which is
similar to methamphetamine but contains an N-ethyl-group. Eth-
cathinone is a rat NET, DAT, and SERT inhibitor and also releases NE
and 5-HT but not DA from rat synaptosomes (Yu et al., 2000). N-
Ethylamphetamine releases NE and also released 5-HT and DAwith
lower potency from rat synaptosomes (Tessel and Rutledge, 1976).
We found no data on the effects of ethcathinone on human
monoamine transporters.
Pentedrone, buphedrone, and pentylone are recently identified
novel designer cathinones (Maheux and Copeland, 2012; Westphal
et al., 2012; Zuba and Byrska, 2013). Buphedrone was detected in
“Vanilla Sky” and other “legal high” pills as a frequent substitute for
mephedrone in eastern Europe (Zuba et al., 2013). Intoxicationwith
buphedrone and its recreational use have recently been described
(Zuba et al., 2013). Pentylone has been detected in “legal high”
samples from the Internet (Brandt et al., 2011) and head shops
(Westphal et al., 2012), and fatalities associated with “bath salts”
have been reported in the United States (Marinetti and Antonides,
2013). Buphedrone and pentedrone are the a-ethyl and a-pentyl b-
keto analogs of methamphetamine, respectively. Pentedrone is
structurally identical to pentylone but without the MDMA-like 3,4-
methylenedioxy group (Fig. 1). Pentylone is a b-keto-analog of
MDMA, similar to methylone and butylone (Simmler et al., 2013),
and contains an a-pentyl group. N,N-dimethylcathinone is the N-
methylated b-keto analog of methamphetamine, and it has similar
but less potent stimulant effects (Dal Cason et al., 1997). We found
no data on the molecular pharmacology of pentylone, pentedrone,
buphedrone, or N,N-dimethylcathinone.
In the present study, we characterized the in vitro pharmacology
of a novel series of cathinones, including methedrone, 4-MEC, 3-
FMC, pentylone, ethcathinone, buphedrone, pentedrone, and N,N-
dimethylcathinone, and the profiles of the non-b-keto amphet-
amine analog comparator drugs 4-MTA, PMA, PMMA, MDMA, N-
ethylamphetamine, and methamphetamine, complementing our
previous characterization of this class of designer drugs (Simmler
et al., 2013). As amphetamine derivatives, these drugs were ex-
pected to interact predominantly with monoamine transporters
and receptors. We determined the potencies of the drugs to inhibit
the human NET, DAT, and SERT. We tested whether the drugs
induce the transporter-mediated release of NE, DA, and 5-HT and
characterized the binding affinities of the drugs for monoamine
transporters, a1 and a2 adrenergic receptors, dopamine D1eD3 re-
ceptors, 5-HT1A, 5-HT2A, and 5-HT2C receptors, the histamine H1
receptor, and the trace amine-associated receptor 1 (TAAR1).
2. Methods
2.1. Drugs
The drugs were supplied by Lipomed (Arlesheim, Switzerland) or Cayman
chemicals (Ann Arbor, MI, USA) as hydrochloride salts (purity > 98.5%). Racemic
drugs were used, with the exception of D-methamphetamine. All of the radioligands
were obtained from Perkin Elmer (Schwerzenbach, Switzerland) or Anawa (Wangen,
Switzerland), with the exception of [3H]RO5166017, which was synthesized at Roche
(Basel, Switzerland).
2.2. Monoamine uptake transporter inhibition
The inhibition of the NET, SERT, and DAT was assessed in human embryonic
kidney 293 (HEK 293) cells that stably expressed the human NET, SERT, and DAT
(Tatsumi et al., 1997) as previously described in detail (Hysek et al., 2012). Cultured
cells were detached and resuspended in uptake buffer. We incubated the cells with
various concentrations of the test compounds and the vehicle control for 10min and
then added [3H]DA, [3H]NE, and [3H]5-HT (5 nM final concentrations) to initiate the
uptake transport of the labeled monoamines at room temperature. Uptake was
stopped after 10 min, and the cells were separated from the buffer by brief centri-
fugation through silicone oil (Hysek et al., 2012). Centrifugation tubes were frozen in
liquid nitrogen and cut to separate the cell pellet from the silicon oil and the assay
buffer layers. The cell pellet was lysed. Scintillation fluid was added, and radioac-
tivity was counted on a beta-counter. Nonspecific uptake was determined for each
experiment in the presence of 10 mM fluoxetine for SERT cells, 10 mM nisoxetine for
NET cells, and 10 mMmazindol for DAT cells and subtracted from the total counts to
yield specific uptake (100%). Nonspecific uptake was <10% of total uptake. The data
were fit by nonlinear regression to variable-slope sigmoidal doseeresponse curves,
and IC50 values were calculated using Prism (GraphPad, San Diego, CA). DAT/SERT
ratios were calculated as 1/DAT IC50: 1/SERT IC50.
2.3. Transporter-mediated monoamine release
We studied transporter-mediated NE, 5-HT, and DA efflux in HEK 293 cells
that overexpressed the respective human monoamine transporter as previously
reported in detail (Simmler et al., 2013). Briefly, we preloaded the cells by
incubating HEK-SERT cells with 10 nM [3H]5-HT, HEK-DAT cells with 10 nM [3H]
DA and 1 mM unlabeled DA, and HEK-NET cells with 10 nM [3H]NE and 10 mM
unlabeled NE for 20 min. The cells were then washed twice, and release was
induced by adding 1000 ml of release buffer that contained the test drugs at
concentrations of 100 mM, with the exception of 4-MTA at the NET for which
10 mM was used. We incubated the HEK-SERT and HEK-DAT cells for 15 min and
the HEK-NET cells for 45 min at 37 "C by shaking at 300 rotations per minute on a
rotary shaker. The release times were based on kinetic evaluation of the release-
over-time curves for MDMA and methamphetamine. After 15 min for [3H]5-HT
and [3H]DA and 45 min for [3H]NE, a sufficient amount of radioactivity was
released to allow for comparisons with the control conditions. We then stopped
release by removing the buffer and gently washing the cells twice with cold
buffer. We quantified the radioactivity that remained in the cells. Nonspecific
“pseudo-efflux,” which arises from substrate that diffuses out of the cells and
reuptake inhibition (Rosenauer et al., 2013; Scholze et al., 2000), was assessed
using the transporter inhibitors nisoxetine (HEK-NET cells), citalopram (HEK-
SERT cells), and mazindol (HEK-DAT cells) at 10 mM. Thus, these uptake inhibitors
served as negative control conditions. Methamphetamine and MDMA were used
as comparator compounds that are known to induce monoamine release in this
L.D. Simmler et al. / Neuropharmacology 79 (2014) 152e160 153
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assay (positive control in each experiment; Simmler et al., 2013). All of the
conditions were normalized to radioactive counts of the assay buffer control
condition. We then used analysis of variance followed by Dunnett’s test to
compare the effects of the drug with the negative control condition (i.e., the
activity of the transport inhibitors nisoxetine, citalopram, and mazindol is
considered nonspecific release). Drugs that induced significantly higher maximal
monoamine efflux compared with the respective transporter inhibitors, which
induced slight nonspecific release, were considered monoamine releasers. The
assays allow qualitative classification of a drug as a releaser or non-releaser but
not quantitative comparisons between transporters.
Fig. 1. Monoamine uptake inhibition presented as doseeresponse curves for the inhibition of [3H]NE, [3H]DA, and [3H]5-HT into NET-, DAT-, and SERT-transfected HEK 293 cells,
respectively. The data are expressed as the mean # SEM of 3e5 independent experiments. The lines show the data fit by nonlinear regression. IC50 values are shown in Table 2. The
radioactivity in the cells (100%) amounted to 3718 # 240 dpm for NE, 7200 # 993 dpm for DA, and 8191 # 1068 dpm for 5-HT (mean # SEM, n ¼ 42).
Table 1
Monoamine transporter inhibition.
NET DAT SERT DAT/SERT ratio
IC50 [mM] (95% CI) IC50 [mM] (95% CI) IC50 [mM] (95% CI) Ratio (95% CI)
4-MTAa 1.52 (1.3e1.9) 22 (15e32) 0.54 (0.37e0.80) 0.02 (0.01e0.05)
PMAa 0.80 (0.50e1.0) 71 (60e83) 2.37 (2.0e2.9) 0.03 (0.02e0.05)
PMMAa 1.20 (0.75e1.8) 49 (18e135) 1.77 (1.1e2.9) 0.04 (0.01e0.16)
MDMAa,b 0.45 (0.33e0.60) 17 (12e24) 1.36 (1.0e2.0) 0.08 (0.04e0.16)
Methedrone 2.24 (1.4e3.5) 35 (15e79) 4.73 (3.2e6.9) 0.14 (0.04e0.46)
N-Ethylamphetaminea 0.20 (0.15e0.27) 5.86 (4.8e7.1) 8.77 (6e13) 1.5 (0.9e2.7)
4-MEC 2.23 (1.6e3.2) 4.28 (3.4e5.4) 7.93 (3.5e18) 1.85 (0.6e5.3)
Pentylone 0.99 (0.72e1.4) 1.34 (1.0e1.7) 8.37 (5.4e13) 6.2 (3.2e13)
Ethcathinone 0.44 (0.34e0.56) 5.00 (3.7e6.8) 48 (4e529) 9.6 (0.6e142)
Methamphetaminea,b 0.064 (0.04e0.09) 1.05 (0.74e1.5) 23 (14e40) >10
3-FMC 0.19 (0.13e0.29) 1.7 (1.0e3.0) 56 (7e472) >10
Buphedrone 0.65 (0.51e0.81) 4.24 (3.3e5.5) 70 (2e2700) >10
Pentedrone 0.61 (0.52e0.72) 2.50 (2.0e3.2) 135 (5e3700) >10
N,N-Dimethylcathinone 7.71 (5e12) 27 (21e36) >500 >10
Values are means of three to five independent experiments and 95% confidence intervals (CI).
Drugs are ranked according to the DAT/SERT ratio ¼ 1/DAT IC50: 1/SERT IC50.
a Non-beta-keto-amphetamine comparator compounds.
b Values from Simmler et al. (2013).
L.D. Simmler et al. / Neuropharmacology 79 (2014) 152e160154
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Fig. 2. Qualitative assessment of monoamine release. HEK 293 cells that expressed NET, DAT, and SERT were loaded with [3H]NE, [3H]DA, and [3H]5-HT, respectively, washed, and
incubated with drugs. Monoamine release is expressed as the percent drug-induced reduction of monoamine cell content compared with DMSO vehicle (0% release, 100% activity in
the cells). The radioactivity in the cells (0% release) amounted to 736 # 24 dpm for NE, 2191 # 66 dpm for DA, and 2872 # 98 dpm for 5-HT (mean # SEM, n ¼ 18). 100% release
would indicate that all monoamine was released from the cells (0% remaining activity in the cells). Non-releasing monoamine transporter blockers induce nonspecific “pseudo-
efflux” (dashed line), which arises from substrate that diffuses out of the cells and reuptake inhibition. High concentrations of the test drugs were used (100 mM, except for 4-MTA at
the NET [10 mM]). The assays allow the qualitative classification of a drug as a releaser or non-releaser but not quantitative comparisons between transporters. The data are
expressed as the mean # SEM of 3e4 independent experiments (3e7 experiments for MDMA and methamphetamine) with negative controls added in each experiment. Statis-
tically, total release of the test drugs was compared with the nonspecific effects of the negative control drugs (nisoxetine for NE, mazindol for DA, and citalopram for 5-HT) using
analysis of variance followed by Dunnett’s test. *p < 0.05, **p < 0.01, and ***p < 0.001, significant effects compared with controls.
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2.4. Radioligand binding assays
The radioligand binding assays were performed as described previously (Hysek
et al., 2012; Revel et al., 2011; Simmler et al., 2013). Briefly, membrane preparations
of HEK 293 cells (Invitrogen, Zug, Switzerland) that overexpress the respective
transporters (Tatsumi et al., 1997) or receptors (human genes except for TAAR1 re-
ceptors that were rat/mouse; Revel et al., 2011) were incubated with the radio-
labeled selective ligands at concentrations equal to Kd, and ligand displacement by
the compounds was measured. Specific binding of the radioligand to the target re-
ceptor was defined as the difference between the total binding and nonspecific
binding determined in the presence of selected competitors in excess. The following
radioligands and competitors, respectively, were used: N-methyl-[3H]-nisoxetine
and indatraline (NET), [3H]citalopram and indatraline (SERT), [3H]WIN35,428 and
indatraline (DAT), [3H]8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and
indatraline (5-HT1A receptor), [3H]ketanserin and spiperone (5-HT2A receptor), [3H]
mesulergine and mianserin (5-HT2C receptor), [3H]prazosin and risperidone (a1
adrenergic receptor), [3H]rauwolscine and phentolamine (a2 adrenergic receptor),
[3H]SCH 23390 and butaclamol (DA D1 receptor), [3H]spiperone and spiperone (DA
D2 and D3 receptors), [3H]pyrilamine and clozapine (histaminergic H1 receptor), and
[3H]RO5166017 and RO5166017 (TAAR1). IC50 values were determined by calculating
nonlinear regression curves for a one-site model using three to five independent 10-
point concentrationeresponse curves for each compound. Ki (affinity) values, which
correspond to the dissociation constants, were determined using the ChengePrusoff
equation.
3. Results
3.1. Monoamine uptake transporter inhibition
The effects of the cathinones and comparator drugs on mono-
amine transporter function are presented in Fig. 1. The corre-
sponding IC50 values for monoamine transport inhibition and DAT/
SERT inhibition ratios are shown in Table 1. With the exception of
N,N-dimethylcathinone, which was a weak NET and DAT inhibitor,
all of the compounds shared potent effects as NET inhibitors,
whereas their DAT and SERT inhibition potencies varied consider-
ably, reflected by the wide range of DAT/SERT inhibition ratios. The
para-ring-substituted compounds, including 4-MTA, PMA, PMMA,
and methedrone, were potent SERT and NET inhibitors but weak
DAT inhibitors, similar to MDMA. The DAT/SERT ratio was <0.5 for
all of these MDMA-like drugs. Additionally, methedrone was the
only cathinone in the present series of drugs with an MDMA-like
profile and DAT/SERT ratio <1. Generally, with the exception of
methedrone, all of the cathinones examined in this series prefer-
entially inhibited the NET and DAT more than the SERT. 3-FMC,
pentedrone, buphedrone, and N,N-dimethylcathinone exhibited
very low potency at the SERT, and the DAT/SERT inhibition ratios
were all >10. Ethcathinone was 10-fold less potent at the SERT vs.
the DAT, whereas its non-b-keto analog ethylamphetamine was
equipotent at the DATand SERT, confirming that the addition of a b-
keto group enhanced the DAT inhibitory properties over SERT
inhibitory properties (Simmler et al., 2013). In contrast, ring sub-
stitutions enhanced serotonergic properties. 4-MEC, the 4-ring-
methylated analog of ethcathinone, was 6-fold more potent at the
SERT than ethcathinone. Similarly, the 3,4-ring methoxylated
analog of pentedrone, pentylone, was at least 10-fold more potent
at the SERT than pentedrone.
3.2. Transporter-mediated monoamine release
The drug effects on the transporter-mediated release of NE, DA,
and 5-HT from transmitter-preloaded cells are depicted in Fig. 2. By
means of this quantitative assessment at high drug concentrations,
we identified whether the drugs induce specific NE, DA, and 5-HT
release compared with the non-releasing controls nisoxetine,
mazindol, and citalopram. All of the non-b-keto amphetamines and
most of the cathinones tested in this series induced the release of at
least one monoamine. Pentedrone and N,N-dimethylcathinone did
not induce monoamine release and thus were pure uptake
inhibitors. Methedrone and 3-FMC released all three monoamines
similarly to all of the non-b-keto amphetamines methamphet-
amine, MDMA, PMMA, PMA, and N-ethylamphetamine. In contrast,
ethcathinone and 4-MTA released NE and 5-HT but had no effect on
DA release. 4-MEC and pentylone weakly released 5-HT but not DA
or NE, whereas buphedrone released NE but not DA or 5-HT.
3.3. Binding affinities
Table 2 shows the binding profiles of the test drugs expressed as
the potencies of the drugs (Ki) to inhibit radioligand binding to the
NET, DAT, and SERT and different monoamine receptors. Impor-
tantly, none of the drugs exhibited very high affinity (<100 nM) for
any of the monoamine transporters or human receptors. Sub-
micromolar affinity (<1 mM) DAT interactions were found with the
cathinones 4-MEC, pentylone, ethcathinone, and pentedrone but
not non-b-keto amphetamines. Conversely, the non-b-keto am-
phetamines but not the cathinones showed affinity for the rat and
mouse TAAR1. Some of the test drugs showed relevant binding
(<10 mM) to 5-HT1A receptors (ethcathinone, N-ethylamphetamine,
and methamphetamine), 5-HT2A receptors (4-MEC, N,N-dime-
thylcathinone, 4-MTA, and MDMA), 5-HT2C receptors (4-MEC, 3-
FMC, N,N-dimethylcathinone, 4-MTA, and N-ethylamphetamine),
and a2 receptors (4-MTA, N-ethylamphetamine, and metham-
phetamine). None of the drugs tested bound to DA D1eD3 or his-
tamine H1 receptors.
The pure uptake inhibitors and releasers typically differed with
regard to their Ki:IC50 ratio. Most of the releasers showed higher
functional potency compared with binding potency, resulting in
ratios >6 for the NET and >1 for the DAT and SERT, with some
exceptions for drugs that released monoamines only at high drug
concentrations (>10 mM).
4. Discussion
We characterized the monoamine receptor binding profiles and
interactions with monoamine transporters of a series of seven
novel designer cathinones that are components of “bath salts” or
“legal highs.” The pharmacological profiles of the seven cathinone
derivatives were compared with their non-b-keto analogs or
related non-b-keto-substituted amphetamines. All of the cath-
inones inhibited monoamine transport as expected based on their
amphetamine structure. However, considerable differences were
found among these cathinones and compared with the non-b-keto
amphetamines, similar to other cathinone derivatives (Baumann
et al., 2013; Eshleman et al., 2013; Iversen et al., 2013; Rosenauer
et al., 2013; Simmler et al., 2013).
First, the compounds markedly differed with regard to their
serotoninergic vs. dopaminergic properties as expressed by DAT/
SERT ratios. A low DAT/SERT ratio may be associated with a lower
abuse potential of a drug (Baumann et al., 2011; Rothman and
Baumann, 2006; Simmler et al., 2013; Wee et al., 2005), although
lipophilicity, bloodebrain barrier transport (Simmler et al., 2013),
and pharmacokinetic factors are also involved. Second, some
cathinones were pure uptake inhibitors, whereas others were
substrate releasers. Third, the cathinones typically did not bind to
rodent TAAR1, in contrast to the non-b-keto-amphetamines.
4.1. Methedrone is a serotonergic cathinone comparable to para-
(4)-substituted amphetamines and MDMA
Methedrone was the cathinone with the highest selectivity for
the SERT in both the present and our previously studied series of
compounds (Simmler et al., 2013) and also induced monoamine
efflux, exhibiting a profile identical to MDMA. Methedrone,
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therefore, is the most MDMA-like cathinone in terms of the
monoamine transporter interaction profile. Both methedrone and
PMMA are para-methoxy- or methylthio-amphetamines, similar
to PMA and 4-MTA. PMA, PMMA, and 4-MTA have long been
associated with particularly high clinical toxicity and many fatal-
ities mostly attributable to 5-HT syndrome, hyperthermia, and
associated multi-organ failure (De Letter et al., 2001; Johansen
et al., 2003; Lurie et al., 2012; Vevelstad et al., 2012). Similarly,
fatal methedrone intoxication was recently described (Wikstrom
et al., 2010). The present study showed that all of these para-
substituted amphetamines are potent NET and SERT inhibitors
with low potency at the DAT, as previously shown for 4-MTA
(Huang et al., 1992) and 4-trifluoromethylmethcathinone (Cozzi
et al., 2013). These drugs released NE and 5-HT and at high con-
centrations (>10 mM) also released DA, as previously shown for 4-
MTA, PMA, and 4-trifluoromethylmethcathinone in vitro and
in vivo (Cozzi et al., 2013; Gobbi et al., 2008; Gough et al., 2002;
Huang et al., 1992; Quinn et al., 2006; Sotomayor-Zarate et al.,
2012). Importantly, the in vivo hyperthermic properties of the
para-substituted amphetamines are stronger than those of MDMA
(Daws et al., 2000) and have been associated with serotonergic
and adrenergic receptor activation (Carmo et al., 2003). Therefore,
hyperthermic complications should be of particular concernwhen
these or similar para-substituted serotonergic cathinones are used
recreationally.
4.2. 4-MEC and pentylone are equipotent DAT and SERT inhibitors
and also release 5-HT
All of the cathinones, with the exception of methedrone, were
more potent at the catecholamine transporters comparedwith the
SERT. 4-MEC and pentylone inhibited all of the monoamine
transporters with approximately equal potency that was similar to
cocaine but also released 5-HT similar to MDMA. 4-MEC and
pentylone are cathinones with profiles that are very similar to
ethylone, butylone, and methylone (Simmler et al., 2013). 4-MEC,
pentylone, and butylone (Simmler et al., 2013) released only 5-HT
and not DA, differentiating them from the popular cathinone de-
rivative mephedrone, which releases both 5-HT and DA in vitro
(Hadlock et al., 2011; Simmler et al., 2013) and in vivo (Baumann
et al., 2012; Kehr et al., 2011). The release of 5-HT by 4-MEC and
pentylone may reduce the stimulant-like and addictive properties
compared with mephedrone (Bauer et al., 2013). The monoamine
uptake transporter inhibition profile for 4-MEC described in the
present study is consistent with a previous report (Iversen et al.,
2013), but no data are available for pentylone.
4.3. Ethcathinone and 3-FMC are methamphetamine-like
cathinones
Ethcathinone was a weaker SERT inhibitor than its non-b-keto
analog N-ethylamphetamine, confirming that cathinones are
more potent inhibitors of the NET and DAT than the SERT
compared with their non-b-keto amphetamine analogs (Iversen
et al., 2013; Simmler et al., 2013). Ethcathinone and 3-FMC
exhibited monoamine uptake transporter inhibition profiles that
were similar to methamphetamine and flephedrone (Simmler
et al., 2013). Additionally, ethcathinone released NE and 5-HT
but not DA, as shown in previous studies using rat synapto-
somes (Yu et al., 2000), and 3-FMC released all monoamines.
Similar DA and 5-HT release has been documented for flephe-
drone, the positional isomer of 3-FMC (Simmler et al., 2013).
Ethcathinone and 3-FMC can be classified as methamphetamine-
like cathinones (Simmler et al., 2013), although ethcathinone did
not release DA. Ta
bl
e
2
M
on
oa
m
in
e
tr
an
sp
or
te
r
an
d
re
ce
pt
or
bi
nd
in
g
af
fi
ni
ti
es
.
N
ET
D
A
T
SE
RT
5-
H
T 1
A
5-
H
T 2
A
5-
H
T 2
C
a 1
A
a 2
A
D
1
D
2
D
3
H
1
TA
A
R 1
ra
t
TA
A
R 1
m
ou
se
4-
M
TA
a
2.
2
#
1.
3
6.
7
#
1.
8
1.
3
#
0.
2
>
18
1.
5
#
0.
4
1.
8
#
1.
0
>
6
7.
4
#
1.
0
>
12
.5
>
10
>
16
>
13
0.
28
#
0.
04
0.
04
#
0.
01
PM
A
a
28
.2
#
12
.2
18
.5
#
3.
9
7.
1
#
0.
8
>
20
11
.2
#
2.
1
>
13
>
6
>
25
>
12
.5
>
10
>
16
>
13
0.
66
#
0.
01
0.
14
#
0.
1
PM
M
A
a
14
.4
#
4.
5
24
.5
#
3.
9
10
.1
#
2.
5
>
20
13
.6
#
3.
0
>
13
>
6
>
25
>
12
.5
>
10
14
.0
#
3.
4
>
13
1.
25
#
0.
2
0.
26
#
0.
1
M
D
M
A
a,
b
26
.8
#
8.
7
8.
4
#
3.
3
13
.0
#
2.
2
12
.2
#
0.
8
5.
9
#
2.
7
>
13
>
6
15
.0
#
10
>
12
.5
25
.2
#
12
>
16
>
13
0.
37
#
0.
12
2.
4
#
1.
1
M
et
he
dr
on
e
25
.3
#
12
.9
14
.0
#
7.
8
17
.0
#
5.
2
>
20
>
13
>
13
>
6
>
25
>
12
.5
>
10
>
16
>
13
>
10
>
10
N
-E
th
yl
am
ph
et
am
in
ea
2.
1
#
0.
8
1.
1
#
0.
02
26
.4
#
6.
1
3.
4
#
0.
5
>
13
6.
0
#
5.
2
>
6
2.
9
#
0.
3
>
12
.5
>
10
>
16
>
13
2.
5
#
1.
4
>
10
4-
M
EC
6.
8
#
0.
5
0.
89
#
0.
01
7.
7
#
0.
4
>
20
3.
8
#
1.
6
5.
2
#
0.
3
>
6
>
18
>
12
.5
>
10
>
16
>
13
>
10
>
10
Pe
nt
yl
on
e
9.
0
#
2.
4
0.
24
#
0.
02
2.
0
#
0.
5
>
18
>
13
>
13
>
6
>
25
>
12
.5
>
10
>
16
>
13
>
10
>
10
Et
hc
at
hi
no
ne
0.
22
#
0.
1
0.
88
#
0.
1
37
.6
#
9.
0
8.
5
#
1.
1
>
13
9.
3
#
0.
2
>
6
15
.5
#
1.
9
>
12
.5
>
10
>
16
>
13
>
10
>
10
M
et
ha
m
ph
et
am
in
ea
,b
3.
0
#
2.
2
1.
8
#
0.
7
24
.6
#
10
.5
8.
1
#
0.
8
>
13
>
13
>
6
6.
1
#
1.
6
>
12
.5
>
10
>
16
>
13
0.
35
#
0.
1
0.
55
#
0.
2
3-
FM
C
5.
0
#
1.
8
2.
1
#
0.
4
36
.1
#
1.
4
>
18
>
13
6.
1
#
2.
2
>
6
10
#
2.
2
>
12
.5
>
10
>
16
>
13
>
10
>
10
Bu
ph
ed
ro
ne
8.
5
#
4.
2
1.
3
#
0.
3
28
.6
#
18
.7
>
18
>
13
>
13
>
6
23
.9
#
4.
2
>
12
.5
>
10
>
16
>
13
>
10
>
10
Pe
nt
ed
ro
ne
4.
5
#
1.
3
0.
34
#
0.
03
17
.3
#
6.
1
>
18
>
13
>
13
>
6
35
.4
#
16
>
12
.5
>
10
>
16
>
13
>
10
>
10
N
,N
-D
im
et
hy
lc
at
hi
no
ne
23
.8
#
13
4.
7
#
1.
1
>
30
>
18
6.
5
#
0.
8
6.
5
#
0.
8
>
6
25
.4
#
11
>
12
.5
>
10
>
16
>
13
>
10
>
10
N
A
,n
ot
as
se
ss
ed
.
V
al
ue
s
ar
e
K
i
gi
ve
n
as
mM
(m
ea
n
#
SD
,n
¼
3e
5)
.
a
Co
m
pa
ra
to
r
co
m
po
un
ds
.
b
V
al
ue
s
fo
r
M
D
M
A
ar
e
fr
om
Si
m
m
le
r
et
al
.(
20
13
).
L.D. Simmler et al. / Neuropharmacology 79 (2014) 152e160 157
40
4.4. Pentedrone and N,N-dimethylcathinone are pure monoamine
uptake inhibitors
Pentedrone and N,N-dimethylcathinone are uptake inhibitors
only similar to cocaine and the pyrovalerone cathinones pyro-
valerone, MDPV, and naphyrone (Baumann et al., 2013; Cameron
et al., 2013; Eshleman et al., 2013; Simmler et al., 2013). These
pure uptake inhibitors likely do not enter the intracellular space
of the synapse via the transporter, which may be associated with
less intracellular pharmacological effects and toxicity compared
with substrate-type releasers (Eshleman et al., 2013). All non-
releaser compounds, including pentedrone and N,N-dimethylca-
thinone, and the pyrovalerones pyrovalerone, MDPV, and
naphyrone (Simmler et al., 2013) are tertiary amines, contain an
a-propyl group, or share both structural characteristics, sug-
gesting that these structures may prevent uptake by the trans-
porters. Pentedrone and N,N-dimethylcathinone preferentially
inhibited the catecholamine NET and DAT vs. SERT, although with
lower potency and catecholamine transporter selectivity
compared with pyrovalerone and MDPV (Simmler et al., 2013). 4-
or 3,4-substitutions at the phenyl ring result in serotonergic
selectivity, reflected by the low DAT/SERT inhibition ratio for
MDMA, 4-MTA, PMA, PMMA, and methedrone. Similarly, the 4-
or 3,4-phenyl ring-substituted compounds methylethcathinone,
pentylone, and naphyrone but not MDPV (Simmler et al., 2013)
have some activity at the SERT. None of the cathinone derivatives
characterized in the present study exhibited very high potency at
the DAT or the high DAT/SERT inhibition ratio >100 previously
shown for MDPV (Baumann et al., 2013; Simmler et al., 2013) and
associated with high reinforcing efficacy and compulsive use
(Aarde et al., 2013; Watterson et al., in press). Nevertheless, the
DAT/SERT inhibition ratios for buphedrone, pentedrone, and N,N-
dimethylcathinone were all >10, similar to methamphetamine
(Simmler et al., 2013), possibly indicating high abuse potential
(Bauer et al., 2013).
Buphedrone is a catecholamine-selective transporter inhibitor,
similar to pentedrone. Buphedrone did not release DA or 5-HT,
similar to pentedrone, but it released NE. Buphedrone, therefore,
has characteristics of both the pyrovalerone- and
methamphetamine-like cathinones (Simmler et al., 2013).
4.5. Profiles of monoamine receptor and transporter binding
For the cathinones, submicromolar affinity interactions were
observed with the monoamine transporters but not with other
receptors, indicating that interactions with monoamine receptors
likely do not contribute much to the in vivo effects of these drugs.
We previously showed that cathinones exhibit approximately 10-
fold lower affinity for TAAR1 receptors compared with their non-
b-keto analogs (Simmler et al., 2013). We extended this observation
by showing that a series of additional cathinones consistently did
not show relevant TAAR1 binding affinity, in contrast to a series of
additional non-b-keto amphetamines. Animal studies indicate that
non-b-keto amphetamines, such asMDMA andmethamphetamine,
inhibit their own neurochemical and locomotor stimulant effects
via TAAR1 activation (Di Cara et al., 2011). The lack of this TAAR1-
mediated “auto-inhibition” with the cathinones may contribute to
more stimulant-like and addictive properties in this new class of
designer drugs compared with traditional amphetamines (Simmler
et al., 2013).
Hallucinogens interact with 5-HT1, 5-HT2A, and 5-HT2C receptors
(Nichols, 2004), and several of the drugs tested in the present study
showed low-affinity binding to these receptors. Consistent with our
previous study (Simmler et al., 2013) and the work by others
(Eshleman et al., 2013), no submicromolar binding was observed at
5-HT1A, 5-HT2A, or 5-HT2C receptors for any of the drugs. Further-
more, others showed that several cathinones did not act as func-
tional agonists or antagonists at these 5-HT receptors or that their
functional potencies were very low (Eshleman et al., 2013). Actions
at 5-HT receptors are therefore more likely to result from the drug-
induced release of endogenous 5-HT rather than from direct in-
teractions of the drugs with these 5-HT receptors as is the case with
substituted phenethylamine hallucinogens (Nichols, 2004). In
contrast, submicromolar affinity for 5-HT2B receptors has been re-
ported for naphyrone and mephedrone (Iversen et al., 2013). We
did not assess 5-HT2B receptor binding in the present study. 5-HT2B
receptors have been implicated in drug-associated cardiac valve
fibrosis (Roth, 2007) and the behavioral effects of MDMA (Doly
et al., 2008). Some previously described cathinones but none of
the cathinones investigated in the present study exhibited low
micromolar affinity for a1 adrenergic receptors. Low-affinity a2
receptor binding was observed for most non-b-keto amphetamines
and some of the cathinones in the present study and our previous
study (Simmler et al., 2013). Substrate releasers show higher
transporter inhibition potency compared with binding affinity,
resulting in Ki binding to IC50 uptake inhibition ratios>1 (Eshleman
et al., 2013; Rudnick and Wall, 1992; Simmler et al., 2013). This
phenomenon was also observed for most but not all monoamine
releasers in the present study.
The present study has limitations. First, we used a static
monoamine release assay (Rosenauer et al., 2013; Simmler et al.,
2013; Verrico et al., 2007), which is confounded by back diffusion
of the released monoamines. This assay is useful to determine
whether a drug is a substrate releaser. Superfusion assays may be
more suitable to also accurately determine the monoamine-release
potency of the drugs (Eshleman et al., 2013). Second, stereo-
selective effects have been described for amphetamines, including
substituted cathinones (Dal Cason et al., 1997), but we used only
racemic drugs, similar to those recreationally used. Third, we did
not investigate the effects of the drug on intracellular targets, such
as the vesicular monoamine transporter or monoamine oxidase,
which are affected by amphetamines (Eshleman et al., 2013; Green
and El Hait, 1980) and contribute to their toxic effects (Steinkellner
et al., 2011). Finally, we did not provide in vivo data. However,
in vitro and in vivo pharmacological profiles were shown to be
consistent for several cathinones (Baumann et al., 2012; Cozzi et al.,
2013; Cozzi and Foley, 2003; Kehr et al., 2011).
Notably, no relevant interactions with the vesicular mono-
amine transporter were observed for a series of first-generation
cathinones (Eshleman et al., 2013). In summary, the novel
designer cathinones evaluated in the present study were all potent
inhibitors of the NET, but marked differences were found in their
DAT and SERT inhibition profiles and ability to also release
monoamines.
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1. Introduction
New psychoactive substances [1] are constantly emerging on
the illicit drug market. Many of these novel designer substances are
amphetamine derivatives and typically marketed as ‘‘bath salts’’,
‘‘research chemicals’’ or ‘‘legal highs’’ via the Internet [2].
Pharmacological information is typically not available for these
newly emerging designer substances. Interactions with the
norepinephrine (NE), dopamine (DA), and serotonin (5-hydroxy-
tryptamine [5-HT]) transporters (NET, DAT, and SERT, respectively)
to block or release monoamines can be expected based on the
amphetamine-like core structure of many of these substances. In
addition, chemical modifications typically alter absolute or relative
potencies at the NET and DAT relative to the SERT or substrate
release properties, thereby affecting stimulant-like and reinforcing
properties [3,4]. Additional interactions with the 5-HT2A receptor
may result in hallucinogenic-like actions. Substances that pre-
dominantly act on the NET and DAT have stimulant-like properties
similar to amphetamine, whereas substances that mostly act on
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the SERT may have more ‘‘empathogenic’’ properties similar to 3,4-
methylenedioxymethamphetamine (MDMA, Ecstasy) [4,5]. Asses-
sing the in vitro pharmacological profiles of novel substances is a
relatively rapid approach for gaining a first impression of their
potential clinical effects and toxicology, in addition to user reports.
Accordingly, the pharmacology of many novel designer cathinones
(‘‘bath salts’’ and ‘‘research chemicals’’) has recently been
characterized in vitro [4,6–10]. The aim of the present study was
to describe the effects on monoamine uptake and release of novel
psychoactive substances that are not cathinones, but have been
introduced into the illicit drug market as ‘‘legal highs’’ to typically
mimic the subjective effects of MDMA or amphetamine-type
stimulants. Aminoindanes, such as 5,6-methylenedioxy-2-ami-
noindane (MDAI) and 5-iodoaminoindane (5-IAI), became increas-
ingly available over the Internet starting in 2010 as legal and, in the
case of MDAI, allegedly less-neurotoxic alternatives to MDMA [11–
13]. Piperazines have been used for more than a decade [14] and
are commonly found in Ecstasy pills as substitutes for MDMA
[15,16]. Toxicity associated with the use of ‘‘ivory wave,’’ which
contains the pipradrol derivatives desoxypipradrol (2-diphenyl-
methylpiperidine [2-DPMP]) or diphenylprolinol (diphenyl-2-
pyrrolidinemethanol [D2PM]) was increasingly reported starting
in 2010 [17–19]. The present study investigated the aminoindanes
2-aminoindane (2-AI), 5-IAI, and MDAI, the piperazines meta-
chlorophenylpiperazine (m-CPP), trifluoromethylphenylpiperazine
(TFMPP), and 1-benzylpiperazine (BZP), and the pipradrol deriva-
tives D2PM and 2-DPMP (Fig. 1). Similar data on MDMA and other
novel psychoactive substances have previously been published
[4,6]. We determined the potencies of the compounds to inhibit the
human NET, DAT, and SERT. We tested whether the compounds
induce the transporter-mediated release of NE, DA, and 5-HT and
characterized the binding affinities of the compounds for mono-
amine transporters, a1 and a2 adrenergic receptors, dopamine D1-
D3 receptors, 5-HT1A, 5-HT2A, and 5-HT2C receptors, the histamine H1
receptor, and trace amine-associated receptor 1 (TAAR1). Most of the
substances examined herein were previously studied using rodent
transporters, but only a few were also studied using human
transporters and receptors [7]. However, more comprehensive
analyses are needed at both human transporters and receptors.
Similar data on novel designer cathinones and classic stimulants,
including amphetamine, methamphetamine, MDMA, and cocaine
have previously been obtained using identical methods [4,6].
2. Methods
2.1. Chemicals
MDMA, methylphenidate, m-CPP, TFMPP, and BZP were supplied
by Lipomed (Arlesheim, Switzerland), and 5-IAI, 2-AI, 2-DPMP, and
D2PM were supplied by Cayman Chemicals (Ann Arbor, MI, USA) as
racemic hydrochloride salts (purity > 98.5%). MDAI was synthesized
as a racemic hydrochloride salt in our laboratory according to
Nichols et al. [20]. Radiochemicals (3H-isotopes) were obtained from
Anawa (Wangen, Switzerland) or Perkin Elmer (Schwerzenbach,
Switzerland), with the exception of [3H]RO5166017, which was
synthesized at Roche (Basel, Switzerland).
2.2. Monoamine uptake transport inhibition
The inhibition of the NET, SERT, and DAT was assessed in human
embryonic kidney 293 (HEK 293) cells that stably expressed the
human NET, SERT, and DAT [21] as previously described in detail
[22]. Cultured cells were detached and resuspended in uptake
buffer. We incubated the cells with various concentrations of the
test compounds and the vehicle control for 10 min and then added
[3H]DA, [3H]NE, or [3H]5-HT (5 nM final concentrations) to initiate
the uptake transport of the labeled monoamines at room
temperature. Uptake was stopped after 10 min by separation of
the cells from the buffer by rapid centrifugation at high speed
through silicone oil [22]. The uptake times were based on kinetic
evaluations showing that uptake is complete after 5 min [22]. The
centrifugation tubes were frozen in liquid nitrogen and cut to
separate the cell pellet from the silicone oil and assay buffer layers.
The cell pellet was lysed. Scintillation fluid was added, and
radioactivity was counted on a beta-counter. Nonspecific uptake
was determined for each experiment in the presence of 10 mM
fluoxetine for SERT cells, 10 mM nisoxetine for NET cells, and
10 mM mazindol for DAT cells and subtracted from the total counts
to yield specific uptake (100%). Nonspecific uptake was <15% of
total uptake. The data were fit by non-linear regression to variable-
slope sigmoidal dose-response curves, and IC50 values were
calculated using Prism (GraphPad, San Diego, CA, USA). DAT/SERT
ratios were calculated as 1/DAT IC50:1/SERT IC50. The DAT/SERT
ratio is considered useful to predict the characteristics of the
psychoactive effects of novel psychoactive substances [4,23–25].
Higher relative potency at the DAT may indicate a higher abuse
potential while relatively increased activity on the 5-HT system is
linked to reduced abuse potential and more MDMA-like psycho-
tropic effects [25]. Stimulant amphetamines such as metham-
phetamine exhibit a DAT/SERT ratio >10, while MDMA and other
substances with MDMA-like psychotropic effects exhibit a DAT/
SERT ratio close to 0.1 [4,26].
2.3. Transporter-mediated monoamine release
We studied the effects of 100 mM of the test compounds on
transporter-mediated NE, 5-HT, and DA efflux in HEK 293 cells that
overexpressed the respective human monoamine transporter as
previously reported in detail [4]. Briefly, we preloaded the cells by
incubating SERT cells with 10 nM [3H]5-HT, DAT cells with 10 nM
[3H]DA and 1 mM unlabeled DA, and NET cells with 10 nM [3H]NE
and 10 mM unlabeled NE for 20 min. The cells were then washed
twice, and release was induced by adding 1000 ml of release buffer
Fig. 1. Structures of novel psychoactive substances that mimic the effects of 3,4-
methylenedioxymethamphetamine (MDMA) or methylphenidate. 2-Aminoindane
(2-AI), 5-iodo-2-aminoindane (5-IAI), and 5,6-methylenedioxy-2-aminoindane
(MDAI) are recreationally used aminoindanes. Meta-chlorophenylpiparazine (m-
CPP), trifluoromethylphenylpiperazine (TFMPP), and 1-benzylpiperazine (BZP) are
piperazines commonly found in pills sold as Ecstasy. Diphenylprolinol (diphenyl-2-
pyrrolidinemethanol [D2PM]) and desoxypipradrol (2-diphenylmethylpiperidine [2-
DPMP]) are pipradrol derivatives sold as ‘‘legal highs’’ (‘‘ivory wave’’) and structurally
similar to methylphenidate.
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that contained the test compounds at concentrations of 100 mM.
We incubated the SERT and DAT cells for 15 min and NET cells for
45 min at 37 8C by shaking at 300 rotations per minute on a rotary
shaker. The release times were based on kinetic evaluation of the
release-over-time curves for MDMA. After 15 min for [3H]5-HT and
[3H]DA and 45 min for [3H]NE, a sufficient amount of radioactivity
was released to allow for comparisons with the control conditions.
We then stopped release by removing the buffer and gently
washing the cells twice with cold buffer. We quantified the
radioactivity that remained in the cells. Nonspecific ‘‘pseudo-
efflux,’’ which arises from substrate that diffuses out of the cells
and reuptake inhibition [27,28], was assessed for each experiment
using the transporter inhibitors nisoxetine (NET cells), citalopram
(SERT cells), and mazindol (DAT cells) at 10 mM as negative control
conditions. We then used analysis of variance followed by
Dunnett’s test to compare test drug-induced monoamine release
with nisoxetine, citalopram, and mazindol (negative controls).
Compounds that induced significantly higher maximal mono-
amine efflux compared with the respective transporter inhibitors,
which induced slight nonspecific release, were considered
monoamine releasers. MDMA was used as a positive control
condition in each experiment. Previously published data on
cathinones [6] were obtained from the same experiments and
tested along-side with the drugs described here. Therefore the
data on MDMA are the same as previously published [6] and data
on cathinones [6] can be compared with those obtained with the
data shown here. All of the conditions were normalized to
radioactive counts of the assay buffer control condition. The
assays allowed qualitative classification of a drug as a releaser or
non-releaser at 100 mM, but not quantitative comparisons
between transporters.
2.4. Radioligand binding assays
The radioligand binding assays were performed as described
previously [4,22,29]. Briefly, membrane preparations of HEK 293
cells (Invitrogen, Zug, Switzerland) that overexpress the respective
transporters [21] or receptors (human genes, with the exception of
TAAR1 receptors that were rat/mouse; [29]) were incubated with
the radiolabeled selective ligands at concentrations equal to Kd,
and ligand displacement by the compounds was measured.
Specific binding of the radioligand to the target receptor was
defined as the difference between the total binding and nonspecific
binding determined in the presence of selected competitors in
excess. The following radioligands and competitors, respectively,
were used: N-methyl-[3H]-nisoxetine and indatraline (NET),
[3H]citalopram and indatraline (SERT), [3H]WIN35,428 and
indatraline (DAT), [3H]8-hydroxy-2-(di-n-propylamino)tetralin
and indatraline (5-HT1A receptor), [
3H]ketanserin and spiperone
(5-HT2A receptor), [
3H]mesulergine and mianserin (5-HT2C recep-
tor), [3H]prazosin and risperidone (a1 adrenergic receptor),
[3H]rauwolscine and phentolamine (a2 adrenergic receptor),
[3H]SCH 23390 and butaclamol (DA D1 receptor), [
3H]spiperone
and spiperone (DA D2 and D3 receptors), [
3H]pyrilamine and
clozapine (histaminergic H1 receptor), and [
3H]RO5166017 and
RO5166017 (TAAR1). IC50 values were determined by calculating
nonlinear regression curves for a one-site model using three to five
independent 10-point concentration-response curves for each
compound. Ki (affinity) values, which correspond to the dissocia-
tion constants, were determined using the Cheng-Prusoff equation.
Similarly obtained data on MDMA has previously been published
[4,6].
3. Results
3.1. Monoamine uptake transporter inhibition
The effects of the test compounds on monoamine transporter
function are presented in Fig. 2. The corresponding IC50 values for
monoamine transport inhibition and DAT/SERT inhibition ratios
are shown in Table 1. With the exception of m-CPP and TFMPP, all
of the tested compounds inhibited NET with IC50 values of 0.1–
1 mM. For comparison, clinically used NET inhibitors such as
reboxetine, indatraline, or duloxetine are slightly more potent and
inhibited NET with IC50 values of 0.036, 0.43 and 0.126 mM in the
same or similar assays [22].
DAT and SERT inhibition potencies varied considerably,
resulting in a wide range of DAT/SERT inhibition ratios. Both
ring-substituted aminoindanes, 5-IAI and MDAI, and both phenyl-
piperazines, m-CPP and TFMPP, preferentially inhibited the SERT
over the DAT, similar to MDMA [4,6]. The pipradrol derivatives
D2PM, 2-DPMP, and methylphenidate were all considerably more
potent DAT vs. SERT inhibitors. 2-AI and BZP showed only low
potency as DAT or SERT inhibitors (IC50 values > 10 mM).
3.2. Transporter-mediated monoamine release
The effects of the test compounds on the transporter-mediated
release of NE, DA, and 5-HT from transmitter-preloaded cells are
depicted in Fig. 3. As expected, MDMA induced significant efflux of
NE, DA, and 5-HT compared with the nonspecific ‘‘release’’
observed with the pure uptake inhibitors nisoxetine, mazindol,
and citalopram, respectively. The aminoindanes were releasers of
at least one monoamine. 5-IAI released 5-HT and DA. MDAI
Table 1
Monoamine uptake transport inhibition.
NET DAT SERT DAT/SERT ratio
IC50 [mM] (95% CI) IC50 [mM] (95% CI) IC50 [mM] (95% CI) Ratio (95% CI)
Aminoindans
5-IAI 0.76 (0.60–0.98) 23 (15–35) 2.5 (1.9–3.4) 0.11
MDAI 0.65 (0.50–0.84) 31 (23–41) 8.3 (3.2–22) 0.2
2-AI 0.54 (0.42–0.69) 58 (4–905) >100 >1
Piparazines
m-CPP 1.67 (1.2–2.4) 31 (25–38) 1.2 (0.9–1.6) 0.04
TFMPP 17.5 (8–39) >100 5.2 (3.8–7.0) < 0.05
BZP 0.41 (0.33–0.53) 17 (15–19) 57 (40–81) 3.39
Pipradrol derivatives
D2PM 0.41 (0.34–0.50) 0.86 (0.74–1.0) 38 (4.7–307) 44.36
2-DPMP 0.14 (0.11–0.18) 0.07 (0.06–0.08) >10 >100
Methylphenidate 0.13 (0.10–0.16) 0.12 (0.09–0.16) >100 >100
Values are means of three to four independent experiments and 95% confidence intervals (CI). DAT/SERT ratio = 1/DAT IC50: 1/SERT IC50.
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released 5-HT and NE. 2-AI released NE and DA. Among the
piperazines, BZP released DA, m-CPP released 5-HT, and TFMPP did
not induce the efflux of any monoamine. None of the pipradrol
derivatives or methylphenidate was a substrate releaser.
3.3. Binding affinities
Table 2 shows the binding profiles of the test compounds
expressed as the potencies of the compounds (Ki) to inhibit
radioligand binding to the NET, DAT, and SERT and different
monoamine receptors. Among the aminoindanes, the binding
profile of MDAI was similar to MDMA [4,6], whereas 5-IAI
exhibited submicromolar affinities (<1 mM) for the 5-HT1A, 5-
HT2A, a2A, and D3 receptors. In contrast to MDMA [4,6], the
phenylpiperazines m-CPP and TFMPP showed submicromolar
(<1 mM) binding to many monoamine receptors, including the 5-
HT1A, 5-HT2A, 5-HT2C, a2A, and D1-3 receptors. The pipradrol
derivatives and methylphenidate potently bound to the DAT, but
not to any other sites. The aminoindanes, and the phenylpiper-
azines showed affinity for the rat and mouse TAAR1, similar to
MDMA [4,6]. Binding potencies at the monoamine transporters
were typically weak, except for the high-affinity (<100 nM)
binding of the pipradrol derivatives at the DAT.
4. Discussion
All of the novel substances characterized in the present study
interacted with the monoamine transporters. High potency of a
compound to inhibit the catecholamine transporter NET and
DAT in vitro is associated with greater psychostimulant potency
in humans [4]. These compounds typically exhibit a DAT/SERT
ratio >1 and a high abuse potential [4]. Predominant drug
activity at the SERT [22] and a DAT/SERT inhibition ratio of
typically 0.01–0.1 are expected to result in subjective drug
effects similar to those of MDMA or other empathogens [4,6].
These serotonergic compounds produce subjective well-being
and enhanced empathy and sociability in humans without
marked psychostimulation [5,30]. Additionally, compounds
which predominantly act on SERT and NET [6] have been
associated with 5-HT syndrome, hyperthermia and resulting
organ failure. Furthermore, compounds which act as monoamine
releasers (i.e., MDMA or methamphetamine [4,6]) enter the
intracellular space via the transporter. In contrast to pure
transporter blockers (i.e., cocaine), monoamine releasers are
expected to have more subsequent intracellular pharmacological
and neurotoxic consequences [31,32].
The in vitro pharmacological profiles of the compounds studied
herein may be useful to predict the clinical effects according to the
associations noted above. The profiles can also be compared with
those of cocaine and a series of recreationally used amphetamine
and cathinone derivatives previously characterized using the same
in vitro assays [4,6].
4.1. Aminoindanes
The aminoindanes 5-IAI and MDAI preferentially inhibited the
NET and SERT and less potently inhibited the DAT, similar to
MDMA [4,6], but with approximately two-fold lower potency. 5-
IAI and MDAI released 5-HT through the SERT, similar to MDMA.
MDAI also shared the NE-releasing property and receptor binding
profile of MDMA [4,6]. Similar inhibitory effects of 5-IAI and MDAI
on human monoamine transporters have recently been shown [7],
Fig. 2. Monoamine uptake inhibition presented as dose-response curves for the inhibition of [3H]NE, [3H]DA, and [3H]5-HT into NET-, DAT-, and SERT-transfected HEK 293
cells, respectively. The data are expressed as the mean ! SEM of 3-4 independent experiments. The data were fit by nonlinear regression. The corresponding IC50 values are shown
in Table 2.
L.D. Simmler et al. / Biochemical Pharmacology 88 (2014) 237–244240
48
but no comparable data on monoamine release are available. In
contrast to the human transporter studies, both MDAI and 5-IAI
were relatively more potent SERT and DAT vs. NET inhibitors in rat
brain synaptosomes [33]. Similar to our data, MDAI released 5-HT,
but not DA, and 5-IAI released both 5-HT and DA from rat brain
synaptosomes [33]. 5-IAI and MDAI substituted for MDMA in drug
discrimination studies [20,34], but were considered less neuro-
toxic than MDMA [20,34,35]. This profile may increase the
popularity of these aminoindanes [13]. The comparable mono-
amine transporter inhibition and release profile to MDMA [4,6]
would predict that MDAI has very similar subjective effects to
MDMA, and this is supported by user reports [12,36]. Rare severe
complications include serotonin syndrome and hyperthermia [36],Ta
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Fig. 3. Monoamine release induced by 100 mM of test compound. HEK 293 cells that
expressed NET, DAT, and SERT were loaded with [3H]NE, [3H]DA, and [3H]5-HT,
respectively, washed, and incubated with a high concentration of the compounds
(100 mM). Monoamine release is expressed as the percent reduction of monoamine
cell content compared with vehicle (0% = no release). 100% release would indicate
that all of the monoamine was released from the cells. In such a batch assay, non-
releasing monoamine transporter blockers induce nonspecific ‘‘pseudo-efflux’’
(dashed line, open bars), which arises from substrate that diffuses out of the cells
and reuptake inhibition. Only compounds that produced significantly more
monoamine efflux (*p < 0.05, ***p < 0.001) compared with the non-releasing
uptake inhibitors (negative controls, open bars) nisoxetine (HEK-NET cells),
mazindol (HEK-DAT cells), and citalopram (HEK-SERT cells) were considered
monoamine releasers. The known monoamine releaser MDMA served as a positive
control condition for each experiment. The data are expressed as the mean ! SEM of
3–4 independent experiments (with negative and positive controls added in each
experiment).
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also similar to MDMA. In contrast to MDAI and MDMA [4,6], 5-IAI
exhibited relevant binding to 5-HT receptors, including the 5-HT2A
receptor that is implicated in the action of hallucinogens [37]. 5-IAI
is also considered a less potent MDMA substitute, but dysphoria,
anxiety, and hallucinations have also been reported [13]. In
contrast to the substituted aminoindanes, 2-AI selectively
inhibited the NET, but not the DAT or SERT. This profile is
relatively similar to BZP in the present study, but most other
amphetamines also typically more potently inhibit the DAT [4,6].
2-AI also released NE and DA. No comparable data on the
pharmacology of 2-AI have been reported. Based on the profile in
the present study, 2-AI likely has only mild psychostimulant
effects in humans.
4.2. Piperazines
Although piperazines have been widely used since the 1990s,
and their pharmacology and toxicology have been reviewed
[14,38–41], only few and conflicting original data are available on
their pharmacological mechanism. In the present study, BZP
inhibited the NET and released DA. Early studies in rats found that
BZP inhibits the uptake of not only NE and DA, but also 5-HT [42],
which is very inconsistent with our data obtained with human
transporters and recent rat studies [43]. Similar to the present
study, BZP produced the transporter-mediated release of DA, but
not 5-HT from rat synaptosomes in vitro [43]. BZP enhanced
electrically induced NE release from rabbit arteries [44], likely
reflecting its NET-inhibiting properties. BZP also induced a robust
increase in extracellular DA in vivo, but only weakly increased 5-HT
dialysate levels at higher doses [43]. Speculations that BZP may act
as an a2-adrenergic antagonist [44] in humans seem unlikely,
given the lack of binding to this and other monoamine receptors in
the present study. We also did not confirm the results of an early
rat study that reported the 5-HT antagonistic properties of BZP
[45]. Thus, our data indicate that BZP is an indirect DA and NE
agonist without serotonergic properties. In animals, BZP induced
place preference in rats [46] and was self-administered in
monkeys, and it substituted for amphetamine in discrimination
studies [47]. In humans, 100 mg BZP produced subjective and
cardiostimulant effects similar to 7.5–10 mg amphetamine
[48,49], consistent with the five- to 10-fold lower potency of
BZP at the NET and DAT compared with amphetamine [4]. In
healthy women, a dose of 200 mg BZP produced cardiostimulant
and subjective effects that were considered similar to those
generally seen with stimulants [50], but a direct comparison with
other compounds is lacking. The clinical toxicity of BZP mainly
includes hallucinations, agitation, seizures, and hyperthermia [40].
Drug users associated more unpleasant effects and hallucinations
with BZP than with MDMA [51]. The phenylpiperazines TFMPP and
m-CPP preferentially inhibited the SERT as previously reported
[52,53]. TFMPP did not act as a 5-HT releaser, and m-CPP only
weakly released 5-HT in the present study. SERT-mediated 5-HT
release from rat brain synaptosomes or slices has previously been
documented for both TFMPP [43,54] and m-CPP [54–56]. Further
studies are needed to determine whether the phenylpiperazines
differentially interact with the human and rat SERT and whether
additional proteins present in the synaptosomal preparations, but
not in transfected HEK-293 cells may explain this discrepancy. Also
needing clarification is the extent to which the in vivo serotonergic
action of m-CPP is linked to 5-HT release vs. uptake inhibition. In
fact, m-CPP has been shown to bind more potently to the SERT than
the 5-HT releaser fenfluramine and not to induce long-term 5-HT
depletion [53], which are both characteristics of SERT inhibitors
rather than 5-HT releasers. m-CPP did not release DA or NE from
synaptosomes [56], consistent with our data. Furthermore, we
confirmed the previously documented binding of TFMPP and
m-CPP to rat 5-HT receptors [52] for the human 5-HT1A, 5-HT2A,
and 5-HT2C receptors. In rhesus monkeys, TFMPP has no
reinforcing properties and does not maintain responding for
amphetamine [47]. Additionally, TFMPP reduced the self-admin-
istration of BZP and responding for cocaine [47]. Altogether, the
preclinical data indicate that both m-CPP and TFMPP are both
indirect and direct serotonergic agonists without relevant dopa-
minergic activity. However, their precise interaction with the
human SERT and the nature of their serotonergic action in vivo
require further investigations. m-CPP is frequently found in
Ecstasy pills as a replacement for MDMA [57,58]. Recreational
users consider m-CPP to have less desirable psychotropic effects
and more adverse effects, including nausea, compared with MDMA
[51,58]. In experimental studies in humans, m-CPP produced
mostly dysphoria, weakness, dizziness, anxiety, and nausea [59–
61] and less, if any, positive subjective effects, drug liking, and
cardiovascular stimulation in direct comparisons with MDMA [62].
The lower clinical potency and efficacy of m-CPP compared with
MDMA may be explained by its lower potency as a DAT and NET
inhibitor compared with MDMA [4,6] or by its lower efficacy to
induce the release of 5-HT. The effects of TFMPP have not been
directly compared with other psychoactive substances in
humans. TFMPP alone produced moderate dysphoria and
amphetamine-type stimulation [63], but not the usual increases
in euphoria seen after MDMA administration [64] using the same
psychometric scale. Unsurprisingly, therefore, the use of TFMPP
alone does not appear to be common [51]. In contrast, BZP in
combination with either m-CPP or TFMPP is sometimes sold as
Ecstasy [16,41]. Because BZP releases DA, and m-CPP and TFMPP
are direct and indirect serotonergic agonists, their combination
would be expected to mimic the psychoactive profile of MDMA.
In rats, the combination of BZP and TFMPP elevated brain DA and
5-HT levels similarly to MDMA [43]. In humans, the combination
of BZP and TFMPP produced stimulation and ‘‘good’’ drug effects,
but no euphoria [65]. The BZP-TFMPP combination was not well
tolerated at higher doses and frequently produced agitation,
anxiety, hallucinations, and vomiting [66], whereas these
adverse effects were infrequently observed after MDMA admin-
istration in a similar laboratory study [67]. As noted above, the
BZP-TFMPP combination has reduced reinforcing properties
compared with BZP alone [47], consistent with the abuse-
lowering effects of 5-HT.
4.3. Pipradrol derivatives
D2PM and 2-DPMP were selective catecholamine transporter
inhibitors without transporter-mediated substrate-releasing prop-
erties, similar to methylphenidate. 2-DPMP was a DAT/NET
inhibitor that was equally potent to methylphenidate, whereas
D2PM was less potent. Consistent with our findings, 2-DPMP has
been previously shown to inhibit the human NET and DAT, but not
SERT [7], and block the uptake of DA and NE into synaptic rat brain
vesicles [68,69]. 2-DPMP also blocked NE uptake into rabbit aortic
strips, but did not induce NE release [70], also consistent with our
results. Compared with classic stimulants, 2-DPMP was a 10-fold
more potent DAT blocker than cocaine [4]. Consistent with the
greater DAT-inhibiting potency, 2-DPMP also more potently
increased electrically evoked DA release in rat brain slices
compared with cocaine [71]. We found no other data on the
monoamine uptake and releasing properties of D2PM. The
pharmacological profile of the pipradrol derivatives was very
similar to the pyrovalerone cathinones MDPV and naphyrone that
were characterized in the same assays [4], although naphyrone
also inhibits the SERT. MDPV and naphyrone rather than 2-DPMP
have been found in some samples of ‘‘ivory wave’’ [72]. Similar to
MDPV [4] and naphyrone [73], 2-DPMP and D2PM are highly
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lipophilic. Compared with methylphenidate, 2-DPMP lacks polar
groups that are typically targeted by metabolic enzymes, resulting
in a longer half-life [74,75]. The clinical toxicity of 2-DPMP and
D2PM is long-lasting (24–72 h) and involves sympathomimetic
stimulation and predominantly psychiatric symptoms, including
agitation, hallucinations, and insomnia [17,18]. Altogether, the
pipradrol derivatives are potent and selective catecholamine
uptake inhibitors, consistent with their potent and prolonged
psychostimulant actions. The pharmacological profile is also likely
associated with high abuse liability and an increased risk of
psychiatric complications.
4.4. TAAR1 binding
The aminoindanes and phenylpiperazines, but not BZP or
pipradrol derivatives, exhibited potent TAAR1 binding affinity
comparable to MDMA [4,6]. In the present series, all of the
serotonergic compounds also bound TAAR1, whereas the affinity
for TAAR1 has previously been documented for amphetamine and
methamphetamine [4], which only weakly interact with the SERT.
Drug activity at the SERT and TAAR1 are both considered to
counteract the abuse liability associated with dopaminergic drug
properties. Higher serotonergic vs. dopaminergic activity has been
associated with a lower abuse potential of a drug [4,23–25].
Amphetamines such as MDMA and methamphetamine have been
shown to inhibit their own neurochemical and locomotor
stimulant effects via TAAR1 activation [76]. The lack of serotonergic
activity and lack of TAAR1-mediated ‘‘auto-inhibition’’ in particular
with the pipradrol derivatives may contribute to the more
stimulant-like and addictive properties of this class of designer
compounds compared with classic amphetamines, including
MDMA [4].
4.5. Limitations
Knowing the mechanism of action of novel compounds in vitro
helps to predict potential clinical effects and abuse potential.
However, many additional factors also play a role such as brain
tissue penetration and pharmacokinetics which need to be further
assessed in vivo.
5. Conclusion
In summary, the aminoindanes, 5-IAI and MDAI inhibited the
SERT and released 5-HT, similar to MDMA [4]. Among the
piperazines, BZP interacted with the DAT and NET, and m-CPP
and TFMPP interacted with the SERT and serotonergic receptors.
The pipradrol derivatives were all potent and selective catechol-
amine transporter blockers without substrate-releasing proper-
ties. The predominant actions of D2PM and 2-DPMP on DAT likely
predict a high abuse liability. Further studies are needed to
determine potential differences between data obtained with
human or rodent transporter studies and to further validate
predictions of clinical effects based on such data.
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Abstract
The pharmacology of novel psychoactive substances is mostly unknown. We evaluated the
transporter and receptor interaction profiles of a series of para-(4)-substituted amphetamines and
pyrovalerone cathinones. We tested the potency of these compounds to inhibit the norepinephrine
(NE), dopamine (DA), and serotonin (5-HT) transporters (NET, DAT, and SERT, respectively) using
human embryonic kidney 293 cells that express the respective human transporters. We also tested
the substance-induced efflux of NE, DA, and 5-HT from monoamine-loaded cells, binding affinities to
monoamine receptors, and 5-HT2B receptor activation. Para-(4)-substituted amphetamines, includ-
ing 4-methylmethcathinone (mephedrone), 4-ethylmethcathinone, 4-fluoroamphetamine, 4-fluor-
omethamphetamine, 4-fluoromethcatinone (flephedrone), and 4-bromomethcathinone, were relati-
vely more serotonergic (lower DAT:SERT ratio) compared with their analogs amphetamine,
methamphetamine, and methcathinone. The 4-methyl, 4-ethyl, and 4-bromo groups resulted in
enhanced serotonergic properties compared with the 4-fluoro group. The para-substituted
amphetamines released NE and DA. 4-Fluoramphetamine, 4-flouromethamphetamine, 4-methyl-
methcathinone, and 4-ethylmethcathinone also released 5-HT similarly to 3,4-methylenedioxy-
methamphetamine. The pyrovalerone cathinones 3,4-methylenedioxypyrovalerone, pyrovalerone,
α-pyrrolidinovalerophenone, 3,4-methylenedioxy-α-pyrrolidinopropiophenone, and 3,4-methylene-
dioxy-α-pyrrolidinobutiophenone potently inhibited the NET and DAT but not the SERT. Naphyrone
was the only pyrovalerone that also inhibited the SERT. The pyrovalerone cathinones did not release
monoamines. Most of the para-substituted amphetamines exhibited affinity for the 5-HT2A receptor
but no relevant activation of the 5-HT2B receptor. All the cathinones exhibited reduced trace
amine-associated receptor 1 binding compared with the non-β-keto-amphetamines. In conclusion,
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para-substituted amphetamines exhibited enhanced direct and indirect serotonergic agonist
properties and are likely associated with more MDMA-like effects. The pharmacological profile of
the pyrovalerone cathinones predicts pronounced stimulant effects and high abuse liability.
& 2015 Elsevier B.V. and ECNP. All rights reserved.
1. Introduction
Novel psychoactive substances (“designer drugs”) are newly
misused psychotropic drugs that may pose a threat to public
health that is comparable to previously listed drugs of abuse.
Novel psychoactive substances are typically sold through the
Internet (i.e., “Internet drugs”) and misbranded as “research
chemicals,” “bath salts,”, and “plant food” and labeled “not
for human consumption.” The substances are typically chemi-
cally slightly different from already scheduled drugs to
circumvent regulations and are therefore also termed “legal
highs”. Over the last few years, we have seen an unprece-
dented growth in the number of new psychoactive substances
on the illicit drug market. More than 300 novel substances
have been detected since 2005 (European Monitoring Center
for Drugs and Drug Addiction, 2014a). Currently, more than
one new substance is identified in one of the EU countries
every week (European Monitoring Center for Drugs and Drug
Addiction, 2014a). In most cases, pharmacological data are
not available for the newly misused substances. Many novel
psychoactive substances are amphetamine derivatives that
can be expected to interact with the norepinephrine (NE),
dopamine (DA), and serotonin (5-hydroxytryptamine [5-HT])
transporters (NET, DAT, and SERT, respectively) to inhibit
monoamine transport or induce transporter-mediated mono-
amine release. However, chemical substitutions at the amphe-
tamine core structure may significantly alter the absolute or
relative potency of these newly designed substances at the
NET and DAT relative to the SERT (Baumann et al., 2012;
Blough et al., 2014; Cozzi et al., 2013; Eshleman et al., 2013;
Iversen et al., 2013; Simmler et al., 2013, 2014a, 2014b).
Consequently, more noradrenergic and dopaminergic sub-
stances may have greater sympathomimetic and reinforcing
properties (Simmler et al., 2013). Conversely, more seroto-
nergic substances are likely associated with more MDMA-like
properties, including empathogenic effects, serotonin syn-
drome, and hyperpyrexia (Simmler et al., 2013, 2014a). In
addition, novel amphetamines may directly activate mono-
amine receptors. Characterizing the primary pharmacody-
namic properties of novel designer amphetamines in vitro
provides a basis for further preclinical studies and the eva-
luation of potential clinical effects, abuse potential, and acute
toxicity of these novel substances. Such data are useful for
clinical toxicologists and regulatory agencies for scheduling
purposes. Therefore, the aim of the present study was to
determine the effects of a series of para-(4)-substituted
amphetamines and of a series of pyrovalerone cathinones on
monoamine uptake and release and interactions with various
monoamine receptors.
Para-(4)-phenyl-substituted amphetamines, which have eme-
rged in recent years, include 4-methylmethcathinone (mephe-
drone) and 4-ethylmethcathinone and particularly several
para-halogenated compounds, including 4-fluoroamphetamine,
4-fluoromethamphetamine, 4-fluoromethcatinone (flephedr-
one), and 4-bromomethcathinone. 4-Methylmethcathinone has
been the most popular and still is a very commonly misused
cathinone in the EU (Elliott and Evans, 2014; Helander et al.,
2014; Rust et al., 2012; Winstock et al., 2011). 4-Ethyl-
methcatinone was detected in 2011 in the EU (European
Monitoring Center for Drugs and Drug Addiction, 2011), and
its use is discussed in Internet user forums. Similarly, the use of
4-bromomethcathinone is also discussed in user forums, but no
scientific data are available. 4-Fluoroamphetamine appeared in
2007 in the EU, followed later by 4-fluoromethamphetamine
and 4-fluoroephedrine. 4-Fluoroephedrine may serve as a
precursor for the synthesis of 4-fluoromethamphetamine.
4-Fluoroamphetamine and 4-fluoromethamphetamine have also
been detected in patients with acute toxicity associated with
novel psychoactive substances and forensic cases (Helander
et al., 2014; Johansen and Hansen, 2012; Rohrich et al., 2012;
Rust et al., 2012). Users report that the subjective effects of
4-methlylmethcathinone (Carhart-Harris et al., 2011) and
4-fluoroamphetamine (Erowid, 2014) are comparable to those
of MDMA. Pharmacological information is available only for
some of these novel substances, including 4-methylmethcat-
inone (Baumann et al., 2012; Eshleman et al., 2013; Simmler
et al., 2013), 4-fluoroamphetamine (Marona-Lewicka et al.,
1995), and 4-fluoromethcathinone (Eshleman et al., 2013;
Simmler et al., 2013). Because 4-fluoroamphetamine and MDMA
are relatively more serotonergic than amphetamine and metha-
mphetamine (Marona-Lewicka et al., 1995; Simmler et al.,
2013), we hypothesized that a substitution at the 4-position as a
characteristic of these novel para-substituted substances would
also result in a shift toward more serotonergic than dopami-
nergic pharmacology. Thus, such para-substituted substances
may also be designed to mimic the effects of MDMA.
Pyrovalerone cathinones include 3,4,-methylenedioxypyro-
valerone (MDPV), pyrovalerone, α-pyrrolidinovalerophenone (α-
PVP), naphyrone, 3,4-methylenedioxy-α-pyrrolidinopropiophe-
none (MDPPP), 3,4-methylenedioxy-α-pyrrolidinobutioph-
enone (MDPBP), α-pyrrolidinopropiophenone (α-PPP), and
α-pyrrolidinobutiophenone (α-PBP). All these cathinones are
characterized by a pyrrolidine ring structure, making them
different structurally and possibly also pharmacologically from
other synthetic cathinones (Marusich et al., 2014; Simmler
et al., 2013). Among the pyrovalerone cathinones, MDPV is
currently the most widely detected and used, both in the EU
(European Monitoring Center for Drugs and Drug Addiction,
2014b; Helander et al., 2014; Zuba and Byrska, 2013) and US
(Leffler et al., 2014; Marinetti and Antonides, 2013; Spiller
et al., 2011). In fact, MDPV has become the most frequently
detected and used of all cathinones (“bath salts”) in some EU
countries (Helander et al., 2014; Zuba and Byrska, 2013) and
the US (Leffler et al., 2014). More recently, a second generation
of MDPV-like cathinones, including α-PVP, MDPPP, and MDPBP,
has been detected and/or used in several EU countries (Eiden
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et al., 2013; Helander et al., 2014; Westphal et al., 2011; Zuba
and Byrska, 2013) and the US (Elliott and Evans, 2014; Smollin
et al., 2011; Thornton et al., 2012). MDPV has been associated
with severe clinical toxicity (Spiller et al., 2011) and a high
potential for addiction (Aarde et al., 2013). Similarly, α-PVP has
recently been associated with cases of severe acute psychosis
and cardiac arrest (Eiden et al., 2013). Pharmacologically, both
MDPV and α-PVP are very potent inhibitors of the NET and DAT
but not SERT (Baumann et al., 2013; Marusich et al., 2014;
Meltzer et al., 2006; Simmler et al., 2013). Of the second
generation MDPV analogs, α-PPP and α-PBP also inhibit the NET
and DAT similarly to MDPV (Marusich et al., 2014), but no data
are available on MDPBP and MDPPP. We hypothesized that these
and other cathinones with a pyrovalerone structure would
inhibit the NET and DAT but not SERT, similar to MDPV
(Marusich et al., 2014; Meltzer et al., 2006; Simmler et al.,
2013). Naphyrone also potently inhibits the SERT, unlike other
pyrovalerone cathinones, and this exemplifies the necessity to
pharmacologically assess each substance individually to avoid
drawing false conclusions from structural relationships with
previously assessed analogs. We predicted that these pyrova-
lerone cathinones are distinct from other cathinones, in which
they are pure uptake inhibitors and do not act as substrate
releasers as previously shown for MDPV (Baumann et al., 2013;
Simmler et al., 2013).
We tested whether the substances inhibit the human NET,
DAT, and SERT. We also determined the transporter-mediated
release of NE, DA, and 5-HT and characterized the binding
affinities of the compounds for monoamine transporters,
α1- and α2-adrenergic receptors, dopamine D1–D3 receptors,
serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, the histamine
H1 receptor, and trace amine-associated receptor 1 (TAAR1).
For example, 5-HT2A receptors mediate the effects of hallu-
cinogens (Nichols, 2004) and TAAR1 play a role in the addictive
properties of psychoactive substances (Pei et al., 2014).
Furthermore, some novel psychoactive substances have been
reported to bind to the serotonin 5-HT2B receptor (Iversen
et al., 2013), which has been implicated in endocardial fibrosis
induced by serotonergic substances. Therefore, we also tested
functional activity at the 5-HT2B receptor.
Some of the substances, including MDMA, amphetamine, met-
hamphetamine, methcathinone, mephedrone, flephedrone,
MDPV, naphyrone, and pyrovalerone, have previously been cha-
racterized using the same assays as those used in the present
study (Simmler et al., 2013), but we retested them herein
because of their structural similarity to the other substances
that were evaluated, to our knowledge, for the first time.
2. Experimental procedures
2.1. Drugs
MDMA, d-amphetamine, d-methamphetamine, methcathinone,
4-methylmethcathinone, 4-fluoromethcathione, 4-fluoroam-
phetamine, 4-fluoroephedrine, ephedrine, MDPBP, MDPPP,
MDPV, pyrovalerone, and α-PVP were purchased from Lipomed
(Arlesheim, Switzerland). 4-Fluoromethamphetamine, 4-etyl-
methcathinone, and 4-bromomethcathinone were purchased
from Cayman Chemicals (Ann Arbor, MI, USA). Naphyrone was
synthesized as previously described (Simmler et al., 2013). All
the drugs were obtained as racemic hydrochloride salts, with
the exception of amphetamine and methamphetamine, for
which the (+)-enantiomer was used and ephedrine, for which
the (-)-enantiomer was used. Purity was at least 98% for all of
the substances. Radiochemicals (tritium isotopes) were
obtained from Anawa (Wangen, Switzerland) or Perkin-Elmer
(Schwerzenbach, Switzerland), with the exception of [3H]
RO5166017, which was synthesized at Roche (Basel,
Switzerland).
2.2. Monoamine uptake transport inhibition
Inhibition of the NET, SERT, and DAT was assessed in human
embryonic kidney 293 (HEK 293) cells that stably expressed the
human NET, SERT, and DAT (Tatsumi et al., 1997) as previously
described (Hysek et al., 2012). Cultured cells were detached
and resuspended in uptake buffer. We incubated the cells with
various concentrations of the test compounds and the vehicle
control for 10 min and then added [3H]DA, [3H]NE, and [3H]5-HT
(5 nM final concentration) to initiate uptake transport of the
labeled monoamines at room temperature. Uptake was stopped
after 10 min by separation of the cells from the buffer by rapid
high-speed centrifugation through silicone oil (Hysek et al.,
2012). The uptake times were based on previous kinetic
evaluations that showed that uptake is complete after 5 min
(Hysek et al., 2012). The centrifugation tubes were frozen in
liquid nitrogen and cut to separate the cell pellet from the
silicone oil and assay buffer layers. The cell pellet was then
lysed. Scintillation fluid was added, and radioactivity was
counted on a beta-counter. Nonspecific uptake was determined
for each experiment in the presence of 10 μM fluoxetine for
SERT cells, 10 μM nisoxetine for NET cells, and 10 μM mazindol
for DAT cells and subtracted from the total counts to yield
specific uptake (100%). Nonspecific uptake was o15% of total
uptake. The data were fit by non-linear regression to variable-
slope sigmoidal dose–response curves, and IC50 values were
calculated using Prism (GraphPad, San Diego, CA, USA). DAT:
SERT inhibition ratios were calculated as 1/DAT IC50:1/SERT
IC50. The DAT:SERT inhibition ratio is useful for predicting the
characteristics of the psychoactive effects of novel psychoac-
tive substances (Baumann et al., 2011; Simmler et al., 2013;
Wee et al., 2005). Higher relative potency at the DAT may
indicate a higher abuse potential, whereas relatively increased
activity of the 5-HT system is linked to a reduction of abuse
potential and more MDMA-like psychotropic effects
(Wee et al., 2005). Stimulant amphetamines, such as metham-
phetamine, have a DAT:SERT inhibition ratio 410, whereas
MDMA and other substances with MDMA-like psychotropic
effects have a DAT:SERT inhibition ratio close to 0.1
(Baumann et al., 2012; Simmler et al., 2013, 2014a, 2014b).
2.3. Transporter-mediated monoamine release
We studied the effects of 100 mM of the test compounds on
transporter-mediated NE, 5-HT, and DA efflux in HEK 293 cells
that overexpressed the respective human monoamine trans-
porter as previously reported in detail (Simmler et al., 2013).
Briefly, we preloaded the cells by incubating SERT cells with
10 nM [3H]5-HT, DATcells with 10 nM [3H]DA and 1 mM unlabeled
DA, and NETcells with 10 nM [3H]NE and 10 mM unlabeled NE for
20 min. The cells were then washed twice, and release was
induced by adding 1000 ml of release buffer that contained the
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Table 1 Monoamine transporter inhibition.
NET DAT SERT DAT/SERT inhibition ratio
IC50 (mM) (95% CI) IC50 (mM) (95% CI) IC50 (mM) (95% CI) Ratio (95% CI)
Para-(4)-substituted amphetamines
4-Fluoroephedrine 4.5 (2.0–11) 163 (40–668) 134 (76–236) 0.8 (0.1–5.9)
4–Fluoroamphetamine 0.20 (0.14–0.28) 3.7 (2.4–5.7) 19 (11–33) 5.1 (1.9–14)
4–Fluoromethamphetamine 0.22 (0.14–0.35) 7.7 (2.5–24) 8.7 (3.8–20) 1.1 (0.2–8.0)
MDMA 0.36 (0.23–0.57) 31 (8–118) 2.0 (1.4–3.0) 0.06 (0.01–0.4)
4–Fluoromethcathinone 0.36 (0.17–0.75) 14 (7.5–24) 49 (30–80) 3.6 (1.3–11)
4–Bromomethcathinone 0.41 (0.30–0.57) 5.6 (2.7–12) 2.2 (1.7–2.8) 0.4 (0.1–1.0)
4–Ethylmethcathinone 2.5 (1.7–3.7) 31 (13–72) 4.3 (3.2–5.9) 0.14 (0.04–0.5)
4–Methylmethcathinone 0.26 (0.17–0.39) 5.7 (4.3–7.5) 2.2 (1.6–2.9) 0.4 (0.2–0.7)
Non para-(4)-substituted amphetamines
Ephedrine 0.32 (0.21–0.50) 46 (27–79) 230 (72–735) 5.0 (0.9–27)
Amphetamine 0.07 (0.05–0.1) 1.3 (0.8–2.0) 45 (24–85) 35 (12–106)
Methamphetamine 0.14 (0.09–0.22) 1.1 (0.7–1.7) 18 (3–116) 17 (1.8–166)
Methcathinone 0.12 (0.09–0.15) 2.4 (1.7–3.4) 46 (30–71) 19 (8.8–42)
Pyrovalerone cathinones
MDPPP 0.97 (0.62–1.5) 0.53 (0.27–1.1) 75 (49–114) 141 (45–422)
MDPBP 0.16 (0.11–0.24) 0.11 (0.07–0.16) 15 (5.4–39) 132 (34–557)
MDPV 0.04 (0.03–0.05) 0.05 (0.04–0.06) 9.6 (3.4–27) 192 (57–675)
Naphyrone 0.11 (0.05–0.27) 0.22 (0.16–0.31) 0.80 (0.6–1.2) 3.6 (1.9–7.5)
α–PVP 0.02 (0.01–0.03) 0.04 (0.01–0.1) 4 100 4 1000
Pyrovalerone 0.05 (0.04–0.07) 0.07 (0.05–0.11) 23 (9.7–54) 327 (88–1080)
Values are means of three to four independent experiments and 95% confidence intervals (CI). DAT/SERT inhibition ratio=1/DAT IC50 :
1/SERT IC50.
Figure 1 Chemical structures of novel psychoactive substances. A. Para-(4)-substituted amphetamines, 3,4-methylenedioxy-
methamphetamine (MDMA, “ecstasy”), and other classic non-para-substituted amphetamines. B. Pyrovalerone-type cathinones.
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test compounds at concentrations of 100 mM. We incubated the
SERT and DAT cells for 15 min and NET cells for 45 min at 37 1C
with shaking at 300 rotations per minute on a rotary shaker.
The release times were based on kinetic evaluation of the
release-over-time curves for MDMA. After 15 min for [3H]5-HT
and [3H]DA and 45 min for [3H]NE, a sufficient amount of
radioactivity was released to allow for comparisons with the
control conditions. We then stopped release by removing the
buffer and gently washing the cells twice with cold buffer. We
quantified the radioactivity that remained in the cells. Non-
specific “pseudo-efflux,” which arises from nonspecific sub-
strate release and subsequent reuptake inhibition (Scholze
et al., 2000), was assessed for each experiment using the
transporter inhibitors nisoxetine (NET cells), citalopram (SERT
cells), and mazindol (DAT cells) at 10 mM as negative control
conditions. We then used analysis of variance followed by the
Least Significant Difference test to compare substance-induced
monoamine release with nisoxetine, citalopram, and mazindol
as negative controls. Substances that induced significantly
higher monoamine efflux at 100 mM compared with the respec-
tive transporter inhibitors, which induced slight nonspecific
release, were considered monoamine releasers.
2.4. Radioligand binding assays
The radioligand binding assays were performed as described
previously (Hysek et al., 2012; Revel et al., 2011; Simmler
et al., 2013). Briefly, membrane preparations of HEK 293
cells (Invitrogen, Zug, Switzerland) that overexpress the
respective transporters (Tatsumi et al., 1997) or receptors
(human genes plus TAAR1 rat and mouse genes; Revel et al.,
2011) were incubated with the radiolabeled selective ligands
at concentrations equal to Kd, and ligand displacement by
the compounds was measured. Specific binding of the radi-
oligand to the target receptor was defined as the difference
between total binding and nonspecific binding determined in
the presence of selected competitors in excess. The follow-
ing radioligands and competitors, respectively, were used:
N-methyl-[3H]-nisoxetine and indatraline (NET), [3H]citalo-
pram and indatraline (SERT), [3H]WIN35,428 and indatraline
(DAT), [3H]8-hydroxy-2-(di-n-propylamino)tetralin and inda-
traline (5-HT1A receptor), [
3H]ketanserin and spiperone (5-
HT2A receptor), [
3H]mesulergine and mianserin (5-HT2C
receptor), [3H]prazosin and risperidone (α1 adrenergic recep-
tor), [3H]rauwolscine and phentolamine (α2 adrenergic recep-
tor), [3H]SCH 23390 and butaclamol (D1 receptor), [
3H]
spiperone and spiperone (D2 and D3 receptors), [3H]pyrila-
mine and clozapine (histaminergic H1 receptor), and [3H]
RO5166017 and RO5166017 (TAAR1). IC50 values were deter-
mined by calculating nonlinear regression curves for a one-
site model using three to five independent 10-point concen-
tration–response curves for each compound. Ki (affinity)
values, which correspond to the dissociation constants, were
determined using the Cheng–Prusoff equation. As indicated in
Table 2, previously published binding affinity data for some of
the substances are included for comparative purposes
(Simmler et al., 2013).
2.5. Functional serotonin 5-HT2B receptor activity
The 5-HT2B receptor functional assay was performed as
previously described (Jensen et al., 2008). Briefly, human
5-HT2B receptor-expressing HEK 293 cells were incubated at
37 1C in 96-well plates coated with poly-D-lysine. The
growth medium was removed by snap inversion, and 100 ml
of Fluo-4 solution (calcium indicator; Molecular Probes) was
added. The plates were incubated for 45 min at 31 1C. The
Fluo-4 solution was removed by snap inversion, and 100 ml of
Fluo-4 solution was added for the second time. The cells
were then incubated for another 45 min at 31 1C. Immedi-
ately before testing, the cells were washed with HBSS
(Gibco) and 20 mM HEPES (assay buffer; Gibco) using an
EMBLA cell washer, and 100 ml assay buffer was added. The
plate was placed in a fluorescence imaging plate reader
(FLIPR), and 25 ml of the test substances diluted in assay
buffer was added on line. The increase in fluorescence was
then measured. EC50 values were derived from the concen-
tration–response curves using nonlinear regression. Efficacy
(maximal activity) is expressed relative to the activity of
5-HT, which was used as a control set to 100%.
2.6. Cytotoxicity
Cell membrane integrity during uptake and release testing
was verified after 4 h treatment at 371C with each of the
drugs (100 μM) using the ToxiLight BioAssay (Lonza, Basel,
Switzerland).
3. Results
3.1. Monoamine uptake transporter inhibition
The monoamine transporter inhibition profiles are shown in
Figure 2 and 3, and the corresponding IC50 values and DAT:SERT
inhibition ratios are listed in Table 1. In all cases, the para-
(4) substitution (Figure 1A) reduced the potency of the
amphetamines to inhibit both NET and DAT compared with the
non-para-(4)-substituted amphetamines (Table 1). In contrast,
the potency to inhibit the SERT increased for all of the
substituted amphetamines, with the exception of 4-fluoro-
methcathinone compared with methcathinone (Table 1). As a
result, the para-substituted substances were all relatively more
serotonergic than dopaminergic compared with their parent
compounds, reflected by their lower DAT:SERT inhibition ratios
(Table 1 and Figure 2). This was also evident for 4-
fluoromethcathinone and methcathinone, despite equal SERT
inhibition potencies. In the case of 4-fluoroephedrine,
4-methylmethcathinone, 4-ethylmethcathinone, and 4-bromo-
methcathinones, the para substitution left-shifted the SERT
inhibition curves over the DAT inhibition curves (DAT:SERT
inhibition ratioso1), resulting in monoamine transporter inhibi-
tion profiles that were more similar to MDMA and less similar to
the parent compounds (methcathinone and ephedrine;
Figure 2). In contrast, all of the pyrovalerone cathinones
(Figure 1B) were very potent catecholamine transporter (NET
and DAT) inhibitors with very low serotonergic activity,
reflected by very high DAT:SERT inhibition ratios (Table 1 and
Figure 3). One exception was naphyrone, which also inhibited
the SERT at submicromolar concentrations. The 3,
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4-methylene ring substitution that is found in MDMA and MDPV
increased serotonergic activity compared with the non-
substituted compounds methamphetamine and α-PVP, respec-
tively. Similarly, para-methylation in pyrovalerone increased the
serotonergic property of the compound compared with α-PVP.
However, in the case of the pyrovalerones (MDPV and pyrova-
lerone), SERT inhibition potency was very low, even in the
presence of these substitutions. In fact, all of the pyrovalerone
Figure 2 Effects of para-(4)-substituted and non-substituted amphetamines on monoamine transport. Monoamine uptake inhibition
is presented as concentration–response curves for the inhibition of [3H]NE, [3H]DA, and [3H]5-HT into NET-, DAT-, and SERT-
transfected HEK 293 cells, respectively. The data are expressed as the mean7SEM of 3–4 independent experiments. The lines
represent the data fit by nonlinear regression. The corresponding IC50 values are shown in Table 1.
Figure 3 Effects of pyrovalerone cathinones on monoamine transport. Monoamine uptake inhibition is presented as concentration–
response curves for the inhibition of [3H]NE, [3H]DA, and [3H]5-HT into NET-, DAT-, and SERT-transfected HEK 293 cells, respectively.
The data are expressed as the mean7SEM of 3–4 independent experiments. The lines represent the data fit by nonlinear regression.
The corresponding IC50 values are shown in Table 1.
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cathinones (Figure 1B) did not appear to interact with the SERT
at submicromolar concentrations, with the exception of naphyr-
one (Figure 3).
3.2. Transporter-mediated monoamine release
Monoamine release is shown in Figure 4. All the para-substituted
amphetamine derivatives released NE and DA similarly to their
non-substituted classic analogs amphetamine, methampheta-
mine, and methcathinone. In addition, 4-fluoramphetamine,
4-flouromethamphetamine, 4-methylmethcathinone, 4-ethyl-
methcathinone, amphetamine, and methamphetamine signifi-
cantly released 5-HT similarly to the classic 5-HT releaser MDMA.
4-Fluoromethcathinone, 4-bromomethcathinone, methcathi-
none, and ephedrine only released catecholamines and not
5-HT, whereas 5-fluoroephedrine released only NE. The pyrova-
lerone cathinones did not release monoamines (Figure 4) and
thus acted as pure and potent uptake inhibitors (Table 1).
3.3. Binding affinities
The monoamine transporter and receptor binding affinities are
shown in Tables 2 and 3. The pyrovalerone cathinones exhibited
high affinity for the DATand mostly also for the NET, consistent
with their high DATand NET blocking potency (Table 1). Most of
the para-substituted amphetamines exhibited affinity for the
serotonin 5-HT2A receptor in the low micromolar range, similar
to MDMA and dissimilar to amphetamine and methamphetamine
(Table 3). The cathinones (β-keto-amphetamines) showed lower
binding affinity for TAAR1 compared with the non-β-keto-
amphetamines (Table 2).
3.4. Functional activity at serotonin 5-HT2B
receptors
None of the substances tested exhibited relevant activation
of the 5-HT2B receptor (Table 3). Amphetamine was the
most potent activator with an IC50 of only 9.7 μM. However,
there was only very low efficacy of 9%.
3.5. Cytotoxicity
None of the drugs showed cytotoxicity at the highest
concentration tested in the functional assays.
4. Discussion
The goal of the present study was to describe the mechanism of
action of two series of novel psychoactive substances: para-(4)-
substituted (mostly halogenated) amphetamines and pyrovaler-
one cathinones. All the para-(4)-substituted amphetamines
evaluated in this study exhibited more serotonergic properties
than their non-substituted amphetamine analogs. In particular,
4-bromomethcatinone, 4-ethylmethcathinone, and 4-methy-
lmethcathinone were more potent SERT inhibitors than DAT
inhibitors, similar to MDMA. These findings are consistent with
previous studies that reported an increase in serotonergic
potency in para-ring-substituted amphetamines or phenethyla-
mines (Baumann et al., 2012; Eshleman et al., 2013; Simmler
et al., 2013). Para-methylation (as in 4-methylmethcathinone)
reduced the potency of DAT and increased the potency of SERT
inhibition compared with methcathinone, consistent with pre-
vious studies (Eshleman et al., 2013; Simmler et al., 2013).
Similarly, the para-methylation of amphetamine has previously
been shown to result in reduced DAT inhibition and increased
SERT inhibition (Wee et al., 2005). The para-flourination of
ephedrine, amphetamine, and methamphetamine resulted in
relatively more serotonergic properties, reflected by lower DAT:
SERT inhibition ratios compared with the non-substituted
analogs in the present study, confirming data on 4-
fluoroamphetamine in rat brain synaptosomes (Marona-
Lewicka et al., 1995; Wee et al., 2005) and 4-
flouromethcathinone in human cell assays (Eshleman et al.,
2013; Simmler et al., 2013). The presence of an ethyl or methyl
group in the para position resulted in more pronounced
serotonergic properties compared with a fluoro group, consis-
tent with previous data on 4-methcathinone and fluorometh-
cathinone vs. cathinone (Simmler et al., 2013) and 4-
methylamphetamine and 4-fluoroamphetamine vs. ampheta-
mine (Wee et al., 2005). With regard to haloamphetamines,
para substitution with fluoride only moderately increased the
relative serotonergic properties (DAT:SERT inhibition ratio) of
several compounds in the present study (5- to 15-fold), whereas
bromide was more effective (48-fold) and close to chloride (64-
fold; Marona-Lewicka et al., 1995) but still less effective than
iodine (548-fold; Marona-Lewicka et al., 1995). Finally, other
para-substituted amphetamines, including 4-methylthioamphe-
tamine, para-methoxyamphetamine, para-methoxymetham-
phetamine, methedrone, and 4-trifluoromethylm-
ethcathinone, have previously been shown to preferentially
interact with the SERTand NETover the DAT (Cozzi et al., 2013;
Simmler et al., 2014a). The entactogenic effects of the popular
recreational drug MDMA depend on its serotonergic effects
(Hysek et al., 2012). Consequently, substances that predomi-
nantly increase 5-HT can be expected to produce MDMA-like
subjective effects. In addition, the serotonergic properties of
these substances likely increase the risk for serotonergic
toxicity, including serotonin syndrome and hyperthermia
(Liechti et al., 2005; Simmler et al., 2011). In behavioral drug
discrimination studies, 4-fluoroamphetamine, which is only
moderately more serotonergic than amphetamine, is similar
to amphetamine (Marona-Lewicka et al., 1995). In contrast, 4-
chloroamphetamine and 4-iodoamphetamine, which are more
serotonergic (Marona-Lewicka et al., 1995), were behaviorally
similar to MDMA-like drugs (Marona-Lewicka et al., 1995). 4-
Methylmethcathinone exhibited a DAT:SERT inhibition ratio
more similar to MDMA than to amphetamine in the present
study but was more dopaminergic in other in vitro studies
(Eshleman et al., 2013; Iversen et al., 2013; Simmler et al.,
2013). In vivo, mephedrone has been shown to increase DA
similarly to amphetamine (Kehr et al., 2011) and 5-HT similarly
to MDMA (Baumann et al., 2012; Kehr et al., 2011). Behavio-
rally, mephedrone was similar to MDMA (Baumann et al., 2012).
The subjective effects of 4-methylmethcathinone are also
reported to be similar to MDMA (Carhart-Harris et al., 2011)
but also to cocaine (Winstock et al., 2011). Thus, mephedrone
appears to exhibit both empathogenic and stimulant
properties.
In the present study, we also characterized the widely used
cathinone MDPV, its analogs pyrovalerone and α-PVP, and two
novel and similar compounds, MDPBP and MDPPP. These
pyrovalerone cathinones all potently inhibited both NET and
DAT, confirming previous studies with MDPV (Baumann et al.,
371Monoamine transporter and receptor interaction profiles of novel psychoactive substances
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Figure 4 Effect of all substances on monoamine release. HEK 293 cells that expressed NET, DAT, and SERTwere loaded with [3H]NE,
[3H]DA, and [3H]5-HT, respectively, washed, and incubated with a high concentration of the compounds (100 mM). All para-
substituted and non-substituted amphetamines released NE, DA, or 5-HT (substances on the left of the vertical dashed line). In
contrast, the pyrovalerone cathinones did not release monoamines (substances on the right of the vertical dashed line). Monoamine
release is expressed as the percent reduction of monoamine cell content compared with vehicle (0%=no release; 100% release would
indicate that all the monoamine was released from the cells). Non-releasing monoamine transporter blockers induce nonspecific
“pseudo-efflux” (horizontal dashed line, open bars), which arises from substrate that diffuses out of the cells and from subsequent
reuptake inhibition. Compounds that produced significantly more monoamine efflux (npo0.05, nnpo0.01, nnnpo0.001) compared
with the non-releasing uptake inhibitors (negative controls, open bars) nisoxetine (HEK-NET cells), mazindol (HEK-DAT cells), and
citalopram (HEK-SERT cells) were considered monoamine releasers. The data are expressed as the mean7SEM of 3–4 independent
experiments.
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Table 2 Monoamine transporter and receptor binding affinities.
NET DAT SERT α1A α2A D1 D2 D3 H1 TAAR1rat TAAR1mouse TAAR1human
Para-(4)-substituted amphetamines
4-Fluoroephedrine 17.672.4 27.7715 39.1711 4 4.9 8.471.2 4 12 4 20 4 17 4 13 2.671.2 17.678.3 4 20
4-Fluoroamphetamine 13.571.5 11.074.2 32.179.4 4 4.9 4.470.3 4 12 4 20 4 17 4 13 0.0870.04 0.3270.10 2.371.9
4-Fluoromethamphetamine 9.070.6 10.871.4 35712 4 4.9 2.670.3 4 12 4 20 4 17 7.171.6 0.2470.1 1.770.9 6.574.4
MDMAb 26.878.7 8.473.3 13.072.3 4 6 15.0710 4 12 25713 4 17 4 13 0.3770.1 2.471.1 14.671.8
4-Fluoromethcathinonea 4 25 12.273.1 4 30 1.570.1 4 20 4 12 4 30 4 17 4 13 5.471.7 4 10 4 20
4-Bromomethcathinone 6.571.4 3.670.3 8.372.2 8.273.0 12.770.2 4 12 410 4 17 2.170.1 1.870.1 12.972.7 4 20
4-Ethylmethcathinone 16.272.2 28716 17.573.6 8.473.4 21.177.6 4 12 410 4 17 4 13 4 20 4 20 4 20
4-Methylmethcathinonea 4 25 3.470.8 4 30 3.572.2 11.075.0 4 12 4 30 4 9 4 13 4.372.0 4 10 4 20
Non para-(4)-substituted amphetamines
Ephedrine 4 30 4 30 4 30 4 12 4.170.5 4 12 4 25 4 17 4 13 3.770.9 4 15 17.174.1
Amphetaminea 1.070.6 5.773.8 4 25 4 6 2.870.8 4 12 4 30 4 17 4 13 0.2370.2 0.0970.06 0.2270.13
Methamphetamineb 3.072.2 1.870.7 24.6710 4 6 6.171.6 4 12 4 30 4 17 4 13 0.3570.1 0.5570.24 1.470.5
Methcathinoneb 1.470.7 1.370.2 4 30 3.971.3 11.973.9 4 12 4 30 4 9 4 13 4.171.2 4 10 4 20
Pyrovalerone cathinones
MDPBP 1.170.1 0.0270.002 4.171.2 4 4.9 9.471.6 4 12 4 20 4 17 4 13 4 20 4 20 4 20
MDPPP 3.571.0 0.1870.05 11.771.0 4 15 13.970.9 4 12 4 10 4 17 8.770.6 16.176.7 4 20 4 20
MDPVa 0.0870.02 0.0170.002 2.970.1 4 6 4 20 4 12 4 30 4 9 4 13 7.271.1 4 10 4 20
Naphyronea 0.1870.02 0.0470.01 0.1870.02 4 6 7.972.8 4 12 4 20 4 17 2.370.3 4 20 4 20 4 20
α-PVP 0.0670.02 0.00770.002 4 30 4 15 4 20 4 12 4 10 4 17 4 13 16.376.4 4 20 4 20
Pyrovaleronea 0.0670.01 0.0370.005 5.070.3 4 6 4 20 4 12 4 30 4 9 10.771.5 4 12 4 10 4 20
Values are Ki given as mM (mean 7SD).
aValues are from Simmler et al. (2013) except for the TAAR1 human binding.
bValues are from Simmler et al. (2014a, 2014b) except for the TAAR1 human binding.
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2013; Eshleman et al., 2013; Meltzer et al., 2006; Simmler
et al., 2013), pyrovalerone (Meltzer et al., 2006; Simmler
et al., 2013), and α-PVP (Marusich et al., 2014; Meltzer et al.,
2006). Very recently, α-PBP and α-PPP have similarly been
shown to be selective and potent catecholamine uptake
inhibitors (Marusich et al., 2014). In addition, none of the
pyrovalerone derivatives tested in the present study released
monoamines, as expected with regard to earlier findings with
pyrovalerones (Baumann et al., 2013; Simmler et al., 2013).
The pyrovalerone cathinones, which contain a pyrrolidine ring,
likely represent a subgroup of cathinones that are mechan-
istically distinct from most other cathinones that also release
monoamines similarly to the classic amphetamines (Baumann
et al., 2012; Eshleman et al., 2013; Simmler et al., 2013). The
pyrovalerones with the longest α-side chain, including α-PVP,
MDPV, and pyrovalerone, were the most potent DAT and NET
inhibitors, followed by α-PBP and MDPBP and by α-PPP and
MDPPP, respectively (Marusich et al., 2014, and the present
study). As shown for the para-substituted amphetamines in the
first series of this study, the para-(4) substitution in pyrovaler-
one or the 3,4-methylenedioxy substitution in MDPV, MDPBP,
and MDPPP increased the absolute and relative serotonergic
potency of the substances compared with the non-substituted
parent drug α-PVP in the present study or compared with α-
PBP and α-PPP (Marusich et al., 2014). However, serotonergic
activity remained low for all these substances. Interestingly,
naphyrone was the only pyrovalerone cathinone that also
potently inhibited the SERT, confirming previous studies
(Eshleman et al., 2013; Iversen et al., 2013; Meltzer et al.,
2006; Simmler et al., 2013). With the exception of naphyrone,
a hallmark of all other pyrovalerone cathinones is that they
very potently inhibit the DAT but not SERT. Dopamine
transporter-selective over SERT-selective amphetamines pro-
duce more stimulant and abuse-related effects than sub-
stances with a mixed action at the DAT and SERT (Baumann
et al., 2011; Wee et al., 2005). Accordingly, the very high DAT:
SERT inhibition ratio induced by the pyrovalerone cathinones
predicts particularly pronounced stimulant and addictive
properties for this class of substances. In fact, MDPV and α-
PVP are considered highly addictive (Aarde et al., 2013;
Baumann et al., 2013; Watterson et al., 2014). In addition,
intoxication with MDPV, naphyrone, and α-PVP is associated
with pronounced agitation, prolonged insomnia, psychotic
symptoms, tachycardia, and cardiac arrest (Derungs et al.,
2011; Eiden et al., 2013; European Monitoring Center for Drugs
and Drug Addiction, 2014b; Spiller et al., 2011). Similar
sympathetic stimulation with wild agitation and hallucinations
has also been described with MDPPP (Smollin et al., 2011).
One feature of intoxication with pyrovalerone cathinones is
their long duration of insomnia, which can last up to several
days (Derungs et al., 2011; Eiden et al., 2013). The long
duration of action could be linked to the high potency of the
drugs and an increased risk of overdosing. In addition, the
pyrovalerones are all highly lipophilic substances with
Table 3 Serotonin 5-HT2A and 5-HT2C receptor binding affinities and functional 5-HT2B receptor activity.
5-HT1A 5-HT2A 5-HT2B 5-HT2C
Receptor
bindingKi7SEM
(mM)
Receptor
binding
Ki7SEM
(mM)
Activation potency
EC507SEM (mM)
Activation efficacy %
maximum7SEM
Receptor binding
Ki7SEM (mM)
Para-(4)-substituted amphetamines
4-Fluoroephedrine 4 17 4 13 4 20 0 3.771.1
4-Fluoroamphetamine 4.470.8 11.372.6 11.474.6 49715 7.870.7
4-Fluoromethamphetamine 5.071.9 3.870.7 4 20 0 5.570.6
MDMAb 12.270.8 5.972.7 4 20 0 4 13
4-Fluoromethcathinonea 4 20 1.470.6 4 20 0 4 13
4-Bromomethcathinone 4 20 3.270.6 4 20 0 413
4-Ethylmethcathinone 4 20 6.570.9 4 20 0 9.670.4
4-Methylmethcathinonea 4 20 2.170.7 4 20 0 4 13
Non para-(4)-substituted amphetamines
Ephedrine 4 20 4 13 4 20 0 3.370.7
Amphetaminea 6.771.4 4 13 9.471.6 872 4 13
Methamphetaminea 8.170.7 4 13 4 20 0 4 13
Methcathinonea 12.873.5 3.070.6 4 20 0 4 13
Pyrovalerone cathinones
MDPBP 13.070.02 4 13 4 20 0 4 13
MDPPP 2.570.3 7.570.1 4 20 0 4 13
MDPVa 10.374.7 4 13 4 20 0 4 13
Naphyronea 6.070.2 11.772.2 420 0 4 13
α-PVP 5.270.1 4 13 4 20 0 4 13
Pyrovaleronea 13.472.1 4 13 4 20 0 4 13
aBinding values are from Simmler et al. (2013) and are included for comparison.
bBinding values are from Simmler et al. (2014a, 2014b) and are included for comparison.
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associated high brain penetration (Simmler et al., 2013) and a
high volume of distribution, resulting in longer plasma and
tissue half-lives (Derungs et al., 2011).
Most para-substituted amphetamines in this series exhib-
ited direct affinity for the serotonin 5-HT2A receptor. The
5-HT2A receptor mediates the hallucinogenic effects of
hallucinogens (Nichols, 2004) and also the hallucinogen-like
perceptual changes associated with higher doses of MDMA
(Liechti et al., 2000). Accordingly, these substances act as
indirect and direct serotonergic agonists and may induce
perceptual alterations. None of the compounds showed
relevant activity as agonists at the 5-HT2B receptor. In
contrast, other structurally related novel psychoactive sub-
stances (benzofurans) have been shown to activate the
5-HT2B receptor (Iversen et al., 2013), which has been
suggested to be associated with an increased risk of endo-
cardial fibrosis (Iversen et al., 2013). Thus, our data do not
indicate a risk for endocardial fibrosis for the substances
tested in this series. We found that amphetamines consis-
tently showed higher TAAR1 binding affinities compared with
the cathinones and ephedrins that carry a β-keto or
β-hydroxy group, respectively. Consistently, other cathinones
did not exhibit relevant TAAR1 binding (Simmler et al., 2013,
2014a). We also found that amphetamines not only bind to
rodent receptors but also human TAAR1. In rodents, non-
β-keto amphetamines inhibit their own stimulant effects via
TAAR1 activation (Di Cara et al., 2011). The lack of this
TAAR1-mediated “auto-inhibition” with the cathinones may
contribute to more stimulant-like and addictive properties of
this new class of novel psychoactive substances compared
with traditional amphetamines (Simmler et al., 2013).
A particular strength of the present study was the inclusion
a relatively large number of substances and comprehensive
characterization at many targets. Other studies typically only
assessed monoamine uptake inhibition and not substrate
release or binding affinities for other monoamine receptors.
In addition, in the transporter inhibition assays, we also inc-
luded high concentrations when needed to allow for bet-
ter characterization of full dose–response curves and deter-
mination of higher IC50 values.
The present study also has limitations. For example, we did
not investigate the effects of the drugs on intracellular targets,
such as the vesicular monoamine transporter or monoamine
oxidase, which are affected by amphetamines (Eshleman et al.,
2013). We also focused on pharmacodynamics in vitro. Many
additional factors, such as brain penetration, metabolism, and
pharmacokinetics, also play a role in the clinical effects of
these substances, which require further study in vivo.
5. Conclusion
Para-(4)-substituted amphetamines are more serotonergic
than their non-substituted analogs, likely resulting in more
MDMA-like serotonergic subjective and acute toxic effects.
Pyrovalerone cathinones are potent NET and DAT inhibitors
that are likely associated with significant stimulant-type
effects and toxicity and a high risk of addiction.
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BACKGROUND AND PURPOSE
Benzofurans are newly used psychoactive substances, but their pharmacology is unknown. The aim of the present study was
to pharmacologically characterize benzofurans in vitro.
EXPERIMENTAL APPROACH
We assessed the effects of the benzofurans 5-APB, 5-APDB, 6-APB, 6-APDB, 4-APB, 7-APB, 5-EAPB and 5-MAPDB and
benzodifuran 2C-B-FLY on the human noradrenaline (NA), dopamine and 5-HT uptake transporters using HEK 293 cells that
express the respective transporters. We also investigated the release of NA, dopamine and 5-HT from monoamine-preloaded
cells, monoamine receptor-binding affinity and 5-HT2A and 5-HT2B receptor activation.
KEY RESULTS
All of the benzofurans inhibited NA and 5-HT uptake more than dopamine uptake, similar to
methylenedioxymethamphetamine (MDMA) and unlike methamphetamine. All of the benzofurans also released monoamines
and interacted with trace amine-associated receptor 1 (TA1 receptor), similar to classic amphetamines. Most benzofurans were
partial 5-HT2A receptor agonists similar to MDMA, but also 5-HT2B receptor agonists, unlike MDMA and methamphetamine.
The benzodifuran 2C-B-FLY very potently interacted with 5-HT2 receptors and also bound to TA1 receptors.
CONCLUSIONS AND IMPLICATIONS
Despite very similar structures, differences were found in the pharmacological profiles of different benzofurans and compared
with their amphetamine analogues. Benzofurans acted as indirect monoamine agonists that interact with transporters similarly
to MDMA. The benzofurans also interacted with 5-HT receptors. This pharmacological profile probably results in MDMA-like
entactogenic psychoactive properties. However, benzofurans induce 5-HT2B receptor activation associated with heart valve
fibrosis. The pharmacology of 2C-B-FLY indicates predominant hallucinogenic properties and a risk for vasoconstriction.
Abbreviations
2C-B-FLY, 8-bromo-2,3,6,7-benzo-dihydro-difuran-ethylamine; 4-APB, 4-(2-aminopropyl)benzofuran; 5-APB,
5-(2-aminopropyl)benzofuran; 5-APDB, 5-(2-aminopropyl)-2,3-dihydrobenzofuran; 5-EAPB, 5-(2-ethylaminopropyl)
benzofuran; 5-MAPDB, 1-(2,3-dihydrobenzofuran-5-yl)-N-methylpropan-2-amine; 6-APB, 6-(2-aminopropyl)benzofuran;
6-APDB, 6-(2-aminopropyl)-2,3-dihydrobenzofuran; 7-APB, 7-(2-aminopropyl)benzofuran; β-keto-MDA, β-keto-3,4-
methylenedioxyamphetamine; bromo-dragonFLY, 1-(8-bromobenzo[1,2-b;4,5-b′]difuran-4-yl)-2-aminopropane; DAT,
dopamine transporter; MDMA, 3,4-methylenedioxymethamphetamine; MDA, 3,4-methylenedioxyamphetamine; NET,
noradrenaline transporter; SERT, 5-HT transporter; TA receptor, trace amine-associated receptor
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Introduction
Novel psychoactive substances are newly used designer drugs
(‘Internet drugs’, ‘research chemicals’, ‘legal highs’) that
potentially pose similar health risks to classic illicit sub-
stances. In recent years, the number of newly detected
psychoactive substances on the illicit drug market has dra-
matically increased. In the European Union, 41 novel psy-
choactive substances were identified for the first time in 2010,
49 were identified in 2011, 73 were identified in 2012 and 81
were identified in 2013 within the European Early Warning
System (EMCDDA, 2014).
Benzofurans are a group of novel psychoactive substances
(King, 2014) of particular interest because they are structur-
ally very similar to the popular recreational drug 3,4-
methylenedioxymethamphetamine (MDMA) and its
active metabolite 3,4-methylenedioxyamphetamine (MDA;
Greene, 2013). 5-(2-Aminopropyl)benzofuran (5-APB) and
6-(2-aminopropyl)benzofuran) (6-APB) are benzofuran
analogues of MDA (Figure 1). 5-(2-Aminopropyl)-2,3-
dihydrobenzofuran (5-APDB) and 6-(2-aminopropyl)-2,3-
dihydrobenzofuran (6-APDB) are dihydrobenzofuran
analogues (Figure 1) that were originally synthesized
for research purposes (Monte et al., 1993). 4-(2-
Tables of Links
TARGETS
GPCRsa Transportersb
5-HT1A receptor D1 receptor DAT
5-HT2A receptor D2 receptor NET
5-HT2B receptor D3 receptor SERT
5-HT2C receptor H1 receptor
α1A adrenoceptor TA1 receptor
α2A adrenoceptor
LIGANDS
5-HT Noradrenaline Pyrilamine
Butaclamol Mazindole Rauwolscine
Citalopram MDMA Risperidone
Clozapine Mesulergine RO5166017
Dopamine Methamphetamine SCH23390
Ketanserin Mianserin Spiperone
LSD Phentolamine WIN35428
Nisoxetine Prazosin
These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://
www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and are
permanently archived in the Concise Guide to PHARMACOLOGY 2013/14 (a,bAlexander et al., 2013a,b).
Figure 1
Chemical structures of benzofurans and related amphetamines.
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Aminopropyl)benzofuran (4-APB) and 7-(2-
aminopropyl)benzofuran (7-APB) are positional isomers of
5-APB and 6-APB. 1-(2,3-Dihydrobenzofuran-5-yl)-N-
methylpropan-2-amine (5-MAPDB) is a dihydrobenzofuran
analogue of MDMA, and 5-(2-ethylaminopropyl)benzofuran
(5-EAPB) is a benzofuran analogue of MDMA but with an
N-ethyl group (Figure 1).
5-APB and 6-APB appeared on the drug market in 2010–
2011 (Chan et al., 2013; Jebadurai et al., 2013; Stanczuk et al.,
2013; Archer et al., 2014; Elliott and Evans, 2014; King, 2014),
with reports of intoxication (Chan et al., 2013; Greene, 2013;
Jebadurai et al., 2013; Seetohul and Pounder, 2013). 4-APB
was first reported to the EMCDDA in 2010 (King, 2014) and is
typically detected in products that are sold as 6-APB as a
by-product (Stanczuk et al., 2013; Strano Rossi et al., 2014).
Users report that the effects of 5-APB and 6-APB are compa-
rable with MDMA but more intense (Greene, 2013; Jebadurai
et al., 2013). Adverse effects include nausea, sympathomi-
metic stimulation and agitation (Chan et al., 2013; Greene,
2013). 5-APDB and 6-APDB were first reported to the
EMCDDA in 2012, and another three benzofurans, including
5-EAPB, were first reported in 2013 (King, 2014). Presently, no
published studies have reported the psychotropic and toxic
effects of these benzofurans, but 5-APDB, 6-APDB and 5-EAPB
are being discussed in drug user forums (Bluelight, 2013a,b;
Drugs-Forum, 2013). Little is known about the pharmacology
of benzofurans. 5-APB and 6-APB have been shown to inhibit
the human dopamine, noradrenaline and 5-HT transporters
(DAT, NET and SERT, respectively; Iversen et al., 2013) and are
agonists at the rat 5-HT2A receptor (Dawson et al., 2014) and
human and rat 5-HT2B receptor (Iversen et al., 2013; Dawson
et al., 2014). Additionally, fast cyclic voltammetry experi-
ments in rat brain slices indicated that 5-APB releases dopa-
mine at high concentrations (Dawson et al., 2014). 5-APDB
and 6-APDB also inhibited the monoamine transporters with
greater affinity for the SERT over the DAT compared with
MDA in crude rat synaptosome preparations (Monte et al.,
1993).
The benzodifurans 8-bromo-2,3,6,7-benzo-dihydro-
difuran-ethylamine (2C-B-FLY) and 1-(8-bromobenzo[1,2-
b;4,5-b′]difuran-4-yl)-2-aminopropane) (bromo-dragonFLY)
are known as ‘fly’ drugs because of their chemical structures
(Figure 1). A series of benzodifurans were originally synthe-
sized to study 5-HT2A receptor function (Monte et al., 1997;
Parker et al., 1998; Chambers et al., 2001). The recreational
use of 2C-B-FLY and bromo-dragonFLY began to be reported
in 2007 (Andreasen et al., 2009; Greene, 2013; King, 2014),
and there are case reports of severe agitation, hallucinations,
seizures and fatalities associated with bromo-dragonFLY
(Andreasen et al., 2009; Wood et al., 2009; Nielsen et al.,
2010). 2C-B-FLY and bromo-dragonFLY are potent 5-HT2A
receptor agonists (Monte et al., 1996; Chambers et al., 2001),
but interactions with other monoamine receptors and their
transporters have not been tested.
Systematic evaluations of the pharmacological profiles of
benzofurans are lacking. We determined the potencies of a
series of benzofurans and the benzodifuran 2C-B-FLY to
inhibit the DAT, NET and SERT and tested transporter-
mediated monoamine release in vitro. We also characterized
the binding profiles at monoamine receptors and assessed
5-HT2A and 5-HT2B receptor activation. The 5-HT2A receptor
mediates hallucinogenic effects (Nichols, 2004), and the
5-HT2B receptor has been implicated in drug-associated endo-
cardial fibrosis (Roth, 2007). MDMA, MDA, β-keto-MDA and
methamphetamine were included as comparator substances.
Methods
Monoamine uptake transport inhibition
Inhibition of the human NET, DAT and SERT was assessed in
HEK 293 cells that were stably transfected with the transport-
ers as specified previously (Hysek et al., 2012c). Briefly, the
cells were suspended in uptake buffer. We incubated the cells
for 10 min with different concentrations of the test com-
pounds and then added the corresponding [3H] monoamine
(5 nM final concentration) at room temperature. After
10 min, we stopped uptake by separating the cells from the
buffer using centrifugation through silicone oil (Hysek et al.,
2012c). The centrifugation tubes were frozen in liquid nitro-
gen and cut to separate the cell pellet from the silicone oil
and assay buffer layers. The cell pellet was then lysed. Scin-
tillation fluid was added, and radioactivity was counted on a
β-counter. Non-specific uptake was determined for each
experiment in the presence of 10 μM fluoxetine for SERT
cells, 10 μM nisoxetine for NET cells and 10 μMmazindol for
DAT cells and subtracted from the total counts to yield spe-
cific uptake (100%). The data were fitted by non-linear regres-
sion to variable slope sigmoidal dose–response curves, and
IC50 values were calculated using Prism software (GraphPad,
San Diego, CA, USA). DAT : SERT inhibition ratios were cal-
culated as 1/DAT IC50:1/SERT IC50. Higher relative potency at
the DAT indicates a higher abuse potential, whereas relatively
increased activity of the 5-HT system is linked to a reduction
in abuse potential and more MDMA-like psychotropic effects
(Wee et al., 2005). Stimulant amphetamines, such as meth-
amphetamine, have a DAT : SERT inhibition ratio >10,
whereas MDMA and other substances with MDMA-like psy-
chotropic effects have a DAT : SERT inhibition ratio close to
0.1 (Baumann et al., 2012; Simmler et al., 2013; 2014a,b).
Transporter-mediated monoamine release
We studied the effects of a single high dose (100 μM) of the
test compounds on transporter-mediated NA, 5-HT and dopa-
mine efflux in HEK 293 cells that overexpressed the respective
human monoamine transporter, as previously reported in
detail (Simmler et al., 2013). Briefly, adherent cells were incu-
bated with the respective radiolabeled monoamine (10 nM
[3H]-NA and 10 μM unlabelled NA, 10 nM [3H]-dopamine and
1 μM unlabelled dopamine, and 10 nM [3H]-5-HT) for 20 min
at 37°C. We then washed the cells twice with buffer and
added 1 mL of buffer that contained the test compound
(100 μM final concentration). We stopped [3H]-5-HT and [3H]-
dopamine release after 15 min and [3H]-NA release after
45 min by washing twice with ice-cold buffer. We quantified
the radioactivity that remained in the cells. Non-specific
‘pseudo-efflux’, which arises from non-specific substrate
release and subsequent reuptake inhibition (Scholze et al.,
2000), was assessed for each experiment using the transporter
inhibitors nisoxetine (NET cells), citalopram (SERT cells) and
mazindol (DAT cells) at 10 μM as negative control conditions.
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ANOVA followed by the Holm–Sidak test was used to compare
compound-induced release with the negative controls. Sub-
stances that induced significantly higher monoamine efflux
compared with the negative control were considered mono-
amine releasers.
Radioligand binding assays
The radioligand binding assays were performed as described
previously (Hysek et al., 2012c; Simmler et al., 2013). Briefly,
membrane preparations of HEK 293 cells (Invitrogen, Zug,
Switzerland) that overexpress the respective transporters
(Tatsumi et al., 1997) or receptors (human genes, except rat
and mouse genes for TA1 receptor; Revel et al., 2011) were
incubated with the radiolabeled selective ligands at concen-
trations equal to Kd, and ligand displacement by the com-
pounds was measured. Specific binding of the radioligand to
the target receptor was defined as the difference between the
total binding and non-specific binding determined in the
presence of selected competitors, in excess. The following
radioligands and competitors, respectively, were used:
N-methyl-[3H]-nisoxetine and indatraline (NET), [3H]-
citalopram and indatraline (SERT), [3H]WIN35,428 and inda-
traline (DAT), [3H]-8-hydroxy-2-(di-n-propylamino)tetralin
and indatraline (5-HT1A receptor), [3H]-ketanserin and spiper-
one (5-HT2A receptor), [3H]-mesulergine and mianserin
(5-HT2C receptor), [3H]-prazosin and risperidone (α1 adreno-
ceptor), [3H]-rauwolscine and phentolamine (α2 adrenocep-
tor), [3H]-SCH 23390 and butaclamol (D1 receptor),
[3H]-spiperone and spiperone (D2 and D3 receptors), [3H]-
pyrilamine and clozapine (histamine H1 receptor), and
[3H]-RO5166017 and RO5166017 (TA1 receptor). IC50 values
were determined by calculating non-linear regression
curves for a one-site model using three to five independent
10-point concentration–response curves for each compound.
Ki (affinity) values, which correspond to the dissociation
constants, were determined using the Cheng–Prusoff
equation.
Functional 5-HT2A and 5-HT2B
receptor activity
The 5-HT2B receptor functional assay was performed as
described previously (Jensen et al., 2008). Briefly, human
5-HT2B receptor-expressing HEK 293 cells were incubated at
37°C in 96-well plates coated with poly-D-lysine. The growth
mediumwas removed by snap inversion, and 100 μL of Fluo-4
solution (calcium indicator; Molecular Probes, Eugene, OR,
USA) was added to each well. The plates were incubated for
45 min at 31°C. The Fluo-4 solution was removed by snap
inversion, and 100 μL of Fluo-4 solution was added a second
time. The cells were then incubated for another 45 min at
31°C. Immediately before testing, the cells were washed with
HBSS (Gibco) and 20 mM HEPES (assay buffer; Gibco, Life
Technologies, Zug, Switzerland) using an EMBLA cell washer,
and 100 μL assay buffer was added. The plate was placed in a
fluorescence imaging plate reader (FLIPR), and 25 μL of the test
substances diluted in assay buffer was added online. The
increase in fluorescence was then measured. EC50 values were
derived from the concentration–response curves using non-
linear regression. Efficacy (maximal activity) is expressed rela-
tive to the activity of 5-HT, which was used as a control set to
100%.
Cytotoxicity
To confirm cell integrity during the pharmacological assays,
cytotoxicity was assessed using the ToxiLightTM bioassay
(Lonza, Basel, Switzerland) according to the manufacturer’s
instructions. The assay quantitatively measures the release of
adenylate kinase from damaged cells providing a highly sen-
sitive method for measuring cytolysis (Crouch et al., 1993;
Hysek et al., 2012c; Felser et al., 2014). Cells grown in 96-well
plates were exposed to the compounds at a high concentra-
tion of 100 μM. All test conditions contained DMSO 0.1%
(v:v) which is non-toxic and was also used as negative
control. TritonTM X-100 (0.1%, Sigma-Aldrich, Buchs, Switzer-
land) lyses cells and was used as positive control. After 4 h of
incubation at 37°C, 10 μL of supernatant per well was
removed and combined with 50 μL of ToxiLightTM reagent
and luminescence recorded using a Tecan InfiniteTM 200 Pro
(Tecan, Männedorf, Switzerland) plate reader.
Statistical analyses
The uptake transporter inhibition data were fit by non-linear
regression to variable-slope sigmoidal dose-response curves,
and IC50 values were calculated using Prism software (Graph-
Pad, San Diego, CA, USA). ANOVA followed by the Holm-
Sidak test was used to compare compound-induced release
with the negative controls. Substances that induced signifi-
cantly higher monoamine efflux compared with the negative
control were considered monoamine releasers. IC50 values for
radioligand binding were determined by calculating nonlin-
ear regression curves for a one-site model using three to five
independent 10-point concentration-response curves for
each compound. Ki (affinity) values, which correspond to the
dissociation constants, were determined using the Cheng-
Prusoff equation. EC50 values for 5-HT2 receptor activation
were derived from the concentration-response curves using
nonlinear regression.
Drugs
MDMA, MDA, β-keto-MDA, methamphetamine and 2C-B-
FLY were obtained from Lipomed (Arlesheim, Switzerland).
6-APB, 6-APDB, 5-APB, 5-APDB, 4-APB, 7-APB and 5-MAPDB
were obtained from Cayman Chemicals (Ann Arbor, MI,
USA). 5-EAPB was obtained from the Forensic Institute
(Zurich, Switzerland). All of the drugs were used as racemic
hydrochloride salts, with the exception of d-
methamphetamine. Purity was at least 98% for all of the
substances, with the exception of 2C-B-FLY, whose purity was
approximately 95% as determined by HPLC.
Results
Monoamine uptake transporter inhibition
Uptake inhibition curves are depicted in Figure 2, and the
corresponding IC50 values andDAT : SERT inhibition ratios are
listed in Table 1. All of the benzofurans inhibited the NET at
submicromolar concentrations, similar to MDMA, MDA and
methamphetamine. All of the benzofurans were weak DAT
inhibitors compared with methamphetamine and more
similar to MDMA, which was also a weak DAT inhibitor. Only
BJPNovel psychoactive benzofurans
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5-APB, 6-APB and 5-EAPB were more potent at the DAT com-
pared with MDMA and MDA. In contrast, the dihydrobenzo-
furans 5-APDB, 6-APDB and 5-MAPDB were inactive at the
DAT (IC50 >30 μM). 5-APB, 5-APDB, 6-APB and 5-EAPB inhib-
ited the SERT at submicromolar concentrations and more
potently than MDMA. 6-APDB and 5-MAPDB inhibited the
SERT in the 1–3 micromolar concentration range, similar to
MDMA. 4-APB and 7-APB exhibited low potency at the SERT,
more similar to methamphetamine. The DAT : SERT inhibi-
tion ratio for all of the benzofurans was low, consistent with
greater 5-hydroxytryptaminergic versus dopaminergic activity
that is overall similar to MDMA. The dihydrobenzofurans
(5-APDB, 6-APDB and 5-MAPDB) and 5-APB exhibited the
lowest DAT : SERT inhibition ratios (lower than MDMA). In
contrast, 4-APB and 7-APB exhibited the highest DAT : SERT
inhibition ratios, consistent with their low potency at the
SERT and showing a profile that is between MDMA and
methamphetamine with regard to 5-hydroxytryptaminergic
versus dopaminergic activity. In terms of structure–activity
relationships, the dihydro-compounds 5-APDB and 6-APDB
had similar noradrenergic and 5-hydroxytryptaminergic
activities compared with their analogues 5-APB and 6-APB but
were markedly less potent at the DAT. The monoamine trans-
porter inhibition potencies of the positional isomers 4-APB
and 7-APB were reduced, particularly for the SERT, compared
with their analogues 5-APB and 6-APB. Additionally, the
oxygen in the para-position for 5-APB and 5-APDB resulted in
higher absolute and relative potency at the SERT compared
with 6-APB and 6-APDB respectively. β-Keto-substitution in
the β-keto-MDA versus MDA structures increased dopaminer-
gic versus 5-hydroxytryptaminergic activity. The benzodi-
furan 2C-B-FLY was inactive at all of the monoamine
transporters (IC50 >50 μM).
Monoamine release
At high concentrations, all of the benzofurans released
at least one of the monoamines through the respective
Figure 2
Monoamine uptake transporter inhibition. Concentration–response curves show the uptake inhibition of [3H]-NA, [3H]-dopamine and [3H]-5-HT
in HEK 293 cells transfected with the respective monoamine transporter. The data are expressed as the mean ± SEM of three to four independents
experiments. Curves were fitted to the data with non-linear regression. The corresponding IC50 values are shown in Table 1.
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monoamine transporter, similar to the amphetamines
(Figure 3). In contrast, 2C-B-FLY was not a monoamine
releaser.
Binding affinities
The benzofurans interacted with the monoamine transport-
ers but also with several monoamine receptors (Tables 2 and
3). All of the benzofurans exhibited submicromolar affinity
for the TA1 receptor, except for 5-EAPB, which was inactive at
mouse TA1 receptos. Benzofurans showed mostly higher
potency at TA1 receptors than the classic amphetamines. All
of the benzomonofurans exhibited binding affinities for the
5-HT2A receptor in the micromolar range (0.8–3.4 μM). Func-
tionally, most of them acted as low-potency partial agonists
similar to MDMA and MDA but unlike methamphetamine.
Most of the benzofurans were also partial agonists at the
5-HT2B receptor. In contrast MDMA and methamphetamine
did not stimulate 5-HT2B receptors. With the exception of
7-APB and 5-EAPB, the benzofurans exhibited submicromolar
binding affinities at the 5-HT2C receptor. Binding potencies
at the 5-HT1 receptor varied among different benzofurans.
Only 7-APB showed submicromolar binding affinity. Potent
binding to most of the assessed 5-HT receptor subtypes dis-
tinctly discriminated the benzofurans from the pharmaco-
logical profiles of their related amphetamines, which
exhibited no or low 5-HT1A affinity and did not bind to 5-HT2B
or 5-HT2C receptors except for MDA with a Ki value of 3 μM
at 5-HT2C. Most of the benzofurans bound to α1A- and α2A-
adrenoceptors in the 3–12 and 0.1–6 μM ranges respectively.
There was no binding to dopamine receptors and only low-
affinity binding to histamine H1 receptors (>10 μM for most
of the drugs). The benzodifuran 2C-B-FLY did not bind to the
monoamine transporters but interacted with all of the recep-
tors tested in the present study and particularly exhibited
high affinity for TA1 receptors and all of the 5-HT2 receptors.
Importantly, 2C-B-FLY was a very potent agonist at the 5-HT2A
receptor. 2C-B-FLY thus exhibited a pharmacological profile
that was distinct from the mono-benzofurans and related
amphetamines.
Cytotoxicity
None of the compounds investigated produced cytotoxicity,
thus confirming cell integrity during the functional assays in
this study.
Discussion
We determined the in vitro pharmacological profiles of new
benzofurans that are recreationally abused compared with
their well-known amphetamine analogues. The benzofurans
blocked monoamine transporters and induced transporter-
mediated monoamine release similarly to MDMA. More than
MDMA andmethamphetamine, the benzofurans also directly
stimulated adrenoceptors and 5-HT receptors. The benzodi-
furan 2C-B-FLY was a potent agonist at 5-HT1A, 5-HT2A, 5-HT2B
and 5-HT2C receptors, consistent with the reported hallucino-
genic properties of 2C-B-FLY.
Table 1
Monoamine transporter inhibition
NET DAT SERT DAT/SERT inhibition ratio
IC50 (μM) (95% CI) IC50 (μM) (95% CI) IC50 (μM) (95% CI) Ratio (95% CI)
Benzofurans
5-APB 0.16 (0.08–0.3) 6.1 (4–9) 0.29 (0.17–0.5) 0.05 (0.02–1.2)
5-APDB 0.29 (0.2–0.5) 49 (33–73) 0.58 (0.4–0.9) 0.01 (0.005–0.03)
6-APB 0.19 (0.1–0.3) 3.3 (2.4–4.5) 0.93 (0.7–1.3) 0.29 (0.16–0.54)
6-APDB 0.56 (0.4–0.8) 33 (25–43) 2.3 (1.4–3.9) 0.07 (0.03–0.16)
5-MAPDB 0.96 (0.5–1.7) 77 (62–96) 1.2 (0.7–2) 0.02 (0.01–0.03)
4-APB 0.24 (0.2–0.3) 12 (9–16) 5.5 (3.4–8.7) 0.46 (0.21–1.0)
7-APB 0.27 (0.2–0.3) 20 (16–26) 13 (9–18) 0.65 (0.35–1.1)
5-EAPB 0.56 (0.4–0.7) 4.9 (3–8) 0.72 (0.5–1.1) 0.15 (0.07–0.35)
Benzodifuran
2C-B-FLY 94 (72–124) 187 (161–217) 73 (58–92) 0.39 (0.27–0.57)
Related amphetamines
MDMA 0.36 (0.2–0.6) 16.7 (16.3–17) 2.4 (1.4–3.0) 0.14 (0.08–0.18)
MDA 0.42 (0.3–0.6) 20.5 (20.3–20.6) 4.9 (3.5–6.8) 0.24 (0.17–0.33)
β-Keto-MDA 1.6 (1.1–2.3) 14 (10–18) 21 (15–28) 1.5 (0.8–2.8)
Methamphetamine 0.14 (0.09–0.2) 0.87 (0.84–0.91) 13.6 (13.5–13.8) 15.6 (14.8–16.4)
Values are means of three to four independent experiments and 95% confidence intervals (CI). DAT/SERT inhibition ratio = 1/DAT IC50: 1/SERT
IC50.
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Monoamine uptake transporter inhibition and
monoamine release
All of the benzofurans inhibited the NET at submicromolar
concentrations, similar to MDMA, MDA and methampheta-
mine. NA mediates sympathomimetic stimulation (Hysek
et al., 2011), and this finding predicts the cardiostimulant
and psychostimulant properties of these benzofurans, similar
to MDMA and methamphetamine. Unlike the relatively con-
stant NET inhibition, the potencies of the benzofurans to
inhibit the DAT and SERT notably varied, resulting in
DAT : SERT inhibition ratios that ranged from 0.01 to 0.65.
Specifically, the dihydrobenzofurans 5-APDB and 5-MAPDB
exhibited the highest preference for the SERT versus DAT
(more selective than MDMA), followed by 5-APB, 6-APDB and
5-EAPB, which exhibited a DAT : SERT inhibition ratio similar
to MDMA. With DAT : SERT ratios of 0.46 and 0.65, 4-APB
and 7-APB were the benzofurans with the most dopaminergic
profiles and were relatively more dopaminergic than MDMA.
Stimulants like methamphetamine exhibit a DAT : SERT ratio
>10, whereas MDMA and other entactogens exhibit a
DAT : SERT ratio of 0.01–1 (Simmler et al., 2013; 2014a,b;
Liechti, 2014b). Accordingly, based on their DAT : SERT inhi-
bition ratios, all of the benzofurans can be expected to
produce MDMA-like entactogenic subjective effects in
humans. In contrast to the benzofurans, the benzodifuran
2C-B-FLY blocked monoamine transporters only at very high
concentrations but had high affinity for 5-HT receptors. Thus,
monoamine transporter inhibition is unlikely to contribute
to the mechanism of action of 2C-B-FLY as is also the case
for the structurally similar substance 2C-B and related
compounds of the 2C phenethylamine series containing
methoxy groups at positions 2 and 5 of the benzene ring
(Acuna-Castillo et al., 2002; Hill and Thomas, 2011;
Eshleman et al., 2014).
Only a few other studies have determined the monoam-
ine transporter inhibition profiles of some of the benzo-
furans. Consistent with our findings, 5-APDB and 6-APDB
inhibited the SERT more potently than the DAT in rat syn-
aptosomes (Monte et al., 1993). The oxygen in the para-
position in the 5-APDB and 5-APB structures enhanced the
5-hydroxytryptaminergic versus dopaminergic properties
compared with 6-APDB and 6-APB, respectively, as shown in
the present study and previously for 5-APDB versus 6-APDB
in rat synaptosomes (Monte et al., 1993). Drug discrimination
studies in rats showed that 5-APDB and 6-APDB substituted
for MDMA-like 5-hydroxytryptaminergic drugs but not the
more dopaminergic stimulant amphetamine (Monte et al.,
1993). These behavioural findings support our hypothesis
that 5-APDB and 6-APDB produce subjective effects that are
similar to MDMA, and entactogenic effects have been
reported by users (Bluelight, 2013a,b; Drugs-Forum, 2013).
The monoamine transporter inhibition profiles for 5-APB and
6-APB were determined in one previous study (Iversen et al.,
2013). In contrast to our results, this study showed that 5-APB
and 6-APB inhibited the DAT more potently than the SERT
(Iversen et al., 2013). However, MDMA did not show the
5-hydroxytryptaminergic preference that is typically reported
by others (Rothman et al., 2001; Han and Gu, 2006; Hysek
et al., 2012c; Simmler et al., 2013). Consistent with the
present results, the inhibition profiles for 5-APB and 6-APB
were similar to MDMA and unlike methamphetamine
(Iversen et al., 2013). The reinforcing effects of benzofurans
have not yet been studied in drug self-administration studies.
There is a decrease in reinforcing potency and efficacy among
monoamine-releasing agents when 5-HT releasing potency is
increased relative to dopamine (Wee et al., 2005). The rela-
tively high 5-hydroxytryptaminergic properties of the benzo-
furans in vitro would indicate lower addictive properties (Wee
et al., 2005; Liechti, 2014b), more similar to MDMA, which is
Figure 3
Monoamine release. Monoamine release was induced by a high
concentration of the compound (100 μM) after preloading the
transporter-transfected cells with the respective radiolabelled mono-
amine. All of the benzofurans released NA, dopamine and 5-HT
similarly to methamphetamine and MDMA. In contrast, the benzo-
difuran 2CB-FLY was not a monoamine releaser. Transporter blockers
induced non-specific ‘pseudo-efflux’ (horizontal dashed line, open
bars), which arises from substrate that diffuses out of the cells and
from subsequent reuptake inhibition. Compounds that produced
significantly more monoamine efflux (*P < 0.05, **P < 0.01, ***P <
0.001) compared with the respective non-releasing uptake inhibitors
(negative controls, open bars) were considered monoamine releas-
ers. The data are expressed as the mean ± SEM of three to four
independent experiments.
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not a strong reinforcer in self-administration studies (Lamb
and Griffiths, 1987; Cole and Sumnall, 2003) than to
methamphetamine.
All of the benzofurans also released 5-HT, NA and/or
dopamine through their respective transporters, similar to
their amphetamine analogues and other amphetamine
derivatives (Simmler et al., 2013; 2014a,b). Dopamine release
has also been previously documented for 5-APB in voltam-
metric studies of rat brain slices (Dawson et al., 2014). In
contrast to the benzofurans, 2C-B-FLY did not release mono-
amines. Our release assay was designed to qualitatively assess
monoamine release because we used only one high concen-
tration of the substances to induce transporter-mediated
monoamine efflux. Additional studies that include the assess-
ment of transporter-mediated ionic currents and in vivo
microdialysis could be useful to further characterize and
quantify monoamine release and its contribution to the
mechanism of action of the benzofurans.
Receptor-binding profiles
The present study found several important high-potency
interactions between the benzofurans and various monoam-
ine receptors. 6-APB, 6-APDB, 4-APB, 7-APB and 2C-B-FLY all
bound to α2A-adrenoceptors, which are known to modulate
NA release and sympathomimetic activity (Hysek et al.,
2012a). As expected (Monte et al., 1996), 2C-B-FLY potently
interacted with 5-HT2 receptors. Specifically, 2C-B-FLY
potently bound to the human 5-HT2A receptor (Ki = 0.01 μM),
consistent with the previously documented nanomolar affin-
ity for rat cortical 5-HT2A receptors (Monte et al., 1996). Even
higher potency binding to 5-HT2A receptors has been shown
for the benzodifuran bromo-dragonFLY in rat (Monte et al.,
1996; Chambers et al., 2001) and human (Monte et al., 1996)
5-HT2A receptors. In the present study, 2C-B-FLY was also a
very potent functional 5-HT2A receptor agonist. 2C-B-FLY
resembles the structures of the 2C series phenethylamines,
which are also potent 5-HT2A receptor agonists (Nelson et al.,
1999; Acuna-Castillo et al., 2002; Hansen et al., 2014).
Consistent with the predicted lysergic acid diethylamide
(LSD)-like properties of substances with high 5-HT2A receptor
affinity, both 2C-B-FLY and bromo-dragonFLY completely
substituted for LSD in drug discrimination studies (Monte
et al., 1996). The affinity of 2C-B-FLY for the 5-HT1A receptor
was relatively low, which has also been shown for rat 5-HT1A
receptors (Monte et al., 1996). The 5-HT2A receptor is thought
to mediate the alterations in perception induced by halluci-
nogens (Vollenweider et al., 1998; Nelson et al., 1999;
Nichols, 2004) and therefore is likely to be the key target in
the mechanism of action of benzodifuran hallucinogens.
Interestingly, some of the benzofurans also exhibited micro-
molar affinity for the 5-HT2A receptor and were low-potency
5-HT2A receptor partial agonists similar to MDMA and MDA,
but in contrast to methamphetamine. Binding to 5-HT2A
receptors at micromolar concentrations has also been previ-
ously shown for 5-APB and 6-APB (Iversen et al., 2013). 5-APB
also constricts the rat aorta via an agonist action on 5-HT2A
receptors (Dawson et al., 2014). Thus, some benzofurans
could have hallucinogenic properties because of 5-HT2A recep-
tor stimulation, in addition to their MDMA-like entactogenic
subjective effects. Psychosis and hallucinations have been
reported after the use of 6-APB (Chan et al., 2013; Greene,
2013). However, in drug discrimination studies, 5-APDB and
6-APDB did not substitute for LSD in rats (Monte et al., 1993),
consistent with their lower binding affinity compared with
5-APB and 6-APB. In terms of clinical toxicity, the 5-HT2A
receptor agonist and possible α1-adrenoceptor agonist action
could enhance the risk for vasoconstriction, hyperthermia
and hypertension. Both α1 and 5-HT2A receptors are
implicated in substance-induced vasoconstriction (Blessing
et al., 2003; Docherty and Green, 2010; Dawson et al., 2014)
and associated hypertension (Hysek et al., 2013) and hyper-
thermia (Liechti et al., 2000; Hysek et al., 2012b; Liechti,
2014a) in humans. In fact, hypertension, hyperpyrexia
and cases of severe limb ischaemia have been reported after
the use of bromo-dragonFLY (Thorlacius et al., 2008; Wood
et al., 2009; Nielsen et al., 2010), a benzodifuran structurally
similar to 2C-B-FLY. Direct agonist actions at the 5-HT2A
receptor compared with an indirect action via 5-HT release
can also be expected to result in longer lasting effects as
described for 5-hydroxytryptaminergic hallucinogens
(Schmid et al., 2014) and compared with MDMA (Hysek et al.,
2012c).
In humans, MDMA is mainly inactivated by
O-demethylation but also N-demethylated to the minor but
active metabolite MDA (Hysek et al., 2013). Similarly,
5-MAPDB and 5-EAPB are N-dealkylated (Welter et al., 2015)
to 5-APDB and 5-APB respectively. As shown in the present
study, the N-dealkylated substances MDA, 5-APDB and 5-APB
activate 5-HT2A and 5-HT2B receptors more potently and also
more potently bind to 5-HT2C receptors than their parent
compounds MDMA, 5-MAPDB and 5-EAPB respectively.
Thus, the formation of active metabolites probably adds
enhanced 5-HT2A and 5-HT2B receptor-associated toxicity in
these cases.
2C-B-FLY and several of the benzofurans acted as partial
agonists at the 5-HT2B receptor as previously shown for 5-APB
(Iversen et al., 2013; Dawson et al., 2014) and 6-APB (Iversen
et al., 2013). In contrast, no such 5-HT2B receptor agonist
properties were observed for the classic amphetamines
MDMA and methamphetamine in the present study. 5-HT2B
receptors have been implicated in substance-induced heart
valve fibrosis (Setola et al., 2003; Bhattacharyya et al., 2009).
5-HT2B receptor activation by 2C-B-FLY, 5-APB, 6-APB, 6-APDB
and 7-APB occurred at submicromolar concentrations that are
likely to be present when these drugs are used by drug users
to induce subjective effects.
All of the benzofurans bound to TA1 receptors, many at
even higher potency than MDMA or methamphetamine.
MDMA and methamphetamine inhibit their own neuro-
chemical and locomotor stimulant effects via TA1 receptor
activation (Di Cara et al., 2011). Similar TA1 receptor-
mediated ‘auto-inhibition’ may, therefore, modulate the
effects of benzofurans. In contrast, for cathinones (e.g. β-keto-
amphetamines), more stimulant-like and addictive properties
would be expected based on their lower affinity for TA1 recep-
tors compared with their amphetamine analogues (Simmler
et al., 2013; 2014a).
In terms of structure–activity relationships (Table 4), 3,4-
substitution on the benzene ring (methylenedioxy group in
MDMA and MDA, furans or dihydrofurans) strongly reduced
the DAT/SERT inhibition ratio confirming previous studies
(Nichols, 1994; Han and Gu, 2006; Iversen et al., 2013;
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Simmler et al., 2013). Additionally, the DAT/SERT inhibition
ratio depended on the position of the oxygen on the benzene
ring and was lowest for compounds with the oxygen in the
para-(4)-position and highest for those with the oxygen in
the ortho-(2)-position. This finding was consistent with
the high 5-hydroxytryptaminergic activity of other para-
substituted amphetamines (Nichols, 1994; Rickli et al., 2015).
The dihydrobenzofurans (5-APDB, 6-APDB and 5-MAPDB)
exhibited reduced monoamine transporter inhibition
potency in particular at the DAT resulting in relatively more
5-hydroxytryptaminergic properties compared with their
furan analogues. N-alkylation (MDMA, 5-MAPDB, 5-EAPB,
methamphetamine) moderately reduced activity at 5-HT2A/B
receptors and binding at 5-HT2C receptors. This has previously
been shown for other phenethylamines for simple
N-alkylation (e.g. methyl, ethyl) (Nelson et al., 1999).
N-alkylation had no relevant effect on the interactions with
the monoamine transporter as previously noted for related
amphetamines (Nichols, 1994). 2,5-Substitution on the
benzene ring strongly increased activity at the 5-HT2 recep-
tors and reduced interactions with the monoamine transport-
ers as seen in 2C-B-FLY in the present study and many other
2,5-substituted phenethylamines (2C series) (Hill and
Thomas, 2011; Eshleman et al., 2014). Transporter inhibition
potency was also moderately reduced when the oxygen was
in the ortho-(2)-position (similar to the 2 series) at the
benzene ring as in 7-APB compared with 5-APB, 6-APB or
4-APB. β-Keto-substitution increased dopaminergic versus
5-hydroxytryptaminergic activity extending previous similar
findings (Simmler et al., 2013; 2014a).
Conclusions
Benzofurans are monoamine transporter blockers and mono-
amine releasers, similar to MDMA, but they also interact with
5-HT receptors. This mechanism of action predicts psycho-
tropic and clinical toxicological effects that are similar to the
entactogen MDMA but with additional hallucinogenic prop-
erties. The benzodifuran 2C-B-FLY is a potent hallucinogen,
probably also associated with a risk for clinical complications
related to vasoconstriction (e.g. ischaemia and hypertension).
Although structure–activity relationships exist, the present
study showed that structurally very similar compounds may
exhibit distinct pharmacological profiles, illustrating the
need for pharmacotoxicological profiling of each novel psy-
choactive substance.
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Table 4
Structure–activity relationships
Structure Present in Not present in Pharmacolocial (clinical) activity
3,4-Substitution on
benzene ring
(methylenedioxy or
furan)
MDMA, 5-MAPDB, 5-EAPB Methamphetamine Reduced DAT/SERT inhibition ratio, aincreased
potency to release 5-HT, areduced potency to
release dopamine (more entactogenic, less
stimulant)
MDA, 5-APB, 6-APB,
5-APDB, 6-APDB, 7-APB,
β-keto-MDA
aAmphetamine
Oxygen in
para-(4)-position
5-APB, 5-APDB, 5-MAPDB 7-APB, 4-APB, 6-APB,
6-APDB
Reduced DAT/SERT inhibition ratio (more
serotonergic)
Dihydrobenzofuran 5-APDB, 6-APDB,
5-MAPDB
5-APB, 6-APB, 4-APB,
7-APB
Reduced DAT/SERT inhibition ratio (more
5-hydroxytryptaminergic)
N-Alkyl group MDMA, 5-EAPB, 5-MAPDB MDA, 5-APB, 5-APDB Reduced 5-HT2A/B receptor activation and 5-HT2C
receptor-binding potency (less hallucinogenic)
2,5-Oxy-substitution on
benzene ring
2C-B-FLY All other compounds Strongly increased 5-HT2A/B receptor activation,
strongly increased 5-HT2C receptor-binding
potency (more hallucinogenic)
β-Keto group β-Keto MDA MDA a,bIncreased DAT/SERT ratio (more dopaminergic)
aSimmler et al., 2013.
bSimmler et al., 2014a.
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a b s t r a c t
Background: N-2-methoxybenzyl-phenethylamines (NBOMe drugs) are newly used psychoactive sub-
stances with poorly defined pharmacological properties. The aim of the present study was to characterize
the receptor binding profiles of a series of NBOMe drugs compared with their 2,5-dimethoxy-phene-
thylamine analogs (2C drugs) and lysergic acid diethylamide (LSD) in vitro.
Methods: We investigated the binding affinities of 2C drugs (2C-B, 2C-C, 2C-D, 2C-E, 2C-H, 2C-I, 2C-N, 2C-
P, 2C-T-2, 2C-T-4, 2C-T-7, and mescaline), their NBOMe analogs, and LSD at monoamine receptors and
determined functional 5-hydroxytryptamine-2A (5-HT2A) and 5-HT2B receptor activation. Binding at and
the inhibition of monoamine uptake transporters were also determined. Human cells that were trans-
fected with the respective human receptors or transporters were used (with the exception of trace
amine-associated receptor-1 [TAAR1], in which rat/mouse receptors were used).
Results: All of the compounds potently interacted with serotonergic 5-HT2A, 5-HT2B, 5-HT2C receptors
and rat TAAR1 (most Ki and EC50: <1 mM). The N-2-methoxybenzyl substitution of 2C drugs increased the
binding affinity at serotonergic 5-HT2A, 5-HT2C, adrenergic a1, dopaminergic D1-3, and histaminergic H1
receptors and monoamine transporters but reduced binding to 5-HT1A receptors and TAAR1. As a result,
NBOMe drugs were very potent 5-HT2A receptor agonists (EC50: 0.04e0.5 mM) with high 5-HT2A/5-HT1A
selectivity and affinity for adrenergic a1 receptors (Ki: 0.3e0.9 mM) and TAAR1 (Ki: 0.06e2.2 mM), similar
to LSD, but not dopaminergic D1e3 receptors (most Ki:> 1 mM), unlike LSD.
Conclusion: The binding profile of NBOMe drugs predicts strong hallucinogenic effects, similar to LSD,
but possibly more stimulant properties because of a1 receptor interactions.
© 2015 Elsevier Ltd. All rights reserved.
Abbreviations: 25B-NBOMe, 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl] ethanamine; 25C-NBOMe, 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-
methoxyphenyl)methyl] ethanamine; 25D-NBOMe, 2-(4-methyl-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl] ethanamine; 25E-NBOMe, 2-(4-ethyl-2,5-
dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl] ethanamine; 25H-NBOMe, 2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl] ethanamine; 25I-NBOMe, 2-(4-iodo-
2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl] ethanamine; 25N-NBOMe, 2-(4-nitro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl] ethanamine; 25P-NBOMe,
2-(4-propyl-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl] ethanamine; 25T2-NBOMe, 2-(2,5-dimethoxy-4-ethylthiophenyl)-N-[(2-methoxyphenyl)methyl] ethan-
amine; 25T4-NBOMe, 2-(2,5-dimethoxy-4-isopropylthiophenyl)-N-[(2-methoxyphenyl)methyl] ethanamine; 25T7-NBOMe, 2-(2,5-dimethoxy-4-n-propylthiophenyl)-N-[(2-
methoxyphenyl)methyl] ethanamine; 2C-B, 4-bromo-2,5-dimethoxyphenethylamine; 2C-C, 2-(4-chloro-2,5-dimethoxy)ethanamine; 2C-D, 2-(2,5-dimethoxy-4-methyl)
ethanamine; 2C-E, 1-(2,5-dimethoxy-4-ethylphenyl)-2-aminoethane; 2C-H, 2,5-dimethoxyphenethylamine; 2C-I, 4-iodo-2,5-dimethoxyphenethylamine; 2C-N, 2-(2,5-
dimethoxy-4-nitro)ethanamine; 2C-P, 2-(2,5-dimethoxy-4-propylphenyl)ethanamine; 25CN-NBOH, 2-([2-(4-cyano-2,5-dimethoxyphenyl)ethylamino]-methyl)phenol; 2C-
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ceptor; LSD, lysergic acid diethylamide.
* Corresponding author. Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Hebelstrasse 2, Basel, CH-4031, Switzerland.
E-mail address: matthias.liechti@usb.ch (M.E. Liechti).
Contents lists available at ScienceDirect
Neuropharmacology
journal homepage: www.elsevier .com/locate/neuropharm
http://dx.doi.org/10.1016/j.neuropharm.2015.08.034
0028-3908/© 2015 Elsevier Ltd. All rights reserved.
Neuropharmacology 99 (2015) 546e553
82
1. Introduction
New psychoactive substances are constantly emerging on the
illicit drug market and typically sold via the Internet. Of particular
interest are N-2-methoxybenzyl-phenethylamines (NBOMe drugs),
which are novel and reportedly very potent hallucinogens that have
been increasingly used recreationally (Forrester, 2014; Hill et al.,
2013; Ninnemann and Stuart, 2013; Rose et al., 2013;
Walterscheid et al., 2014; Wood et al., 2015; Zuba, 2012), with
additional potential use as radiotracers (Ettrup et al., 2011, 2010).
Recreationally used NBOMe drugs include 25I-NBOMe, 25C-
NBOMe, 25B-NBOMe, and 25D-NBOMe (Armenian and Gerona,
2014; Poklis et al., 2014; Rose et al., 2013), which are derivatives
of 2,5-dimethoxy-4-substituted phenethylamines (2C drugs; Dean
et al., 2013; Hill and Thomas, 2011; Shulgin and Shulgin, 1991)
(see Fig. 1). N-2-methoxybenzyl substitution enhances the potency
of 2C drugs at serotonergic 5-hydroxytryptamine-2A (5-HT2A) re-
ceptors, resulting in exceptionally potent 5-HT2A receptor agonists
(Braden et al., 2006; Heim, 2004; Nichols et al., 2015) with strong
hallucinogenic properties in animals and humans (Halberstadt and
Geyer, 2014; Srisuma et al., 2015). Pharmacological interactions
between NBOMe drugs and 5-HT2 receptors have been well char-
acterized for some compounds of this novel drug family (Blaazer
et al., 2008; Braden et al., 2006; Ettrup et al., 2011, 2010; Hansen
et al., 2014; Nichols et al., 2008). However, systematic character-
izations of the effects of a larger series of NBOMe drugs at a wider
range of relevant human receptors and comparisons with their 2C
parent drugs are lacking. Importantly, NBOMe drugs have been
reported to produce psycho- and cardiovascular stimulant effects,
in addition to hallucinations. Specifically, sympathomimetic
toxicity, including tachycardia, hypertension, mydriasis, agitation,
and hyperthermia, is commonly reported in cases of acute NBOMe
drug intoxication (Hill et al., 2013; Rose et al., 2013; Srisuma et al.,
2015; Stellpflug et al., 2014; Wood et al., 2015). Pharmacologically,
compounds of the 2C series, including 2C-C, 2C-E, and 2C-I, inhibit
the norepinephrine (NE) and serotonin transporters (NET and SERT,
respectively), similar to amphetamines, although with only very
low potency (Eshleman et al., 2014; Nagai et al., 2007). These
findings raise the question of whether NBOMe drugs may have
similar but more potent stimulant-type pharmacological proper-
ties, including inhibition of the NET, dopamine (DA) transporter
(DAT), and SERT, or interactions with adrenergic a1 receptors that
lead to vasoconstriction.
We assessed the in vitro pharmacology of a series of NBOMe
drugs compared with their 2C parent drugs. We characterized the
binding affinity profiles at monoamine receptors and DAT, NET, and
SERT inhibition potencies. We also determined the functional 5-
HT2A receptor activation potencies because 5-HT2A receptors
mediate hallucinogenic effects (Nichols, 2004). The prototypical
serotonergic hallucinogen lysergic acid diethylamide (LSD) was
included as a comparator drug (Nichols, 2004; Passie et al., 2008).
2. Methods
2.1. Drugs
2C-B, 2C-C, 2C-D, 2C-E, 2C-H, 2C-I, 2C-N, 2C-P, 2C-T-2, 2C-T-4,
2C-T-7, mescaline, 25B-NBOMe, 25C-NBOMe, 25D-NBOMe, 25E-
NBOMe, 25H-NBOMe, 25I-NBOMe, 25N-NBOMe, 25P-NBOMe,
25T2-NBOMe, 25T4-NBOMe, 25T7-NBOMe, and mescaline-NBOMe
were synthesized by Lipomed (Arlesheim, Switzerland) for this
study at no cost. All of the compounds were used as hydrochloride
salts. Purity was >98% for all of the substances. [3H]NE and [3H]DA
were obtained from PerkineElmer (Schwerzenbach, Switzerland),
and [3H]5-HT was obtained from Anawa (Zürich, Switzerland).
2.2. Radioligand receptor and transporter binding assays
The radioligand binding assays were performed as described
previously (Hysek et al., 2012; Simmler et al., 2013). Briefly, mem-
brane preparations of human embryonic kidney (HEK) 293 cells
(Invitrogen, Zug, Switzerland) that overexpress the respective
transporters (Tatsumi et al., 1997) or receptors (human genes, with
the exception of rat and mouse genes for trace amine-association
receptor 1 [TAAR1]; (Revel et al., 2011)) were incubated with the
radiolabeled selective ligands at concentrations equal to Kd, and
ligand displacement by the compounds was measured. Specific
binding of the radioligand to the target receptor was defined as the
difference between the total binding and nonspecific binding that
was determined in the presence of selected competitors in excess.
The following radioligands and competitors, respectively, were
used: N-methyl-[3H]-nisoxetine and indatraline (NET), [3H]cit-
alopram and indatraline (SERT), [3H]WIN35,428 and indatraline
(DAT), [3H]8-hydroxy-2-(di-n-propylamine)tetralin and indatraline
(5-HT1A receptor), [3H]ketanserin and spiperone (5-HT2A receptor),
[3H]mesulgerine and mianserin (5-HT2C receptor), [3H]prazosin
and risperidone (adrenergic a1 receptor), [3H]rauwolscine and
phentolamine (adrenergic a2 receptor), [3H]SCH 23390 and buta-
clamol (D1 receptor), [3H]spiperone and spiperone (D2 and D3 re-
ceptors), [3H]pyrilamine and clozapine, (histaminergic H1
receptor), and [3H]RO5166017 and RO5166017 (TAAR1). IC50 values
were determined by calculating non-linear regression curves for a
one-site model using three to five independent 10-point concen-
trationeresponse curves for each compound. Ki (affinity) values,
which correspond to the dissociation constants, were determined
using the Cheng-Prusoff equation.
2.3. Activity at serotonin 5-HT2A receptor
Human 5-HT2A receptor-expressing NIH-3T3 cells were incu-
bated in HEPES- Hank's Balanced Salt Solution (HBSS) buffer
(700000 cells/100 ml) for 1 h at 37 !C in 96-well poly-D-lysine-coated
plates. To each well 100 ml of Dye solution (FLIPR calcium 5 assay
kit; Molecular Devices, Sunnyvale, CA, USA) was added and plates
were incubated for 1 h at 37 !C. The plates were then placed in a
fluorescence imaging plate reader (FLIPR), and 25 ml of the test
substances diluted in HEPES-HBSS buffer containing 250 mM pro-
benicid were added online. The increase in fluorescence was then
measured. EC50 values were derived from the concen-
trationeresponse curves using nonlinear regression. Efficacy
(maximal activity) is expressed relative to the activity of 5-HT,
which was used as a control set to 100%.
2.4. Activity at serotonin 5-HT2B receptor
Human 5-HT2B receptor-expressing HEK293 cells were incu-
bated in growth medium (DMEM high glucose [Invitrogen, Zug,
Switzerland], 10 ml/l PenStrep [Gibco, Life Technologies, Zug,
Switzerland]), 10% FCS non dialyzed heat inactivated and 250 mg/l
geneticin) at a density of 500000 cells/well at 37 !C in 96-well poly-
D-lysine-coated plates over-night. On the next day the growth
medium was removed by snap inversion, and 100 ml of Fluo-4 so-
lution (calcium indicator; Molecular Probes, Eugene, OR, USA) was
added to each well. The plates were incubated for 45 min at 31 !C.
The Fluo-4 solution was removed by snap inversion, and 100 ml of
Fluo-4 solution was added a second time. The cells were then
incubated for another 45 min at 31 !C. Immediately before testing,
the cells were washed with HBSS (Gibco) and 20 mM HEPES (assay
buffer; Gibco) using an EMBLA cell washer, and 100 ml assay buffer
was added. The plate was placed in a fluorescence imaging plate
reader (FLIPR), and 25 ml of the test substances diluted in assay
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buffer was added online. The increase in fluorescence was then
measured. EC50 values were derived from the concen-
trationeresponse curves using nonlinear regression. Efficacy
(maximal activity) is expressed relative to the activity of 5-HT,
which was used as a control set to 100%.
2.5. Monoamine uptake transporter inhibition
Inhibition of the human NET, DAT, and SERTwas assessed in HEK
293 cells that were stably transfected with transporters as specified
previously (Hysek et al., 2012). Briefly, the cells were suspended in
uptake buffer and incubated for 10 min with different concentra-
tions of the test substances. The corresponding radiolabeled [3H]
monoamine (5 nM final concentration) was then added at room
temperature. After 10 min, uptake was stopped by separating the
cells from the buffer using centrifugation through silicone oil
(Hysek et al., 2012). The centrifugation tubes were frozen in liquid
nitrogen and cut to separate the cell pellet from the silicone oil and
assay buffer layers. The cell pellet was then lysed. Scintillation fluid
was added, and radioactivity was counted on a b-counter.
Nonspecific uptake was determined for each experiment in the
presence of 10 mM fluoxetine for SERT cells, 10 mM nisoxetine for
NETcells, and 10 mMmazindol for DATcells and subtracted from the
total counts to yield specific uptake (100%). The data were fitted by
non-linear regression to variable slope sigmoidal doseeresponse
curves (bottom ¼ 0%), and IC50 values were calculated using Prism
software (GraphPad, San Diego, CA, USA).
2.6. Cytotoxicity
To confirm cell integrity during the pharmacological assays,
cytotoxicity was assessed using the ToxiLight bioassay (Lonza,
Basel, Switzerland) according to the manufacturer's instructions.
The assay quantitatively measures the release of adenylate kinase
from damaged cells, providing a highly sensitive method of
measuring cytolysis (Crouch et al., 1993). Cells that were grown in
96-well plates were exposed to the compounds at a high
concentration of 100 mM. All of the test conditions contained 0.1%
(v:v) dimethylsulfoxide, which is non-toxic at this concentration
and was also used as a negative control. Triton X-100 (0.1%, Sig-
maeAldrich, Buchs, Switzerland) lyses cells and was used as a
positive control. After 4 h incubation at 37 !C, 10 ml of the super-
natant per well was removed and combined with 50 ml of ToxiLight
reagent, and luminescence was recorded using a Tecan Infinite 200
Pro plate reader (Tecan, M€annedorf, Switzerland).
3. Results
3.1. Interactions with serotonin receptors
Table 1 shows binding to serotonin 5-HT1A, 5-HT2A, and 5-HT2C
receptors, activation potency and efficacy at 5-HT2A and 5-HT2B
receptors, and 5-HT receptor binding ratios. All of the compounds
exhibited high binding affinity for 5-HT2A and 5-HT2C receptors
(Ki < 1 mM, with the exception of 2C-H and mescaline). N-2-
methoxybenzyl substitution further increased the average bind-
ing affinity for both 5-HT2A and 5-HT2C receptors 26- and 14-fold
(range: 6e100 and 8e32, respectively), leading to compounds
with up to 8.4-fold higher affinity for these receptors compared
with LSD. Moderate 5-HT2A over 5-HT2C receptor binding prefer-
ence was observed, with 5-HT2A/5-HT2C receptor binding ratios of
3e16 for the 2C drugs and slightly more selective ratios of 5e26 for
the NBOMe drugs. All of the compounds also potently activated 5-
HT2A receptors and typically more potently than LSD (EC50 < 1 mM,
with the exception of 2C-H, mescaline, and mescaline-NBOMe).
However, in contrast to the robust effect on binding to 5-HT2A re-
ceptors, N-2-methoxybenzyl substitution did not consistently
change the activation potency at 5-HT2A receptors and even
reduced the activation efficacy, with the exception of 2C-H. All of
the compounds potently activated the 5-HT2B receptor
(EC50 < 1 mM, with the exception of 2C-H, mescaline, mescaline-
NBOMe, and LSD). N-2-methoxybenzyl substitution increased 5-
HT2B receptor activation 5-fold (range: 0.8e18) but reduced acti-
vation efficacy. All of the 2C drugs potently bound to 5-HT1A
Fig. 1. Chemical structures of 2,5-dimethoxyphenethylamines (2C drugs) and their N-2-methoxybenzyl-substituted analogs (NBOMe drugs).
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receptors (Ki < 0.52 mM, with the exception of 2C-N andmescaline),
although none exhibited the very high affinity of LSD. N-2-
methoxybenzyl substitution decreased binding to 5-HT1A on
average 17-fold (range: 2e86). The 2C drugs preferentially bound to
5-HT2A over 5-HT1A receptors with binding ratios of 14e94, with
the exception of 2C-H and mescaline (Table 1). Receptor selectivity
was markedly increased for 5-HT2A over 5-HT1A receptors for all of
the compounds with N-2-methoxybenzyl substitution, with 5-
HT2A/5-HT1A ratios >100 for 25H-NBOMe and mescaline-NBOMe
and >1000 for all of the other NBOMe drugs.
3.2. Binding to monoamine receptors and transporters
Table 2 shows the binding affinities for monoamine receptors
and transporters. Compared with the 2C drugs, the NBOMe analogs
exhibited higher binding affinities for all receptors and trans-
porters, with the exception of TAAR1. Specifically, all of the NBOMe
drugs and LSD showed high-affinity binding to adrenergic a1A re-
ceptors (Ki < 1 mM, with the exception of mescaline-NBOMe) and
19-fold (range: 11e38) higher binding affinity compared with the
2C drugs (not including mescaline). Most of the compounds also
potently bound to a2A receptors (Ki < 1 mM, with the exception of
2C-H, 2C-N, and mescaline). N-2-methoxybenzyl substitution did
not appreciably alter a2A receptor binding. LSD was the only sub-
stance that exhibited high-affinity binding to dopamine D1-D3 re-
ceptors. Most of the 2C and NBOMe drugs showed low-affinity
binding to D2 receptors, and NBOMe drugs also showed low-affinity
binding to D2 and D3 receptors. N-2-methoxybenzyl substitution
also increased histamine H1 receptor binding 65-fold (range:
2e267) compared with the 2C analogs, resulting in high-affinity
binding for several NBOMe drugs (Table 2). All of the 2C and
NBOMe drugs showed high-affinity binding to TAAR1rat (Ki < 1 mM,
with the exception of mescaline, 25-H-NBOMe, 25-N-NBOMe, and
mescaline-NBOMe). N-2-methoxybenzyl substitution decreased
binding to TAAR1rat 4-fold (range: 2e9). Binding affinity to mono-
amine transporters was low for 2C drugs (Ki > 10 mM). N-2-
methoxybenzyl substitution increased binding to all monoamine
transporters, resulting in low-affinity interactions for most of the
NBOMe drugs (Ki < 1e10 mM, with the exception of mescaline-
NBOMe). LSD did not interact with any of the monoamine
transporters.
3.3. Monoamine uptake transporter inhibition
IC50 values for monoamine uptake inhibition are listed in
Table 3. The 2C drugs did not inhibit or only very weakly inhibited
(IC50 > 10 mM) monoamine uptake. N-2-methoxybenzyl substitu-
tion consistently enhanced monoamine uptake inhibition potency
approximately two-to 15-fold for the NET, two-to five-fold for the
DAT, and two-to 26-fold for the SERT. As a result, 25B-NBOMe, 25C-
NBOMe, 25D-NBOMe, 25E-NBOMe, 25H-NBOMe, and 25I-NBOMe
blocked the NET and/or SERT at 5e10 mM concentrations. LSD did
not inhibit any of the monoamine transporters.
3.4. Cytotoxicity
None of the compounds produced cytotoxicity after 4 h incu-
bation at 37 !C, with the exception of 25T7-NBOMe. 25T7-NBOMe
became toxic after 4 h incubation at 100 mM (but not 10 mM).
Because the assays lasted less than 4 h, this toxicity did not affect
the data.
Table 1
Serotonin receptor interactions.
5-HT1A 5-HT2A 5-HT2B 5-HT2C Selectivity
(binding ratios)
Receptor
binding
Ki ± SD [mM]
Receptor
binding
Ki ± SD [mM]
Activation
potency
EC50 ± SD [mM]
Activation
efficacy %
maximum ± SD
Activation
potency
EC50 ± SD [mM]
Activation
efficacy %
maximum ± SD
Receptor
binding
Ki ± SD [mM]
5-HT2A/
5-HT1A
5-HT2A/
5-HT2C
2Cs
2C-B 0.24 ± 0.04 0.0086 ± 0.003 0.08 ± 0.02 45 ± 7 0.13 ± 0.06 89 ± 13 0.047 ± 0.009 28 4.7
2C-C 0.19 ± 0.01 0.0130 ± 0.005 0.20 ± 0.06 49 ± 10 0.28 ± 0.11 81 ± 14 0.090 ± 0.026 15 6.9
2C-D 0.44 ± 0.01 0.0324 ± 0.005 0.35 ± 0.18 41 ± 3 0.23 ± 0.07 77 ± 17 0.15 ± 0.03 14 4.6
2C-E 0.36 ± 0.04 0.0105 ± 0.001 0.11 ± 0.03 40 ± 2 0.19 ± 0.04 66 ± 7 0.10 ± 0.02 34 10
2C-H 0.07 ± 0.02 1.6 ± 0.3 9.4 ± 0.5 28 ± 5 6.2 ± 2.8 46 ± 18 4.1 ± 0.9 0.04 2.6
2C-I 0.18 ± 0.01 0.0035 ± 0.001 0.06 ± 0.03 45 ± 8 0.15 ± 0.10 70 ± 18 0.040 ± 0.009 51 11
2C-N 2.2 ± 0.1 0.0235 ± 0.011 0.17 ± 0.04 48 ± 10 0.73 ± 0.09 74 ± 20 0.37 ± 0.02 94 16
2C-P 0.11 ± 0.04 0.0081 ± 0.001 0.09 ± 0.06 63 ± 5 0.13 ± 0.01 72 ± 18 0.040 ± 0.005 14 4.9
2C-T-2 0.37 ± 0.04 0.0090 ± 0.002 0.08 ± 0.03 67 ± 16 0.13 ± 0.09 75 ± 14 0.069 ± 0.018 41 7.7
2C-T-4 0.47 ± 0.13 0.0279 ± 0.012 0.22 ± 0.13 87 ± 7 0.16 ± 0.06 68 ± 10 0.18 ± 0.07 17 6.5
2C-T-7 0.52 ± 0.05 0.0065 ± 0.002 0.13 ± 0.05 76 ± 10 0.35 ± 0.25 45 ± 10 0.039 ± 0.013 80 6.0
Mescaline 4.6 ± 0.4 6.3 ± 1.8 10 ± 1.8 56 ± 15 >20 NA 17 ± 2.0 0.73 2.7
N-benzylphenylethylamines (NBOMes)
25B-NBOMe 3.6 ± 0.3 0.0005 ± 0.0000 0.04 ± 0.01 28 ± 7 0.01 ± 0.01 19 ± 5 0.0062 ± 0.0022 7200 12
25C-NBOMe 5.0 ± 0.1 0.0007 ± 0.0002 0.15 ± 0.06 32 ± 2 0.10 ± 0.13 16 ± 5 0.0052 ± 0.0026 7143 7.4
25D-NBOMe 7.1 ± 0.5 0.0010 ± 0.0004 0.09 ± 0.03 27 ± 7 0.10 ± 0.07 22 ± 6 0.013 ± 0.004 7100 13
25E-NBOMe 3.5 ± 0.2 0.0006 ± 0.0001 0.16 ± 0.11 28 ± 15 0.06 ± 0.03 26 ± 10 0.0072 ± 0.0029 5833 12
25H-NBOMe 6.0 ± 0.7 0.0164 ± 0.0014 0.49 ± 0.07 38 ± 10 0.34 ± 0.14 11 ± 5 0.13 ± 0.02 366 7.9
25I-NBOMe 1.8 ± 0.3 0.0006 ± 0.0002 0.24 ± 0.12 27 ± 7 0.13 ± 0.08 32 ± 12 0.0046 ± 0.0020 3000 7.7
25N-NBOMe 4.2 ± 0.6 0.0008 ± 0.0002 0.07 ± 0.03 34 ± 3 0.07 ± 0.03 26 ± 14 0.021 ± 0.003 5250 26
25P-NBOMe 1.8 ± 0.1 0.0011 ± 0.0002 0.22 ± 0.11 42 ± 7 0.17 ± 0.13 23 ± 8 0.0060 ± 0.0015 1636 5.5
25T2-NBOMe 2.2 ± 0.2 0.0006 ± 0.0002 0.10 ± 0.03 38 ± 6 0.04 ± 0.04 31 ± 12 0.0065 ± 0.0006 3667 11
25T4-NBOMe 2.5 ± 0.3 0.0016 ± 0.0004 0.13 ± 0.05 46 ± 8 0.20 ± 0.10 27 ± 11 0.016 ± 0.005 1563 10
25T7-NBOMe 1.8 ± 0.2 0.0011 ± 0.0002 0.26 ± 0.16 41 ± 6 0.31 ± 0.23 14 ± 5 0.0064 ± 0.0013 1636 5.8
Mescaline-NBOMe 21 ± 5.7 0.14 ± 0.03 3.0 ± 0.6 33 ± 11 >20 NA 0.64 ± 0.04 147 4.5
LSD 0.0030 ± 0.0005 0.0042 ± 0.0013 0.26 ± 0.15 28 ± 10 12 ± 0.35 71 ± 31 0.015 ± 0.003 0.71 3.6
Values are Ki given as mM (mean ± SD); NA, not assessed.
A. Rickli et al. / Neuropharmacology 99 (2015) 546e553 549
85
Table 2
Monoamine transporter and receptor-binding affinities.
a1A a2A D1 D2 D3 H1 TAAR1rat TAAR1mouse NETa DATb SERTc
2C-series
2C-B 8.2 ± 2.2 0.32 ± 0.01 12 ± 1.2 2.2 ± 0.3 10 ± 2.0 14 ± 0.5 0.09 ± 0.01 3.0 ± 0.3 31 ± 6.6 >30 9.7 ± 0.3
2C-C 13 ± 1.9 0.53 ± 0.06 13 ± 1.0 2.1 ± 0.4 17 ± 0.3 24 ± 0.9 0.11 ± 0.02 4.1 ± 0.3 >30 >30 24 ± 4.1
2C-D 12 ± 3.2 0.29 ± 0.03 24 ± 5.2 7.1 ± 1.7 >17 >25 0.15 ± 0.03 3.5 ± 0.1 >30 >30 31 ± 2.2
2C-E 7.4 ± 2.8 0.10 ± 0.02 15 ± 0.6 3.2 ± 1.0 19 ± 4.4 >25 0.07 ± 0.01 1.2 ± 0.1 33 ± 2.7 >30 29 ± 4.4
2C-H 7.9 ± 1.8 1.0 ± 0.05 >14 9.0 ± 1.5 >17 >25 0.90 ± 0.16 11 ± 2.2 >30 >30 >30
2C-I 5.1 ± 1.1 0.07 ± 0.01 13 ± 4.1 2.7 ± 0.58 5.0 ± 0.1 6.1 ± 0.5 0.12 ± 0.02 3.3 ± 0.1 15 ± 3.5 >30 4.9 ± 0.3
2C-N >15 1.3 ± 0.2 19 ± 5.2 6.1 ± 2.7 20 ± 3.1 >25 0.34 ± 0.02 >20 >30 >30 32 ± 3.1
2C-P 3.5 ± 0.5 0.09 ± 0.01 8.4 ± 0.9 2.3 ± 0.7 5.2 ± 0.5 21 ± 3.2 0.02 ± 0.01 0.28 ± 0.03 18 ± 2.4 40 ± 4.0 19 ± 0.2
2C-T-2 17 ± 6.4 0.23 ± 0.01 15 ± 1.7 5.1 ± 1.0 11 ± 0.6 >25 0.04 ± 0.01 2.2 ± 0.6 >30 >30 13 ± 0.6
2C-T-4 11 ± 4.4 0.13 ± 0.04 20 ± 6.3 16 ± 2.1 19 ± 1.4 >25 0.05 ± 0.01 4.5 ± 0.9 17 ± 1.1 >30 >30
2C-T-7 13 ± 5.0 0.18 ± 0.001 15 ± 3.1 5.0 ± 0.8 7.5 ± 0.3 >25 0.03 ± 0.01 0.56 ± 0.1 2 27 ± 9.8 34 ± 6.2 12 ± 0.7
Mescaline >15 1.4 ± 0.2 >14 >10 >17 >25 3.3 ± 0.5 11 ± 3.6 >30 >30 >30
N-benzylphenylethylamines (NBOMes)
25B-NBOMe 0.43 ± 0.10 0.43 ± 0.03 9.3 ± 2.0 0.84 ± 0.27 2.7 ± 0.3 0.08 ± 0.02 0.28 ± 0.002 4.5 ± 1.7 1.1 ± 0.3 7.2 ± 0.5 0.84 ± 0.06
25C-NBOMe 0.81 ± 0.26 0.56 ± 0.08 12 ± 1.6 1.6 ± 0.4 3.5 ± 0.3 0.09 ± 0.01 0.52 ± 0.10 15 ± 1.9 1.6 ± 0.6 14 ± 3 1.5 ± 0.1
25D-NBOMe 0.70 ± 0.26 0.37 ± 0.05 8.7 ± 1.4 2.6 ± 0.4 6.4 ± 0.9 0.63 ± 0.06 0.81 ± 0.10 13 ± 4.4 2.2 ± 0.3 14 ± 2.4 1.4 ± 0.2
25E-NBOMe 0.53 ± 0.20 0.26 ± 0.07 4.9 ± 0.9 1.5 ± 0.2 3.2 ± 0.2 1.4 ± 0.2 0.26 ± 0.03 1.1 ± 0.3 3.0 ± 0.2 8.1 ± 0.6 1.7 ± 0.1
25H-NBOMe 0.55 ± 0.05 0.53 ± 0.04 14 ± 2.4 7.7 ± 1.7 20 ± 4.5 4.1 ± 0.4 1.4 ± 0.2 >20 5.5 ± 0.9 35 ± 1.7 2.3 ± 0.1
25I-NBOMe 0.37 ± 0.02 0.32 ± 0.01 6.7 ± 1.1 0.90 ± 0.13 2.1 ± 0.2 0.09 ± 0.01 0.44 ± 0.07 4.0 ± 0.8 1.3 ± 0.5 5.4 ± 0.5 1.0 ± 0.2
25N-NBOMe 0.85 ± 0.11 0.59 ± 0.07 18 ± 6.7 2.4 ± 0.1 4.5 ± 0.8 0.21 ± 0.04 2.2 ± 0.1 >20 7.2 ± 0.5 13 ± 1.2 5.1 ± 0.3
25P-NBOMe 0.31 ± 0.08 0.41 ± 0.07 3.1 ± 0.1 0.87 ± 0.08 2.3 ± 0.3 1.7 ± 0.2 0.06 ± 0.01 0.24 ± 0.03 2.8 ± 0.3 4.7 ± 0.4 5.2 ± 0.4
25T2-NBOMe 0.55 ± 0.17 0.45 ± 0.04 7.7 ± 0.4 1.6 ± 0.3 3.0 ± 0.4 0.49 ± 0.04 0.35 ± 0.02 4.2 ± 0.6 5.9 ± 0.4 8.6 ± 1.8 5.0 ± 0.2
25T4-NBOMe 0.58 ± 0.25 0.26 ± 0.03 4.9 ± 0.5 1.7 ± 0.5 1.9 ± 0.3 5.4 ± 0.3 0.12 ± 0.02 1.6 ± 0.4 4.3 ± 0.8 6.2 ± 1.5 8.1 ± 0.3
25T7-NBOMe 0.34 ± 0.06 0.36 ± 0.02 4.1 ± 0.2 1.0 ± 0.2 1.4 ± 0.2 1.2 ± 0.1 0.09 ± 0.03 1.0 ± 0.2 3.7 ± 1.1 4.8 ± 1.4 3.2 ± 0.2
Mescaline-NBOMe 3.0 ± 1.2 0.81 ± 0.05 >14 9.6 ± 2.6 >17 14 ± 1.2 13 ± 5.6 >20 46 ± 7.5 >30 24 ± 1.3
LSD 0.67 ± 0.18 0.012 ± 0.002 0.31 ± 0.1 0.025 ± 0.0004 0.096 ± 0.005 1.1 ± 0.2 0.45 ± 0.05 10 ± 2.9 >30 >30 >30
a Values are Ki given as mM (mean ± SD). Comparative Ki values for known monoamine transporter inhibitors were: 0.015 ± 0.01 mM for reboxetine at the NET.
b 0.06 ± 0.01 mM for methylphenidate at the DAT.
c 0.005 ± 0.001 mM for citalopram at the SERT.
Table 3
Monoamine transporter inhibition.
NET DAT SERT
IC50 [mM] (95% CI) IC50 [mM] (95% CI) IC50 [mM] (95% CI)
2C-series
2C-B 44 (33e58) 231 (196e271) 18 (12e27)
2C-C 93 (64e137) 305 (243e383) 74 (58e95)
2C-D 45 (28e72) 626 (536e730) 77 (60e98)
2C-E 26 (18e37) 275 (221e343) 62 (52e74)
2C-H 125 (97e161) 857 (752e976) 311 (238e408)
2C-I 22 (16e31) 126 (103e155) 13 (10e16)
2C-N 287 (223e369) >900 154 (112e213)
2C-P 94 (73e120) 198 (136e287) 30 (22e41)
2C-T-2 153 (152e154) 332 (332e332) 62 (62e62)
2C-T-4 134 (92e195) 294 (242e357) 113 (92e138)
2C-T-7 135 (115e163) 261 (210e324) 44 (36e52)
Mescaline >900 841 (590e1200) 367 (291e462)
N-benzylphenylethylamines (NBOMes)
25B-NBOMe 6.7 (5.6e8.1) 117 (89e154) 7.1 (5.7e8.8)
25C-NBOMe 5.9 (4.4e7.8) 70 (56e87) 7.3 (5.6e9.6)
25D-NBOMe 4.0 (3.0e5.3) 106 (81e140) 3.9 (2.6e5.7)
25E-NBOMe 11 (8.3e14) 100 (88e112) 8.3 (6.2e11)
25H-NBOMe 10 (7.8e13) 120 (101e144) 12 (9.7e14)
25I-NBOMe 10 (7.4e14) 65 (46e89) 6.8 (4.8e9.5)
25N-NBOMe 33 (25e44) 245 (194e310) 20 (15e26)
25P-NBOMe 14 (11e16) 82 (61e110) 12 (9.3e16)
25T2-NBOMe 25 (15e42) 67 (54e84) 20 (14e29)
25T4-NBOMe 28 (22e35) 58 (43e80) 14 (11e18)
25T7-NBOMe 34 (29e40) 55 (45e68) 17 (13e23)
Mescaline-NBOMe 89 (61e130) 449 (303e665) 85 (63e116)
LSD >900 >900 >900
Monoamine transporter inhibitors
Reboxetine 0.036 (0.030e0.044) ns ns
Methylphenidate ns 0.12 (0.09e0.16) ns
Citalopram ns ns 0.045 (0.037e0.057)
Values are means of three to four independent experiments and 95% confidence intervals (CI). ns, not shown.
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4. Discussion
We pharmacologically characterized the in vitro receptor inter-
action profiles of novel recreationally abused hallucinogenic N-2-
methoxybenzyl-substituted phenethylamines compared with
their 2C phenethylamine analogs. Both the NBOMe and 2C drugs
potently interacted with serotonin 5-HT2A, 5-HT2B, 5-HT2C re-
ceptors and TAAR1rat. We also found several consistent and
potentially important structure-affinity relationships for the
NBOMe drugs, their 2C analogs, and several targets. Specifically, N-
2-methoxybenzyl substitution increased the binding affinity for
and/or activation potency at serotonergic 5-HT2A, 5-HT2B, 5-HT2C
receptors, adrenergic a1 receptors, dopaminergic D1-3 receptors,
histaminergic H1 receptors, and monoamine transporters but
reduced binding to 5-HT1A receptors and TAAR1.
The 5-HT2A receptor mediates hallucinogenic drug properties
(Halberstadt and Geyer, 2011; Nelson et al., 1999; Nichols, 2004;
Vollenweider et al., 1998) and is therefore considered the key
target of hallucinogenic phenethylamines, including 2C and
NBOMe drugs (Braden et al., 2006; Halberstadt, 2015; Halberstadt
and Geyer, 2014). N-2-methoxybenzyl substitution consistently
increased the already high in vitro affinity of 2C drugs for 5-HT2A
receptors, in agreement with data on 25H-NBOMe and 25I-NBOMe
vs. 2C-H and 2C-I, respectively (Braden et al., 2006; Heim, 2004). All
of the NBOMe drugs exhibited low nanomolar or even sub-
nanomolar affinity for 5-HT2A receptors, confirming studies on
25B-NBOMe, 25C-NBOMe, 25H-NBOMe, 25I-NBOMe, and 25B-
NBOMe that used rat receptors (Braden et al., 2006; Ettrup et al.,
2011, 2010; Nichols et al., 2015) or human receptors (Braden
et al., 2006; Hansen et al., 2014; Nichols et al., 2015). Generally,
5-HT2A receptor affinity correlates with hallucinogenic drug po-
tency in humans (Halberstadt, 2015; Titeler et al., 1988), and
NBOMe drugs can be expected to be extremely potent hallucino-
gens in vivo. Indeed, higher incidences of hallucinations and de-
lusions have been reported in patients with NBOMe compared with
2C drug intoxication (Forrester, 2013, 2014; Srisuma et al., 2015).
Surprisingly, the consistent six-to 100-fold increase in 5-HT2A
receptor affinity that was produced by N-2-methoxybenzyl substi-
tution did not translate into a similar increase in 5-HT2A receptor
activation potency, and the activation efficacy was even reduced
compared with the 2C drugs in our functional assay. In contrast,
others found that N-2-methoxybenzyl substitution in 2C-H or 2C-I
increased the potency for rat or human 5-HT2A receptor activation in
the inositol phosphate hydrolysis assay in vitro (Braden et al., 2006).
However, high-affinity agonist binding does not correlate well with
inositol phosphate turnover (Acuna-Castillo et al., 2002; Roth et al.,
1997), suggesting that additional ligandereceptor interactions
contribute to receptor activation (Halberstadt, 2015; Nichols, 2004).
Additionally, marked discrepancies between inositol phosphate
hydrolysis activation and other in vitro assays and the in vivo effects
of hallucinogens in laboratory animals or humans are well recog-
nized (Nichols, 2004; Saez et al., 1994; Villalobos et al., 2004). Thus,
although most of the effects of hallucinogens are clearly mediated
by 5-HT2A receptor activation (Halberstadt, 2015; Nichols, 2004),
the signaling pathways that mediate these effects have not yet been
conclusively identified (Halberstadt, 2015).
Currently unknown pharmacokinetic characteristics of NBOMe
drugs may also influence drug potency in vivo. For example, dif-
ferences in the in vivo brain binding properties of N-2-
methoxybenzyl-substituted positron emission tomography tracers
were reported for substances with similar in vitro 5-HT2A receptor
binding properties (Ettrup et al., 2011). Most importantly, NBOMe
drugs are used recreationally at higher doses than LSD (Bersani
et al., 2014; Halberstadt and Geyer, 2014), despite their higher 5-
HT2A receptor binding affinities. The lower in vivo potency of
orally administered NBOMe drugs could be explained by their
lower hepatic stability that reduced oral bioavailability compared
with 2C drugs (Leth-Petersen et al., 2014). Thus, high 5-HT2A re-
ceptor binding or activation in vitro is only one factor that poten-
tially predicts hallucinogen potency in vivo. In the first in vivo
studies that evaluated NBOMe drugs in mice, 25I-NBOMe was 14-
times more potent than its analog 2C-I in inducing 5-HT2A
receptor-mediated head-twitch responses (Halberstadt and Geyer,
2014), consistent with the higher 5-HT2A receptor binding in the
present study. In contrast, 25I-NBOMe was slightly less potent in
inducing head twitches than expected, based on its high 5-HT2
binding potency (Nichols et al., 2015) and compared with LSD
(Halberstadt and Geyer, 2013, 2014), consistent with the similar 5-
HT2A receptor activation potency of the two compounds in the
present study but not reflecting the higher receptor binding po-
tency of 25I-NBOMe compared with LSD. Additionally, 2-([2-(4-
cyano-2,5-dimethoxyphenyl)ethylamino]-methyl)phenol (25CN-
NBOH), which is structurally similar to the NBOMe drugs that were
tested in the present study, was a more potent 5-HT2A receptor
agonist than 2,5-dimethoxy-4-iodoamphetamine (DOI) in vitro
(Hansen et al., 2014) but less effective in inducing head-twitch
responses in mice (Fantegrossi et al., 2015). Thus, more in vivo
studies are needed to determine the in vivo potency of novel
NBOMe drugs.
Within the 2C or NBOMe drug series, para-phenyl substitutions
compared with 2C-H or 25H-NBOMe, respectively, enhanced 5-HT2
receptor binding and activation potency, which was expected based
on previous studies (Blaazer et al., 2008; Eshleman et al., 2014;
Hansen et al., 2014; Shulgin and Shulgin, 1991). Interestingly, 5-
HT2A receptor activation potency increased with the size of the 4-
substituent (2C-D < 2C-E < 2C-P) within the 2C series (Blaazer
et al., 2008; Eshleman et al., 2014), whereas it decreased
within the NBOMe series (25D-NBOMe > 25-E-NBOMe >
25P-NBOMe). Similarly, activation potency increased with halogen
size for the 4-halogen-substituted 2C drugs (2C-C < 2C-B < 2C-I)
but not consistently for the NBOMe analogs. Thus, N-2-
methoxybenzyl substitution interacted with 4-phenyl substitu-
tion to affect 5-HT2A receptor activation potency.
In the present study, all of the compounds were partial agonists
at 5-HT2A receptors, but receptor activation efficacy was consis-
tently decreased for the N-2-methoxybenzyl-substituted com-
pounds in the assay used in the present study. The high 5-HT2A
receptor affinity and reduction of partial activation efficacy of the
NBOMe drugs suggest 5-HT2A antagonistic properties of these
compounds, as similarly described for LSD (Nichols, 2004). In fact,
2C drugs have been shown to act as 5-HT2A receptor antagonists
that inhibit 5-HT-induced currents in Xenopus laevis oocytes
(Villalobos et al., 2004). Therefore, 5-HT2A receptor antagonism has
been suggested to also play a role in the mechanism of action of
hallucinogens (Villalobos et al., 2004). Alternatively, other re-
ceptors, such as 5-HT2C and 5-HT1 receptors, may contribute to the
mechanism of action of hallucinogens, or signaling pathways other
than inositol phosphate hydrolysis may be involved (Nichols,
2004). Consistently, N-2-methoxybenzyl substitution increased
binding affinity for 5-HT2C receptors. All of the NBOMe drugs very
potently bound to 5-HT2C receptors, with only low (five-to 26-fold)
selectivity for 5-HT2A receptors over 5-HT2C receptors in the bind-
ing assay, as previously shown for some NBOMe drugs (Ettrup et al.,
2010; Hansen et al., 2014) and generally observed with hallucino-
genic phenethylamines (Eshleman et al., 2014; Glennon et al.,
1992). N-2-methoxybenzyl substitution only slightly increased 5-
HT2A over 5-HT2C receptor binding selectivity. In contrast, N-2-
methoxybenzyl substitution consistently decreased 5-HT1A recep-
tor binding, thus markedly altering 5-HT1A over 5-HT2A receptor
binding ratios for the NBOMe drugs compared with the 2C drugs.
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Thus, NBOMe drugs are unlike LSD, which is a potent 5-HT1A re-
ceptor ligand and full agonist at 5-HT1A receptors (Nichols, 2004).
Importantly, 5-HT1A receptors have been shown to contribute to
the discriminative stimulus effects of some hallucinogens
(Halberstadt, 2015; Nichols, 2004). Additionally, 5-HT1A antago-
nism markedly enhanced the hallucinogenic effects of DMT in
humans (Strassman, 1996). Accordingly, 5-HT1A receptor stimula-
tion has been hypothesized to counteract hallucinogenic activity
(Halberstadt and Geyer, 2011; Nichols, 2004), and lower 5-HT1A
receptor stimulation for the NBOMe drugs may further enhance
their hallucinogenic drug properties. N-2-methoxybenzyl substi-
tution increased 5-HT2B activation, but this is likely not relevant for
the psychotropic properties of the NBOMe drugs (Blaazer et al.,
2008). However, 5-HT2B receptors have been implicated in
substance-induced heart valve fibrosis (Bhattacharyya et al., 2009;
Setola et al., 2003), and the 2C and NBOMe drugs may therefore
have cardiac toxicity if used chronically.
Because NBOMe drugs produce marked sympathomimetic car-
diovascular effects in humans (Wood et al., 2015), we tested
whether these drugs interact with monoamine transporters simi-
larly to cocaine or amphetamines (Simmler et al., 2013, 2014a) and
other novel psychoactive substances (Rickli et al., 2015a, 2015b;
Simmler et al., 2014a; Simmler et al., 2014b). N-2-methoxybenzyl
substitution enhanced monoamine transporter inhibition
compared with the 2C drugs. However, the potency of even the
most potent NBOMe drugs at the NETand SERT was low and only in
the 5e10 mM range, indicating that amphetamine-type monoamine
transporter interactions contribute only little to the cardio-
stimulant effects of NBOMe drugs.
In addition to their very high 5-HT2A binding affinity, we found
that the NBOMe drugs and LSD had high binding affinity for
adrenergic a1A receptors. 2C drugs have been shown to contract
blood vessels (Saez et al., 1994) through direct interactions with
serotonergic 5-HT2 and adrenergic a1 receptors (Lobos et al., 1992).
The vasoconstrictive potency of 2C drugs does not appear to
correlate well with hallucinogenic potency in humans (Saez et al.,
1994) or 5-HT2A receptor activation. For example, 2C-D had
higher affinity for 5-HT2A receptors compared with 2C-H in the
present study but lower potency in contracting the rat aorta (Saez
et al., 1994). Additionally, 2C-N, which exhibited high affinity for 5-
HT2A receptors but not a1 receptors in the present study, did not
present vasoconstrictive activity (Saez et al., 1994). These findings
and the relatively high affinity of the NBOMe drugs for adrenergic
a1 receptors indicate that these receptors might contribute to the
stimulant-type cardiovascular effects that are typically seen in
cases of NBOMe drug intoxication (Srisuma et al., 2015;Wood et al.,
2015). Additionally, the behavioral effects of 25I-NBOMe in mice
showed a rapid peak (withinminutes), whereas the response to 2C-
I was relatively flat (Halberstadt and Geyer, 2014). Thus, such
substance characteristics as the higher lipophilicity of NBOMe
drugsmay further accentuate the clinical drug response. As a result,
there is likely a high risk of overdose with NBOMe drugs, and
several fatalities have been reported (Hill et al., 2013; Srisuma et al.,
2015; Walterscheid et al., 2014; Wood et al., 2015).
Both the 2C and NBOMe drugs bound to TAAR1, with few ex-
ceptions. N-2-methoxybenzyl substitution slightly decreased TAAR1
binding affinity as previously shown for other N-substitutions in
phenethylamines (Lewin et al., 2008). TAAR1 modulates psychotro-
pic drug actions. Importantly, methylenedioxymethamphetamine
inhibits its own stimulant effects via TAAR1 activation (Di Cara et al.,
2011). Whether similar TAAR1-mediated “auto-inhibition” exists for
hallucinogens remains to be determined. One hypothesis is that the
lower TAAR1 activity that is associated with N-2-methoxybenzyl
substitution may also enhance psychostimulant drug properties
in vivo.
LSD exhibited high affinity for D1, D2 and D3 receptors, as pre-
viously shown (Watts et al., 1995) and in contrast to phenethyl-
amines. D2 receptors have been shown to contribute to the
interoceptive effects of LSD in rats (Halberstadt and Geyer, 2013,
2014). Although N-2-methoxybenzyl substitution increased D1-3
receptor binding affinity compared with 2C drugs, NBOMe drugs
were less potent at D1-3 receptors compared with LSD, indicating
that LSD has a unique mixed dopaminergic-serotonergic binding
profile.
In summary, NBOMe drugs are highly potent 5-HT2A receptor
ligands and partial 5-HT2A receptor agonists, similar to the classic
hallucinogen LSD, but with 5-HT2 over 5-HT1 receptor selectivity,
unlike LSD. NBOMe drugs bind to adrenergic a1 receptors and
TAAR1, similar to LSD, but do not bind to dopaminergic D1-3 re-
ceptors, unlike LSD. The in vitro binding profiles of NBOMe drugs
suggest that they have higher hallucinogenic effects and potency
compared with their parent 2C drugs and are similar to the very
potent hallucinogen LSD because of their similar or even higher
potency at 5-HT2A receptors. At higher doses, NBOMe drugs may
also exhibit additional stimulant properties through a1 receptor
interactions.
Conflicts of interest
M.C.H. is an employee of F. Hoffmann-La Roche.
Authorship contributions
Participated in research design: Rickli, Liechti.
Conducted experiments: Rickli, Luethi, Reinisch, Buchy.
Performed data analysis: Rickli, Hoener, Liechti.
Wrote or contributed to the writing of the manuscript: Rickli,
Liechti.
Acknowledgments
This work was supported by the Federal Office of Public Health
(no.13.006497) and Translational Medicine Hub Innovation Fund of
F. Hoffmann-LaRoche and the University of Basel. The authors
thank Sylvie Chaboz for technical assistance, Lipomed (Arlesheim,
Switzerland) for providing the 2C and NBOMe drugs at no cost, and
Michael Arends for text editing.
References
Acuna-Castillo, C., Villalobos, C., Moya, P.R., Saez, P., Cassels, B.K., Huidobro-Toro, J.P.,
2002. Differences in potency and efficacy of a series of phenylisopropylamine/
phenylethylamine pairs at 5-HT2A and 5-HT2C receptors. Br. J. Pharmacol. 136,
510e519.
Armenian, P., Gerona, R.R., 2014. The electric Kool-Aid NBOMe test: LC-TOF/MS
confirmed 2C-C-NBOMe (25C) intoxication at Burning Man. Am. J. Emerg.
Med. 32, 1444.e3e1444.e5.
Bersani, F.S., Corazza, O., Albano, G., Valeriani, G., Santacroce, R., Posocco, F. Bolzan
Mariotti, Cinosi, E., Simonato, P., Martinotti, G., Bersani, G., Schifano, F., 2014.
25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and
toxicity of a new potent and dangerous hallucinogenic drug. Biomed. Res. Int.
2014, 734749.
Bhattacharyya, S., Schapira, A.H., Mikhailidis, D.P., Davar, J., 2009. Drug-induced
fibrotic valvular heart disease. Lancet 374, 577e585.
Blaazer, A.R., Smid, P., Kruse, C.G., 2008. Structure-activity relationships of phe-
nylalkylamines as agonist ligands for 5-HT2A receptors. ChemMedChem 3,
1299e1309.
Braden, M.R., Parrish, J.C., Naylor, J.C., Nichols, D.E., 2006. Molecular interaction of
serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with super-
potent N-benzyl phenethylamine agonists. Mol. Pharmacol. 70, 1956e1964.
Crouch, S.P., Kozlowski, R., Slater, K.J., Fletcher, J., 1993. The use of ATP biolumi-
nescence as a measure of cell proliferation and cytotoxicity. J. Immunol.
Methods 160, 81e88.
Dean, B.V., Stellpflug, S.J., Burnett, A.M., Engebretsen, K.M., 2013. 2C or not 2C:
phenethylamine designer drug review. J. Med. Toxicol. 9, 172e178.
Di Cara, B., Maggio, R., Aloisi, G., Rivet, J.M., Lundius, E.G., Yoshitake, T.,
A. Rickli et al. / Neuropharmacology 99 (2015) 546e553552
88
Svenningsson, P., Brocco, M., Gobert, A., De Groote, L., Cistarelli, L., Veiga, S., De
Montrion, C., Rodriguez, M., Galizzi, J.P., Lockhart, B.P., Coge, F., Boutin, J.A.,
Vayer, P., Verdouw, P.M., Groenink, L., Millan, M.J., 2011. Genetic deletion of
trace amine 1 receptors reveals their role in auto-inhibiting the actions of ec-
stasy (MDMA). J. Neurosci. 31, 16928e16940.
Eshleman, A.J., Forster, M.J., Wolfrum, K.M., Johnson, R.A., Janowsky, A., Gatch, M.B.,
2014. Behavioral and neurochemical pharmacology of six psychoactive
substituted phenethylamines: mouse locomotion, rat drug discrimination and
in vitro receptor and transporter binding and function. Psychopharmacol. Berl.
231, 875e888.
Ettrup, A., Hansen, M., Santini, M.A., Paine, J., Gillings, N., Palner, M., Lehel, S.,
Herth, M.M., Madsen, J., Kristensen, J., Begtrup, M., Knudsen, G.M., 2011. Radio-
synthesis and in vivo evaluation of a series of substituted 11C-phenethylamines
as 5-HT2A agonist PET tracers. Eur. J. Nucl. Med. Mol. Imaging 38, 681e693.
Ettrup, A., Palner, M., Gillings, N., Santini, M.A., Hansen, M., Kornum, B.R.,
Rasmussen, L.K., Nagren, K., Madsen, J., Begtrup, M., Knudsen, G.M., 2010.
Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist
radioligand for PET. J. Nucl. Med. 51, 1763e1770.
Fantegrossi, W.E., Gray, B.W., Bailey, J.M., Smith, D.A., Hansen, M., Kristensen, J.L.,
2015. Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethyl-
amino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with
100-fold selectivity for 5-HT2A receptors, in mice. Psychopharmacol. Berl. 232,
1039e1047.
Forrester, M.B., 2013. 2C series phenethylamine derivative exposures in Texas.
Subst. Abus. 34, 81e82.
Forrester, M.B., 2014. NBOMe designer drug exposures reported to Texas poison
centers. J. Addict. Dis. 33, 196e201.
Glennon, R.A., Raghupathi, R., Bartyzel, P., Teitler, M., Leonhardt, S., 1992. Binding of
phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evi-
dence for a lack of selectivity. J. Med. Chem. 35, 734e740.
Halberstadt, A.L., 2015. Recent advances in the neuropsychopharmacology of
serotonergic hallucinogens. Behav. Brain Res. 277, 99e120.
Halberstadt, A.L., Geyer, M.A., 2011. Multiple receptors contribute to the behavioral
effects of indoleamine hallucinogens. Neuropharmacology 61, 364e381.
Halberstadt, A.L., Geyer, M.A., 2013. Characterization of the head-twitch response
induced by hallucinogens in mice: detection of the behavior based on the dy-
namics of head movement. Psychopharmacol. Berl. 227, 727e739.
Halberstadt, A.L., Geyer, M.A., 2014. Effects of the hallucinogen 2,5-dimethoxy-4-
iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head
twitch response. Neuropharmacology 77, 200e207.
Hansen, M., Phonekeo, K., Paine, J.S., Leth-Petersen, S., Begtrup, M., Brauner-
Osborne, H., Kristensen, J.L., 2014. Synthesis and structure-activity relationships
of N-benzyl phenethylamines as 5-HT2A/2C agonists. ACS Chem. Neurosci. 5,
243e249.
Heim, R., 2004. Synthesis and Pharmacology of Potent 5-HT2A Receptor Agonists
Which Have a Partial N-2-2-methoxybenzyl Structure. Department of Chem-
istry. Freie Universit€at Berlin, Germany, Berlin.
Hill, S.L., Doris, T., Gurung, S., Katebe, S., Lomas, A., Dunn, M., Blain, P., Thomas, S.H.,
2013. Severe clinical toxicity associated with analytically confirmed recreational
use of 25I-NBOMe: case series. Clin. Toxicol. 51, 487e492.
Hill, S.L., Thomas, S.H., 2011. Clinical toxicology of newer recreational drugs. Clin.
Toxicol. 49, 705e719.
Hysek, C.M., Simmler, L.D., Nicola, V., Vischer, N., Donzelli, M., Kr€ahenbühl, S.,
Grouzmann, E., Hoener, M.C., Liechti, M.E., 2012. Duloxetine inhibits effects of
MDMA (“ecstasy”) in vitro and in humans in a randomized placebo-controlled
laboratory study. PLoS One 7, e36476.
Leth-Petersen, S., Bundgaard, C., Hansen, M., Carnerup, M.A., Kehler, J.,
Kristensen, J.L., 2014. Correlating the metabolic stability of psychedelic 5-HT2A
agonists with anecdotal reports of human oral bioavailability. Neurochem. Res.
39, 2018e2023.
Lewin, A.H., Navarro, H.A., Mascarella, S.W., 2008. Structure-activity correlations for
b-phenethylamines at human trace amine receptor 1. Bioorg. Med. Chem. 16,
7415e7423.
Lobos, M., Borges, Y., Gonzalez, E., Cassels, B.K., 1992. The action of the psychoactive
drug 2C-B on isolated rat thoracic aorta. Gen. Pharmacol. 23, 1139e1142.
Nagai, F., Nonaka, R., Kamimura, K. Satoh Hisashi, 2007. The effects of non-medically
used psychoactive drugs on monoamine neurotransmission in rat brain. Eur. J.
Pharmacol. 559, 132e137.
Nelson, D.L., Lucaites, V.L., Wainscott, D.B., Glennon, R.A., 1999. Comparisons of
hallucinogenic phenylisopropylamine binding affinities at cloned human 5-
HT2A, 5-HT2B and 5-HT2C receptors. Naunyn Schmiedeb. Arch. Pharmacol. 359,
1e6.
Nichols, D.E., 2004. Hallucinogens. Pharmacol. Ther. 101, 131e181.
Nichols, D.E., Frescas, S.P., Chemel, B.R., Rehder, K.S., Zhong, D., Lewin, A.H., 2008.
High specific activity tritium-labeled N-(2-2-methoxybenzyl)-2,5-dimethoxy-
4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective
agonist radioligand. Bioorg. Med. Chem. 16, 6116e6123.
Nichols, D.E., Sassano, M.F., Halberstadt, A.L., Klein, L.M., Brandt, S.D., Elliott, S.P.,
Fiedler, W.J., 2015. N-Benzyl-5-methoxytryptamines as potent serotonin 5-HT2
receptor family agonists and comparison with a series of phenethylamine
analogues. ACS Chem. Neurosci. 6, 1165e1175.
Ninnemann, A., Stuart, G.L., 2013. The NBOMe series: a novel, dangerous group of
hallucinogenic drugs. J. Stud. Alcohol. Drugs 74, 977e978.
Passie, T., Halpern, J.H., Stichtenoth, D.O., Emrich, H.M., Hintzen, A., 2008. The
pharmacology of lysergic acid diethylamide: a review. CNS Neurosci. Ther. 14,
295e314.
Poklis, J.L., Nanco, C.R., Troendle, M.M., Wolf, C.E., Poklis, A., 2014. Determination of
4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine
(25B-NBOMe) in serum and urine by high performance liquid chromatography
with tandem mass spectrometry in a case of severe intoxication. Drug Test.
Anal. 6, 764e769.
Revel, F.G., Moreau, J.L., Gainetdinov, R.R., Bradaia, A., Sotnikova, T.D., Mory, R.,
Durkin, S., Zbinden, K.G., Norcross, R., Meyer, C.A., Metzler, V., Chaboz, S.,
Ozmen, L., Trube, G., Pouzet, B., Bettler, B., Caron, M.G., Wettstein, J.G.,
Hoener, M.C., 2011. TAAR1 activation modulates monoaminergic neurotrans-
mission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc.
Natl. Acad. Sci. U. S. A. 108, 8485e8490.
Rickli, A., Hoener, M.C., Liechti, M.E., 2015a. Monoamine transporter and receptor
interaction profiles of novel psychoactive substances: para-halogenated am-
phetamines and pyrovalerone cathinones. Eur. Neuropsychopharmacol. 25,
365e376.
Rickli, A., Kopf, S., Hoener, M.C., Liechti, M.E., 2015b. Pharmacological profile of
novel psychoactive benzofurans. Br. J. Pharmacol. 172, 3412e3425.
Rose, S.R., Poklis, J.L., Poklis, A., 2013. A case of 25I-NBOMe (25-I) intoxication: a
new potent 5-HT2A agonist designer drug. Clin. Toxicol. 51, 174e177.
Roth, B.L., Choudhary, M.S., Khan, N., Uluer, A.Z., 1997. High-affinity agonist binding
is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evi-
dence in favor of a modified ternary complex model. J. Pharmacol. Exp. Ther.
280, 576e583.
Saez, P., Borges, Y., Gonzalez, E., Cassels, B.K., 1994. a-Adrenergic and 5-HT2-sero-
tonergic effects of some b-phenylethylamines on isolated rat thoracic aorta.
Gen. Pharmacol. 25, 211e216.
Setola, V., Hufeisen, S.J., Grande-Allen, K.J., Vesely, I., Glennon, R.A., Blough, B.,
Rothman, R.B., Roth, B.L., 2003. 3,4-Methylenedioxymethamphetamine (MDMA,
“Ecstasy”) induces fenfluramine-like proliferative actions on human cardiac
valvular interstitial cells in vitro. Mol. Pharmacol. 63, 1223e1229.
Shulgin, A.T., Shulgin, A., 1991. PiHKAL e a Chemical Love Story. Transform Press,
Berkeley.
Simmler, L.D., Buser, T.A., Donzelli, M., Schramm, Y., Dieu, L.H., Huwyler, J.,
Chaboz, S., Hoener, M.C., Liechti, M.E., 2013. Pharmacological characterization of
designer cathinones in vitro. Br. J. Pharmacol. 168, 458e470.
Simmler, L.D., Rickli, A., Hoener, M.C., Liechti, M.E., 2014a. Monoamine transporter
and receptor interaction profiles of a new series of designer cathinones.
Neuropharmacology 79, 152e160.
Simmler, L.D., Rickli, A., Schramm, Y., Hoener, M.C., Liechti, M.E., 2014b. Pharma-
cological profiles of aminoindanes, piperazines, and pipradrol derivatives.
Biochem. Pharmacol. 88, 237e244.
Srisuma, S., Bronstein, A.C., Hoyte, C.O., 2015. NBOMe and 2C substitute phenyl-
ethylamine exposures reported to the National Poison Data System. Clin. Tox-
icol. 53, 624e628.
Stellpflug, S.J., Kealey, S.E., Hegarty, C.B., Janis, G.C., 2014. 2-(4-Iodo-2,5-
dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe):
clinical case with unique confirmatory testing. J. Med. Toxicol. 10, 45e50.
Strassman, R.J., 1996. Human psychopharmacology of N,N-dimethyltryptamine.
Behav. Brain Res. 73, 121e124.
Tatsumi, M., Groshan, K., Blakely, R.D., Richelson, E., 1997. Pharmacological profile of
antidepressants and related compounds at human monoamine transporters.
Eur. J. Pharmacol. 340, 249e258.
Titeler, M., Lyon, R.A., Glennon, R.A., 1988. Radioligand binding evidence implicates
the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine
hallucinogens. Psychopharmacol. Berl. 94, 213e216.
Villalobos, C.A., Bull, P., Saez, P., Cassels, B.K., Huidobro-Toro, J.P., 2004. 4-Bromo-
2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethyl-
amines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes. Br. J.
Pharmacol. 141, 1167e1174.
Vollenweider, F.X., Vollenweider-Scherpenhuyzen, M.F., Babler, A., Vogel, H.,
Hell, D., 1998. Psilocybin induces schizophrenia-like psychosis in humans via a
serotonin-2 agonist action. Neuroreport 9, 3897e3902.
Walterscheid, J.P., Phillips, G.T., Lopez, A.E., Gonsoulin, M.L., Chen, H.H.,
Sanchez, L.A., 2014. Pathological findings in 2 cases of fatal 25I-NBOMe toxicity.
Am. J. Forensic Med. Pathol. 35, 20e25.
Watts, V.J., Lawler, C.P., Fox, D.R., Neve, K.A., Nichols, D.E., Mailman, R.B., 1995. LSD
and structural analogs: pharmacological evaluation at D1 dopamine receptors.
Psychopharmacol. Berl. 118, 401e409.
Wood, D.M., Sedefov, R., Cunningham, A., Dargan, P.I., 2015. Prevalence of use and
acute toxicity associated with the use of NBOMe drugs. Clin. Toxicol. 53, 85e92.
Zuba, D.S.K., 2012. Analytical characterization of three hallucinogenic N-(2-
methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs. Drug
Test. Anal. 5, 634e645.
A. Rickli et al. / Neuropharmacology 99 (2015) 546e553 553
89
	
Discussion 
 
This thesis presents the in vitro pharmacological profiles of 75 novel psychoactive 
substances including classical drugs like MDMA, amphetamine, methamphetamine, 
psilocin, mescaline, and LSD. We found a broad spectrum of interactions of these 
compounds with relevant brain monoaminergic target sites. Broadly, we could 
distinguish two main groups by their way of action: 1. Compounds primarily 
interacting with monoamine transporters (Simmler et al. 2014, Simmler et al. 2014, 
Rickli et al. 2015) and 2. Phenethylamine derivatives, which were potent serotonin 5-
HT2A agonists with no or only weak serotonin and/or norepinephrine reuptake 
inhibitors (Rickli et al. 2015). Most of the monoamine uptake inhibitors inhibited the 
NET in low micromolar concentrations. The clinical characteristics of a compound 
(MDMA-like or stimulant-like) were mostly due to different potencies inhibiting the 
dopamine vs. serotonin reuptake, reflected in the DAT/SERT inhibition ratio 
presented in Figure 3.  
The most serotonergic over dopaminergic drugs were trifluoromethylpiperazie 
(TFMPP), 5-(2-aminopropyl)2,3-dihydrobenzofuran (5-APDB), 4-
methylthioamphetamine (4-MTA), 1-(2,3-dihydrobenzoduran-5-yl)-N-methylpropan-2-
amine (5-MAPDB), para-methoxyamphetamine (PMA), para-methoxy-N-
methylamphetamine (PMMA), meta-chorpheylpiperazine (m-CPP), 5-(2-
aminopropyl)benzofuran (5-APB), 6-(2-aminopropyl)-2,3-dihydrobenzofuran (6-
APDB), and MDMA all with a DAT/SERT inhibition ratio below 0.1. In fact, these 
substances are all reportedly relatively similar to MDMA with regards to their clinical 
toxicology. On the other hand, alpha-pyrrolidinopentiophenone (α-PVP), 
methylphenidate, and desoxypipradrol (2-DPMP), and pyrovalerone-cathinones were 
the most dopaminergic compounds in this series of tested substances, with high 
DAT/SERT inhibition ratios (>100). Several in vitro studies with rats and mice 
indicated that the pyrovalerones α-PVP and MDPV show high reinforcing properties 
and clinical reports indicate a high abuse and addiction potential in humans (Karlsson 
et al. 2014, Watterson et al. 2014, Watterson et al. 2014, Aarde et al. 2015, Karila et 
al. 2015).  
In contrast to the pronounced differences in DAT and SERT inhibition potencies, 
nearly all tested monoamine uptake inhibitors potently inhibited the NET with IC50 
values below 1 µM as also found in earlier studies (Eshleman et al. 2013, Simmler et 
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al. 2013). Though, all NPS have sympathomimetic activation in common and these 
appear to correlate with the recreational doses used (Eshleman et al. 2013).   
However, many NPS also possess transporter substrate properties leading to 
substance-induced transporter-mediated monoamine release, similar to MDMA and 
other amphetamines (Baumann et al. 2012, Baumann et al. 2013, Eshleman et al. 
2013, Simmler et al. 2013, Marusich et al. 2014, Saha et al. 2015). 
We found that many of the MDMA-relatives possessed substrate properties for at 
least one of the monoamine transporters. Triple monoamine releaser (similar to 
MDMA, methamphetamine, and amphetamine) were, PMA, PMMA, N-
ethylamphetamine, 3-fluoromethcathinone (3-FMC), 4-fluoroephedrine (4-FEP), 4-
fluoroamphetamine (4-FA), 4-fluoromethamphetamine (4-FMA), 4-
ethylmethcathinone (4-EMC), 4-methylmethcathinone (mephedrone), 5-APB, 6-
APDB, 4-(2-Aminopropyl)benzofuran (4-APB), and 3,4-methylenedioxyamphetamine 
(MDA).  
Most cathinones (excl. pyrovalerone cathinones), were substrates of the DAT and 
induced DA release, whereas DA release was not significant in our assay with 
methedrone, ethcathinone, buphedrone, pentedrone, and N,N-dimethylcathinone. 
Pipradrol structures (diphenylprolinol (D2PM), desoxypipradrol (2-DPMP), and 
methylphenidate) and the pyrovalerone-cathinones (3,4-methylenedioxy-α-
pyrrolidinopropiophenone (MDPPP), 3,4-methylenedioxy-α-pyrrolidinobutiophenone 
MDPBP, methylenedioxypyrovalerone (MDPV), naphyrone, α-PVP, and 
pyrovalerone) did not release monoamines at any of the three transporters together 
with pentedrone, N,N-dimethylcathinone, m-CPP, TFMPP, and the benzodifuran 2C-
B-FLY. Probably, the pyrovalerone-, piperazine-, piperidine- and pyrrolidine 
structures prevented uptake as transporter substrate. These results are in line with 
previous studies, at least described for pyrovalerone-cathinones (Marusich et al. 
2014), lacking substrate properties in contrast to simple ring-substituted cathinones 
(Simmler et al. 2013). Also the enlargement of the alpha-methyl group to alpha-ethyl 
or alpha-propyl may possibly also abolish substrate characteristics.  
 
In contrast to the above discussed monoamine transporter blockers and releasers, 
2C drugs and in particular their NBOMe (N-2-methoxybenzyl)-substituted 
counterparts, showed high affinity at nanomolar concentrations to the serotonin 5-
HT2A receptor. This is a very exciting finding, because NBOMes showed even lower 
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Ki values than LSD (Ki: 0.0042 µM), which was known so far as one of the most 
potent hallucinogenic compound (Braden et al. 2006, Passie et al. 2008, Ettrup et al. 
2011, Hansen et al. 2014, Nichols et al. 2015). However, these compounds had 
similar activation potencies to LSD and were partial agonists like LSD. This was in 
contrast to the structurally different benzodifuran 2C-B-FLY, which was also a highly 
potent 5-HT2A agonist with nearly full agonist properties (Ki: 0.011 µM; activating 
efficacy: 82 %) unlike LSD (Rickli et al. 2015). 
We also found NPS, which interacted with the SERT and the 5-HT2A receptor, with 
characteristics similar to both, MDMA and LSD. Such mixed compounds were 5-iodo-
2-aminoindane (5-IAI), m-CPP, TFMPP, 5-APB, 6-(2-aminopropyl)benzofuran (6-
APB), 4-APB, and 7-(2-Aminopropyl)benzofuran (7-APB), all with Ki values < 1µM for 
the 5-HT2A receptors. Thus hallucinogenic effects are possible in addition to their 
MDMA-type effects, as described at least for 5-IAI, 5-APB and the 
trifluoromethylphenylpiperazine-benzylpiperazine (TFMPP-BZP) combination 
(Coppola et al. 2013, Simmler et al. 2014, McIntyre et al. 2015, Rickli et al. 2015). 
However, intoxications with the catecholamine uptake inhibitor D2PM including 
hallucinogenic-like effects, demonstrate that also less potent serotonin 5-HT2A 
receptor agonists have the potential for this side effect if consumed in high doses 
(Wood et al. 2012). 
Although most effects of the described designer drugs are mediated either over 
interaction with the monoamine transporters SERT, NET, and DAT, or serotonin 
receptors, most investigated structures also displayed affinity around 1 µM at the 
TAAR1rat with 2-(2,5-dimethoxy-4-propylphenyl)ethanamine (2C-P) and 2C-B-FLY 
showing lowest Ki values (0.02 and 0.03 µM), respectively. This is an interesting 
finding because TAAR1 may serve as a promising target to treat drug addiction (Jing 
et al. 2015). 
Nearly all of the tested designer drugs have sympathomimetic effects through the 
indirect increase of catechoalmines and serotonin via direct stimulation of serotonin 
receptors 5-HT2A, and also 5-HT1A, 5-HT2C and 5-HT2B, which is probably involved in 
cardiotoxic effects (Rothman et al. 2009). 
Additionally, 4-fluoromethcathinone, 4-methylmethcathinone, NBOMes, and LSD also 
directly bind to alpha1A receptors in low micromolar concentrations, enhancing 
cardiovascular stimulation (Piascik et al. 2001, Schmid et al. 2015). 
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The clinical interaction study with MDMA produced empathogenic effects. MDMA 
significantly increased subjective feelings of “any drug effect”, “good drug effect”, 
“drug high”, “drug liking”, and “stimulated”. Somatic side effects included increases in 
body temperature, heart rate, systolic and diastolic blood pressure, and mydriasis. 
These effects were transient and manageable in a controlled setting but may easily 
get out of control, in overdose situations, drug-mixing, and/or under hot party 
conditions with inadequate cooling (Liechti et al. 2005, Liakoni et al. 2015).  	  
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Final remarks 
 
The pharmacological profiles of NPS in vitro give a first important picture of the 
pharmacodynamics of these compounds and predictions of the psychotropic and 
somatic effects in vivo. Additional case reports from NPS users enlarge the picture of 
a certain drug, which also gives an idea about the effective doses of a compound. 
Nevertheless, small modifications in the structure of the substance may lead to 
relevant pharmacologic changes with an additional unknown risk of acute and long-
term toxicity.  
Additional evaluation of pharmacokinetic parameters would help for a better 
understanding of psychoactive compounds.  
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